lnp_id,ionizable_lipid,peg_lipid,sterol_lipid,helper_lipid,lipid_molar_ratio,particle_size_nm_std,pdi_std,zeta_potential_mv_std,encapsulation_efficiency_percent_std,loading_capacity_std,target_type,nucleic_acid_sequence,peg_lipid_original,ionizable_lipid_original,helper_lipid_original,sterol_lipid_original,ionizable_lipid_smiles,peg_lipid_smiles,sterol_lipid_smiles,helper_lipid_smiles,synthesis_info,bioactivity_profile,paper_title,paper_authors,paper_doi,paper_journal,paper_year
466,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,173.6,0.184,,78.45,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H1A1B1,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.32 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
467,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,182.6,0.209,,88.62,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H1A1B2,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.32 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
468,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,129.2,0.139,,85.73,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H1A1B3,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.32 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
469,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125.4,0.155,,85.71,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H1A1B4,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.32 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
470,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,126.6,0.193,,76.7,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H1A2B1,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.32 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
471,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,134.6,0.141,,83.02,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H2A4B3,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.05 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
472,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,139.4,0.154,,86.24,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,firefly_luciferase,C14-PEG2000,H2A4B4,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: C57BL/6 mice; administration_route: intramuscular (I.M.); dose: 0.05 mg/kg mLuc; gene_expression_result: measured by IVIS imaging; biodistribution_result: muscle tissue,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
473,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,,,,,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,cre_recombinase,C14-PEG2000,A4B4-S3,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: Ai9 reporter mice (Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J); administration_route: retro-orbital injection; dose: 0.5 mg/kg mCre; gene_expression_result: tdTomato fluorescent signals measured by IVIS imaging and flow cytometry; biodistribution_result: liver tissue (hepatocytes and immune cells); toxicity_profile: no significant hepatotoxicity in repeated dosing; cytokine_response: no significant immunogenicity compared to SM-102,Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
474,Custom lipid,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,,,,,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,cre_recombinase,C14-PEG2000,A4B4-S4,DSPC,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS",animal_model: Ai9 reporter mice (Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J); administration_route: retro-orbital injection; dose: 0.5 mg/kg mCre; gene_expression_result: tdTomato fluorescent signals measured by IVIS imaging and flow cytometry; biodistribution_result: liver tissue (hepatocytes and immune cells),Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
475,SM-102,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,,,,,CONC:0.1(•Ïg/•ÏL)[mRNA],mRNA,"epo, cre_recombinase",C14-PEG2000,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: T-junction device; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against 1°ø PBS in 10,000 MWCO cassette at 4°∆C for 12 h; sterilization: ; storage_buffer: 1°ø PBS","cell_line: HEK-293 (cytotoxicity), TH1-Dual cells (immunogenicity); animal_model: Ai9 reporter mice (Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J), C57BL/6 mice; administration_route: retro-orbital injection; dose: 0.5 mg/kg mCre, 0.25 mg/kg hEPO; gene_expression_result: tdTomato fluorescent signals, hEPO protein expression measured by ELISA; biodistribution_result: liver tissue; toxicity_profile: used as benchmark control; cytokine_response: used as benchmark control",Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery,"['Yue Xu', 'Fanglin Gong', 'Alex Golubovic', 'Amy Strilchuk', 'Jingan Chen', 'Muye Zhou', 'Songtao Dong', 'Breanna Seto', 'Bowen Li']",https://doi.org/10.1073/pnas.2409572122,PNAS,2025
476,OF-02,DMG-PEG2000,cholesterol,DOPE,40:1.5:28.5:30,,,30,,NP:fixed(molar),mRNA,epo,DMG-PEG2k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C","animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: ~30 ng/mL hEPO (6h post-injection, normalized to 1.0)","PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
477,OF-02,DMG-PEG5k,cholesterol,DOPE,40:1.5:28.5:30,112,0.104,20,90,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C","animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: ~36 ng/mL hEPO (6h post-injection, 1.2x relative)","PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
478,OF-02,DMG-PEG5k,cholesterol,DOPE,25.5:1:45:28.5,120,0.111,19,91,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C","animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: ~45 ng/mL hEPO (6h post-injection, 1.5x relative)","PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
479,OF-02,DMG-PEG5k,cholesterol,DOPE,40.3:1.1:14.9:43.7,125,0.067,21,89,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.27x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
480,OF-02,DMG-PEG5k,cholesterol,DOPE,29.0:1.0:21.7:48.3,119,0.111,20,91,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.31x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
481,OF-02,DMG-PEG5k,cholesterol,DOPE,56.5:1.7:31.8:10.0,117,0.068,17,65,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.27x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
482,OF-02,DMG-PEG5k,cholesterol,DOPE,52.7:1.1:28.7:17.5,125,0.049,19,88,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.26x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
483,OF-02,DMG-PEG5k,cholesterol,DOPE,34.9:1.1:16.3:47.7,119,0.093,19,91,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.57x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
484,OF-02,DMG-PEG5k,cholesterol,DOPE,59.9:2.9:20.2:17.0,100,0.083,15,70,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.25x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
485,OF-02,DMG-PEG5k,cholesterol,DOPE,20.4:3.6:42.1:33.9,93,0.139,14,76,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.12x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
486,OF-02,DMG-PEG5k,cholesterol,DOPE,54.8:2.0:10.1:33.1,110,0.077,18,86,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.37x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
487,OF-02,DMG-PEG5k,cholesterol,DOPE,39.7:2.5:27.3:30.6,99,0.117,17,85,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.59x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
488,OF-02,DMG-PEG5k,cholesterol,DOPE,49.1:3.8:33.4:13.7,98,0.119,16,66,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.10x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
489,OF-02,DMG-PEG5k,cholesterol,DOPE,38.6:1.1:44.4:15.9,115,0.055,19,94,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.15x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
490,OF-02,DMG-PEG5k,cholesterol,DOPE,40.7:1.0:26.1:32.2,128,0.107,20,95,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.00x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
491,OF-02,DMG-PEG5k,cholesterol,DOPE,39.7:2.5:27.3:30.6,92,0.079,17,84,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.65x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
492,OF-02,DMG-PEG5k,cholesterol,DOPE,23.1:1.8:41.4:33.7,93,0.113,19,90,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.30x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
493,OF-02,DMG-PEG5k,cholesterol,DOPE,30.6:2.7:21.7:45.0,92,0.138,17,76,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.95x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
494,OF-02,DMG-PEG5k,cholesterol,DOPE,54.4:3.0:32.4:10.2,102,0.084,17,64,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.58x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
495,OF-02,DMG-PEG5k,cholesterol,DOPE,40.3:3.2:20.9:35.6,95,0.079,18,74,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 1.32x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
496,OF-02,DMG-PEG5k,cholesterol,DOPE,39.1:3.8:44.4:12.6,97,0.084,15,73,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.91x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
497,OF-02,DMG-PEG5k,cholesterol,DOPE,22.5:4.0:33.8:39.7,90,0.167,12,70,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.45x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
498,OF-02,DMG-PEG5k,cholesterol,DOPE,25.6:3.2:22.7:48.5,96,0.161,16,71,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: 0.44x relative to Std1,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
499,OF-02,DMG-PEG2000,cholesterol,DOPE,40:1.5:28.5:30,~100,,,,NP:fixed(molar),mRNA,epo,DMG-PEG2k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C","animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: ~30 ng/mL hEPO (benchmark, normalized to 1.0)","PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
500,OF-02,DMG-PEG5k,cholesterol,DOPE,40:1.5:28.5:30,~90,~0.15,~18,~88,NP:fixed(molar),mRNA,epo,DMG-PEG5k,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: mRNA in acidic buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis, ultrafiltration, diafiltration; sterilization: filtered; storage_buffer: trehalose solution (pH ~5), stored at -80°∆C",animal_model: female BALB/c mice (6-8 weeks); administration_route: IM; dose: 0.1 •Ïg hEPO mRNA; gene_expression_result: ~1.2x relative to DMG-PEG2k,"PEGylated lipid screening, composition optimization, and structure?activity relationship determination for lipid nanoparticle-mediated mRNA delivery","['Lingyun Liu', 'Jae-Heon Kim', 'Zhongyu Li', 'Mengwei Sun', 'Trent Northen', 'Jackie Tang', 'Emma Mcintosh', 'Shrirang Karve', 'Frank DeRosa']",10.1039/d5nr00433k,Nanoscale,2025
862,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,183.3 °æ 1.5,,,~80,NP:6(molar),mRNA,firefly_luciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Manual mixing; device_used: Pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: 1200; temperature_condition: Room temperature; post_processing: Buffer dilution to reduce ethanol concentration; sterilization: ; storage_buffer: Room temperature for 20 min,"cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 •Ïg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Standard reference for comparison; biodistribution_result: High liver, skin, lymph node accumulation; toxicity_profile: No significant toxicity in mice",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
863,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,~70,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation (30,000 Da MWCO) at 1500g, 4°∆C; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 •Ïg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: 9.36-fold increase vs manual mixing in HepG2, 4.92-fold in A549; biodistribution_result: High liver, skin, lymph node accumulation; toxicity_profile: No significant toxicity in mice",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
864,ALC-0315,DMG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DMG-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: Comparable to ALC-0159; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
865,ALC-0315,DMG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DMG-C-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 1.70-fold higher than DMG-PEG in HepG2, 1.25-fold in A549; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
866,ALC-0315,DSG-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~65,<0.2,,~80,NP:6(molar),mRNA,firefly_luciferase,DSG-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 20.57-fold lower than DMG-PEG in HepG2; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
867,ALC-0315,C8-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,70.6 °æ 0.5,,,~80,NP:6(molar),mRNA,firefly_luciferase,C8-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 •Ïg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Lower than C16-Ceramide-PEG via microfluidic mixing; biodistribution_result: Mainly injection site and lymph node, minimal liver accumulation; toxicity_profile: No significant toxicity in mice; cytokine_response: Negligible anti-PEG IgM levels",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
868,ALC-0315,C16-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~75,,,~80,NP:6(molar),mRNA,firefly_luciferase,C16-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 •Ïg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Higher than C8-Ceramide-PEG via microfluidic mixing; biodistribution_result: High liver accumulation, highest liver specificity; toxicity_profile: No significant toxicity in mice; cytokine_response: Higher anti-PEG IgM than C8-Ceramide-PEG and ALC-0159",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
869,ALC-0315,DMPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,,,,~80,NP:6(molar),mRNA,firefly_luciferase,DMPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; dose: 100 ng mRNA per well (in vitro); gene_expression_result: 49.25-fold higher than DSPE-PEG in HepG2; toxicity_profile: Cell viability >90%",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
870,ALC-0315,DSPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,92.8,,,60,NP:6(molar),mRNA,firefly_luciferase,DSPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 1 •Ïg mRNA per mouse (in vivo), 100 ng mRNA per well (in vitro); gene_expression_result: Lowest among all tested PEG-lipids; biodistribution_result: Lower liver accumulation, higher lymph node specificity; toxicity_profile: No significant toxicity in mice; cytokine_response: Highest anti-PEG IgM production among tested formulations",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
871,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,~80,,,,NP:6(molar),mRNA,sars_cov2_spike,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Highest spike protein expression among tested formulations; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
872,ALC-0315,C8-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,~80,,,,NP:6(molar),mRNA,sars_cov2_spike,C8-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Comparable to C16-Ceramide-PEG; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, negligible anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
873,ALC-0315,C16-Ceramide-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,90.1 °æ 1.0,,,,NP:6(molar),mRNA,sars_cov2_spike,C16-Ceramide-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Comparable to C8-Ceramide-PEG and ALC-0159; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: ~60% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, moderate anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
874,ALC-0315,DSPE-PEG2000,cholesterol,DSPC,46.3:9.4:42.7:1.6,111.2 °æ 0.3,,,,NP:6(molar),mRNA,sars_cov2_spike,DSPE-PEG,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 1 mM sodium acetate buffer at pH 5.2; organic_phase_composition: Lipids dissolved in ethanol solution; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Diluted 40 times with PBS, concentrated by ultracentrifugation; sterilization: ; storage_buffer: PBS, stored at 4°∆C","cell_line: HepG2, A549; animal_model: BALB/c mice; administration_route: Subcutaneous; dose: 500 ng mRNA per mouse (prime-boost strategy); gene_expression_result: Lowest spike protein expression, especially in HepG2 cells; toxicity_profile: No weight loss, normal biochemical markers; cytokine_response: Lower vaccination efficacy - 29.9% RBD-ACE2 inhibition after 1st dose, >90% after 2nd dose, highest anti-PEG response",Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines,"['Li Zhang', 'Brandon Yi Loong Seow', 'Ki Hyun Bae', 'Yue Zhang', 'Kuo-Chieh Liao', 'Yue Wan', 'Yi Yan Yang']",https://doi.org/10.1016/j.jconrel.2025.01.071,Journal of Controlled Release,2025
1,Custom lipid,DMG-PEG2000,cholesterol,DOPE,60:20:19.5:0.5,108.0 °æ 2.1,0.19 °æ 0.01,'-2.28,92.08 °æ 2.5,,mRNA,"firefly_luciferase, cre_recombinase",DMG-PEG2000,(Z)-5-(octadec-9-en-1-ylamino)-5-oxo-4-(piperidin-1-ylamino)pentyl octanoate,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: dialysis against PBS, 20,000 MWCO; sterilization: ; storage_buffer: PBS at 4°∆C","cell_line: HeLa, C2C12; animal_model: C57BL/6 mice, ROSAmT/mG reporter mice; administration_route: intramuscular (IM); dose: 0.5 mg/kg mRNA; gene_expression_result: 7.8x higher than MC3 in muscle; biodistribution_result: muscle-specific, lower liver accumulation; toxicity_profile: lower ALT/AST levels than ALC-0315",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
2,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,134.6,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H1,DOPE,cholesterol,CCCCCCCCC/C=C/CCCCCCCCC(=O)N(N)CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 7.81 (Log2) in vitro, 3.625E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
3,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,138,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H2,DOPE,cholesterol,CCCCCC(C)CCCC(=O)OCCC(N(C)N)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.32 (Log2) in vitro, 3.494E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
4,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,108.7,0.09,,,,mRNA,firefly_luciferase,DMG-PEG2000,H3,DOPE,cholesterol,CCCCCCC/C=C/CCCCCCCCC(N(C)N)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 7.01 (Log2) in vitro, 1.941E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
5,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,110,0.17,,,,mRNA,firefly_luciferase,DMG-PEG2000,H4,DOPE,cholesterol,CCCCCC(C)CCCC(=O)OCCC(NCCCCN(CCCC)CCCCC)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 7.63 (Log2) in vitro, 4.065E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
6,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,122.6,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H5,DOPE,cholesterol,CCCCCCCCC/C=C/CCCCCCCCC(NCCCCN(CCCC)CCCCCC)C(=O)NCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 9.95 (Log2) in vitro, 1.384E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
7,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,119.9,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H6,DOPE,cholesterol,CCCCCCCC/C=C/C(=O)OCCC(NCCCCN(CCCC)CCCCCC)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 9.61 (Log2) in vitro, 3.299E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
8,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,134.8,0.01,,,,mRNA,firefly_luciferase,DMG-PEG2000,H7,DOPE,cholesterol,CCCCCC(C)CCCC(=O)OCCC(NN1CCCCCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 5.43 (Log2) in vitro, 7.301E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
9,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,132.9,0.09,,,,mRNA,firefly_luciferase,DMG-PEG2000,H8,DOPE,cholesterol,CCCCCCCC/C=C/C(=O)OCCC(NN1CCCCCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 4.09 (Log2) in vitro, 1.892E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
10,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,127.5,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H10,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCC(NCCN(C(C)C)C(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.51 (Log2) in vitro, 3.379E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
11,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,151,0.16,,,,mRNA,firefly_luciferase,DMG-PEG2000,H11,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCC(NCCN(C(C)C)C(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 7.77 (Log2) in vitro, 5.005E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
12,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,147.5,0.17,,,,mRNA,firefly_luciferase,DMG-PEG2000,H12,DOPE,cholesterol,CCCCCC(C)CCCC(=O)OCCC(NCCN(C(C)C)C(C)C)C(=O)NCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 10.15 (Log2) in vitro, 4.675E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
13,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,135.5,0.02,,,,mRNA,firefly_luciferase,DMG-PEG2000,H13,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NCCCCN(CC)CC)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 9.59 (Log2) in vitro, 1.870E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
14,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,128.2,0.12,,,,mRNA,firefly_luciferase,DMG-PEG2000,H14,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCCC(NCCCCN(CC)CC)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 7.62 (Log2) in vitro, 1.952E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
15,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,117.5,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H15,DOPE,cholesterol,CCCCCCCC/C=C/CCCCCCC(=O)OCCC(NCCCCN(CC)CC)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 5.58 (Log2) in vitro, 6.916E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
16,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,134.8,0.1,,,,mRNA,firefly_luciferase,DMG-PEG2000,H31,DOPE,cholesterol,CCCCCC(C)CCCC(=O)OCCC(NCCN1CCCCCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.30 (Log2) in vitro, 8.059E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
17,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,132.9,0.12,,,,mRNA,firefly_luciferase,DMG-PEG2000,H32,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCC(NCCN1CCCCCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.21 (Log2) in vitro, 5.577E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
18,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,133.8,0.1,,,,mRNA,firefly_luciferase,DMG-PEG2000,H33,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCC(NCCN1CCCCCC1)C(=O)NCCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 5.87 (Log2) in vitro, 4.46E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
19,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,137.8,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H34,DOPE,cholesterol,CCCCCCCC/C=C/CCCCCCC(=O)OCCC(NCCN(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 1.46 (Log2) in vitro, 6.802E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
20,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,135.5,0.1,,,,mRNA,firefly_luciferase,DMG-PEG2000,H35,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NCCCN(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 3.10 (Log2) in vitro, 5.662E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
21,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,139,0.1,,,,mRNA,firefly_luciferase,DMG-PEG2000,H36,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCCC(NCCCN(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 3.54 (Log2) in vitro, 1.109E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
22,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,132.8,0.13,,,,mRNA,firefly_luciferase,DMG-PEG2000,H37,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NCCCN(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.21 (Log2) in vitro, 7.084E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
23,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,133.9,0.16,,,,mRNA,firefly_luciferase,DMG-PEG2000,H38,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NCCN(C)C)C(=O)NCCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 6.93 (Log2) in vitro, 3.388E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
24,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,137.9,0.16,,,,mRNA,firefly_luciferase,DMG-PEG2000,H39,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCC(NCCN(C)C)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 4.01 (Log2) in vitro, 2.286E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
25,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,135.4,0.23,,,,mRNA,firefly_luciferase,DMG-PEG2000,H40,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NC1CCN(C(C)C)CC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 0.73 (Log2) in vitro, 1.844E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
26,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,134.6,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H41,DOPE,cholesterol,CCCCCCC/C=C/C(=O)OCCCC(NC1CCN(C(C)C)CC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 0.75 (Log2) in vitro, 3.195E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
27,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,138,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H42,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NC1CCN(C(C)C)CC1)C(=O)NCCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 0.86 (Log2) in vitro, 2.989E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
28,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,121.6,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,H43,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCC(NCCCN1CCOCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 5.87 (Log2) in vitro, 2.472E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
29,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,119.9,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H44,DOPE,cholesterol,CCCCCCCCC/C=C/C(=O)OCCCC(NCCCN1CCOCC1)C(=O)NCCCCCCCCCC/C=C/CCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: -0.87 (Log2) in vitro, 3.911E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
30,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,108.4,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H45,DOPE,cholesterol,CCCCCC(C)CCC(=O)OCCCC(NCCCN1CCOCC1)C(=O)NCCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 5.55 (Log2) in vitro, 2.835E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
31,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,130.2,0.2,,,,mRNA,firefly_luciferase,DMG-PEG2000,H9252,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 0.55 (Log2) in vitro, 6.313E+04 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
32,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,132.6,0.22,,,,mRNA,firefly_luciferase,DMG-PEG2000,H9239,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 0.23 (Log2) in vitro, 5.265E+03 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
33,Custom lipid,DMG-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,120.5,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,H9138,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: 3CR-Ugi reaction; device_used: Automated liquid handler (OT-2); total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: ethanol with lipid components; mixing_time_sec: overnight; temperature_condition: room temperature; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: HeLa; animal_model: mice; administration_route: intramuscular (IM); dose: 0.2 mg/kg mRNA; gene_expression_result: 1.24 (Log2) in vitro, 1.152E+05 in vivo",AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery,"['Yue Xu', 'Shihao Ma', 'Haotian Cui', 'Jingan Chen', 'Shufen Xu', 'Fanglin Gong', 'Alex Golubovic', 'Muye Zhou', 'Kevin Chang Wang', 'Andrew Varley', 'Rick Xing Ze Lu', 'Bo Wang', 'Bowen Li']",https://doi.org/10.1038/s41467-024-50619-z,Nature Communications,2024
202,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,213.2,0.4,1.6,52.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 1)",C14PEG2K,1-A2-6b,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
203,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,221.9,0.35,4.2,69.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 2)",C14PEG2K,2-A2-6b,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
204,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,185.3,0.29,6.2,57.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 3)",C14PEG2K,3-A2-6b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid (barcoding), 0.1 mg/kg FLuc mRNA (validation); gene_expression_result: Top lung-targeting candidate; biodistribution_result: Lung-specific enrichment; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
205,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,205.6,0.29,7.1,63,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 4)",C14PEG2K,4-A2-6b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid (barcoding), 0.1 mg/kg FLuc mRNA (validation); gene_expression_result: Top lung-targeting candidate; biodistribution_result: Lung-specific enrichment; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
206,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,219.7,0.34,'-5.4,51.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 5)",C14PEG2K,11-A2-6b,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
207,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,214.6,0.31,6.6,76.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 6)",C14PEG2K,12-A2-6b,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
208,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,182.5,0.25,'-6.2,73.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 7)",C14PEG2K,1-A2-7b,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
209,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,217,0.41,0.1,77.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 8)",C14PEG2K,2-A2-7b,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
210,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,150.1,0.21,4.5,71.6,"OTHER:b-DNA:FLuc mRNA weight ratio 10:1, Cas9:sgRNA weight ratio 4:1",mRNA,"firefly_luciferase, cre_recombinase, cas9, vegfr2, barcode(dna barcode 9)",C14PEG2K,3-A2-7b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice, Ai14 mice, LLC-GFP lung tumor model; administration_route: intravenous (IV); dose: 1.0 mg/kg (barcoding), 0.1 mg/kg FLuc mRNA (validation), 0.3 mg/kg Cre mRNA, 4.0 mg/kg Cas9 mRNA/VEGFR2 sgRNA; gene_expression_result: Top performing LNP for pulmonary delivery - ~90% of total luminescence in lungs, ~60% tdTomato+ endothelial cells; biodistribution_result: Preferential lung accumulation with depletion from liver and spleen; toxicity_profile: Cell viability >85%, minimal in vivo toxicity in tissue histology","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
211,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,214.9,0.4,1.1,78.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 10)",C14PEG2K,4-A2-7b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid (barcoding), 0.1 mg/kg FLuc mRNA (validation); gene_expression_result: Top lung-targeting candidate; biodistribution_result: Lung-specific enrichment; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
212,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,145.8,0.15,'-1.6,73,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 11)",C14PEG2K,11-A2-7b,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
213,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,143.6,0.22,'-0.4,74.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 12)",C14PEG2K,12-A2-7b,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
214,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,210.3,0.21,'-1.3,54.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 13)",C14PEG2K,1-A2-7b2,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
215,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,182.5,0.24,'-3,59.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 14)",C14PEG2K,2-A2-7b2,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS",cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Spleen-enriched delivery; toxicity_profile: Cell viability >85%,"High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
216,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,206.3,0.31,1.9,51.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 15)",C14PEG2K,3-A2-7b2,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
217,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,221.1,0.25,'-8.4,75.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 16)",C14PEG2K,4-A2-7b2,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
218,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,212.3,0.27,'-0.7,54.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 17)",C14PEG2K,11-A2-7b2,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
219,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,173.2,0.21,4.3,85.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 18)",C14PEG2K,12-A2-7b2,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
220,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,136.4,0.23,2.8,84.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 19)",C14PEG2K,1-A2-8b,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
221,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,138.3,0.21,'-0.8,75.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 20)",C14PEG2K,2-A2-8b,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid, 0.25 mg/kg FLuc mRNA (validation); gene_expression_result: Liver-targeting LNP; biodistribution_result: Liver-enriched delivery; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
222,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,116.2,0.27,'-3.6,85.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 21)",C14PEG2K,3-A2-8b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
223,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,110.5,0.22,2.6,77.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 22)",C14PEG2K,4-A2-8b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
224,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,149.1,0.25,'-0.1,71.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 23)",C14PEG2K,11-A2-8b,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
225,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,151.5,0.23,3.1,87.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 24)",C14PEG2K,12-A2-8b,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS",cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; gene_expression_result: Greatest enrichment in lungs but also enriched in liver and spleen; biodistribution_result: High lung enrichment but not lung-specific; toxicity_profile: Cell viability >85%,"High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
226,DLin-MC3-DMA,C14-PEG2000,cholesterol,DSPC,25:0.75:19.25:5,,,,,,mRNA,"cre_recombinase, cas9, vegfr2",C14PEG2K,MC3,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Similar to CAD LNPs; device_used: Similar to CAD LNPs; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: ; organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"animal_model: Ai14 mice, LLC-GFP lung tumor model; administration_route: intravenous (IV); dose: 0.3 mg/kg Cre mRNA, 4.0 mg/kg Cas9 mRNA/VEGFR2 sgRNA; gene_expression_result: Gold standard lung-tropic LNP control, lower performance than LNP-CAD9; biodistribution_result: Lung-targeted delivery","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
227,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,164.2,0.18,'-1.6,48.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 25)",C14PEG2K,1-A2-9b,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
228,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,186.2,0.26,5.8,66.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 26)",C14PEG2K,2-A2-9b,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
229,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,169.9,0.2,'-8.8,54.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 27)",C14PEG2K,3-A2-9b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
230,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,172.1,0.23,5.2,50.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 28)",C14PEG2K,4-A2-9b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
231,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,153.1,0.18,2.9,48.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 29)",C14PEG2K,11-A2-9b,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
232,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,135.1,0.14,9.2,69.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 30)",C14PEG2K,12-A2-9b,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CC(CCCCCC)CC)OC(=O)CC(CCCCCC)CC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
233,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,167.1,0.23,12.7,54.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 31)",C14PEG2K,1-A2-9b2,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
234,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,164.2,0.19,'-6.4,73.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 32)",C14PEG2K,2-A2-9b2,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
235,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,157.1,0.17,'-10.7,53.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 33)",C14PEG2K,3-A2-9b2,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
236,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,171.9,0.1,14.7,64.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 34)",C14PEG2K,4-A2-9b2,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
237,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,166.8,0.18,10.4,57.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 35)",C14PEG2K,11-A2-9b2,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
238,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,160.8,0.16,'-4.3,58.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 36)",C14PEG2K,12-A2-9b2,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
239,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,150.3,0.19,'-9.6,39.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 37)",C14PEG2K,1-A3-6b,DOPE,cholesterol,NNCC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
240,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,154.9,0.13,1.2,42.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 38)",C14PEG2K,2-A3-6b,DOPE,cholesterol,NCCCCNCC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
241,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,159.3,0.14,12.6,48.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 39)",C14PEG2K,3-A3-6b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCC)C(=C2)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
242,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,151.4,0.22,6.9,49.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 40)",C14PEG2K,4-A3-6b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCC)C(=C2)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
243,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,135.4,0.12,9.2,46.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 41)",C14PEG2K,11-A3-6b,DOPE,cholesterol,NCCCN(CC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
244,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,156.2,0.16,'-3.6,37,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 42)",C14PEG2K,12-A3-6b,DOPE,cholesterol,NCCN(CC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
245,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,158.1,0.15,6.7,53.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 43)",C14PEG2K,1-A3-7b,DOPE,cholesterol,NNCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
246,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,176,0.16,7.4,77.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 44)",C14PEG2K,2-A3-7b,DOPE,cholesterol,NCCCCNCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
247,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,167.4,0.16,8.9,60.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 45)",C14PEG2K,3-A3-7b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCC)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
248,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,159.8,0.1,2.4,66.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 46)",C14PEG2K,4-A3-7b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCC)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
249,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,143.2,0.14,7,45.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 47)",C14PEG2K,11-A3-7b,DOPE,cholesterol,NCCCN(CC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
250,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,174.6,0.14,8.8,63.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 48)",C14PEG2K,12-A3-7b,DOPE,cholesterol,NCCN(CC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
251,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,175.2 °æ 3.0,0.26 °æ 0.10,1.4 °æ 2.5,78.5 °æ 4.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 49)",C14PEG2K,1-A3-7b2,DOPE,cholesterol,NNCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
252,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,163.1 °æ 6.5,0.19 °æ 0.05,'-7.2 °æ 2.9,78.8 °æ 2.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 50)",C14PEG2K,2-A3-7b2,DOPE,cholesterol,NCCCCNCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
253,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,162.2 °æ 2.7,0.23 °æ 0.06,6.2 °æ 1.6,79.3 °æ 1.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 51)",C14PEG2K,3-A3-7b2,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCC)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
254,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,159.9 °æ 3.6,0.10 °æ 0.06,5.2 °æ 2.4,77.9 °æ 6.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 52)",C14PEG2K,4-A3-7b2,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCC)C(=C2)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
255,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,162.3 °æ 3.0,0.13 °æ 0.02,6.4 °æ 1.2,79.0 °æ 3.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 53)",C14PEG2K,11-A3-7b2,DOPE,cholesterol,NCCCN(CC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
256,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,151.7 °æ 4.9,0.21 °æ 0.03,'-0.5 °æ 1.3,79.4 °æ 3.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 54)",C14PEG2K,12-A3-7b2,DOPE,cholesterol,NCCN(CC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
257,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,155.1 °æ 5.2,0.16 °æ 0.03,'-8.2 °æ 1.4,57.8 °æ 2.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 55)",C14PEG2K,1-A3-8b,DOPE,cholesterol,NNCC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
258,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,151.7 °æ 3.2,0.25 °æ 0.08,1.4 °æ 0.9,63.9 °æ 3.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 56)",C14PEG2K,2-A3-8b,DOPE,cholesterol,NCCCCNCC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS",cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; gene_expression_result: Greatest enrichment in lungs but also enriched in liver and spleen; biodistribution_result: High lung enrichment but not lung-specific; toxicity_profile: Cell viability >85%,"High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
259,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,162.3 °æ 2.6,0.25 °æ 0.10,4.7 °æ 1.7,41.8 °æ 2.2,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 57)",C14PEG2K,3-A3-8b,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCCC)C(=C2)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
260,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,140.8 °æ 4.5,0.16 °æ 0.07,8.6 °æ 0.9,40.6 °æ 3.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 58)",C14PEG2K,4-A3-8b,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(OC(=O)CC(CC)CCCCC)C(=C2)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
261,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,173.5 °æ 5.8,0.20 °æ 0.05,'-5.6 °æ 6.3,57.6 °æ 3.0,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 59)",C14PEG2K,11-A3-8b,DOPE,cholesterol,NCCCN(CC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
262,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,146.7 °æ 6.5,0.25 °æ 0.06,5.1 °æ 2.7,59.2 °æ 2.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 60)",C14PEG2K,12-A3-8b,DOPE,cholesterol,NCCN(CC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
263,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,161.7 °æ 6.8,0.22 °æ 0.06,7.9 °æ 1.9,46.9 °æ 2.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 61)",C14PEG2K,1-A3-9b2,DOPE,cholesterol,NNCC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
264,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,168.9 °æ 3.1,0.18 °æ 0.02,'-2.4 °æ 0.9,65.6 °æ 3.0,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 62)",C14PEG2K,2-A3-9b2,DOPE,cholesterol,NCCCCNCC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
265,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,169.2 °æ 5.5,0.22 °æ 0.07,2.6 °æ 1.8,54.3 °æ 2.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 63)",C14PEG2K,3-A3-9b2,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C2)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
266,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,184.3 °æ 6.4,0.12 °æ 0.04,5.8 °æ 3.4,48.0 °æ 2.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 64)",C14PEG2K,4-A3-9b2,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C2)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
267,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,173.9 °æ 5.3,0.12 °æ 0.03,'-0.9 °æ 1.2,47.1 °æ 5.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 65)",C14PEG2K,11-A3-9b2,DOPE,cholesterol,NCCCN(CC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
268,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,154.3 °æ 4.8,0.13 °æ 0.07,8.7 °æ 1.4,37.2 °æ 3.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 66)",C14PEG2K,12-A3-9b2,DOPE,cholesterol,NCCN(CC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
269,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,192.2 °æ 5.1,0.08 °æ 0.05,'-1.2 °æ 0.8,77.8 °æ 3.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 67)",C14PEG2K,1-A2-7,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
270,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,178.9 °æ 3.7,0.18 °æ 0.04,1.4 °æ 1.9,84.0 °æ 6.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 68)",C14PEG2K,2-A2-7,DOPE,cholesterol,NCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
271,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,193.7 °æ 5.0,0.07 °æ 0.05,4.4 °æ 4.0,74.6 °æ 3.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 69)",C14PEG2K,3-A2-7,DOPE,cholesterol,NC1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
272,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,181.2 °æ 3.9,0.10 °æ 0.05,1.5 °æ 7.5,82.2 °æ 4.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 70)",C14PEG2K,4-A2-7,DOPE,cholesterol,NCCN1CCN(CC1)CC2=CC(=C(O)C(=C2)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
273,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,195.1 °æ 6.3,0.12 °æ 0.04,8.6 °æ 15.5,81.0 °æ 4.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 71)",C14PEG2K,11-A2-7,DOPE,cholesterol,NCCCN(CC1=CC(=C(O)C(=C1)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC)CCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
274,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,181.8 °æ 4.8,0.11 °æ 0.09,13.2 °æ 0.4,79.8 °æ 5.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 72)",C14PEG2K,12-A2-7,DOPE,cholesterol,NCCN(CC1=CC(=C(O)C(=C1)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC)CCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
275,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,203.4 °æ 4.9,0.18 °æ 0.09,3.8 °æ 1.4,85.2 °æ 4.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 73)",C14PEG2K,1-A2-6,DOPE,cholesterol,NNCC1=CC(=C(O)C(=C1)OC(=O)CCCCCC)OC(=O)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; gene_expression_result: Spleen-enriched delivery; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
276,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,174.0 °æ 5.5,0.23 °æ 0.05,7.9 °æ 1.3,81.2 °æ 2.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 74)",C14PEG2K,5-A2-6b,DOPE,cholesterol,CN(C)CCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
277,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,164.2 °æ 5.7,0.13 °æ 0.09,6.5 °æ 0.9,85.1 °æ 2.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 75)",C14PEG2K,9-A2-6b,DOPE,cholesterol,CCCCCCCC(CCCN)NCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
278,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,143.6 °æ 8.7,0.09 °æ 0.08,3.3 °æ 3.8,85.3 °æ 4.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 76)",C14PEG2K,6-A2-7,DOPE,cholesterol,CN(CCCC)NCC1=CC(=C(O)C(=C1)OC(=O)CCCCCCCC)OC(=O)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
279,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,195.5 °æ 9.9,0.29 °æ 0.07,'-9.7 °æ 2.2,80.6 °æ 2.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 77)",C14PEG2K,8-A2-7b,DOPE,cholesterol,CCCCCCCC(CCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
280,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,179.2 °æ 7.4,0.25 °æ 0.09,5.8 °æ 1.3,80.6 °æ 3.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 78)",C14PEG2K,8-A2-7b2,DOPE,cholesterol,CCCCCCCC(CCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
281,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,181.7 °æ 4.9,0.24 °æ 0.05,1.4 °æ 0.6,83.1 °æ 3.0,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 79)",C14PEG2K,5-A2-8b,DOPE,cholesterol,CN(C)CCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
282,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,141.6 °æ 11.1,0.21 °æ 0.04,3.9 °æ 2.1,82.4 °æ 3.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 80)",C14PEG2K,6-A2-8b,DOPE,cholesterol,CN(CCCC)NCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
283,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,171.4 °æ 4.5,0.16 °æ 0.04,6.7 °æ 2.0,78.5 °æ 4.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 81)",C14PEG2K,7-A2-8b,DOPE,cholesterol,CCCCCN(CCC)NCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
284,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,155.0 °æ 6.5,0.15 °æ 0.05,1.5 °æ 0.7,79.7 °æ 3.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 82)",C14PEG2K,8-A2-8b,DOPE,cholesterol,CCCCCCCC(CCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
285,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,156.3 °æ 5.1,0.26 °æ 0.11,6.3 °æ 0.9,82.4 °æ 3.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 83)",C14PEG2K,9-A2-8b,DOPE,cholesterol,CCCCCCCC(CCCN)NCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
286,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,190.5 °æ 4.3,0.30 °æ 0.12,4.3 °æ 3.7,83.4 °æ 3.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 84)",C14PEG2K,10-A2-8b,DOPE,cholesterol,NCCCCCCCCCCNCC1=CC(=C(O)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
287,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,191.3 °æ 3.4,0.16 °æ 0.10,4.8 °æ 2.2,84.4 °æ 3.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 85)",C14PEG2K,9-A2-9,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
288,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,190.4 °æ 4.1,0.23 °æ 0.08,'-1.8 °æ 0.8,84.2 °æ 2.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 86)",C14PEG2K,6-A3-6b,DOPE,cholesterol,CN(CCCC)NCC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
289,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,204.3 °æ 5.3,0.16 °æ 0.07,'-6.4 °æ 0.6,81.8 °æ 4.7,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 87)",C14PEG2K,10-A3-6b,DOPE,cholesterol,NCCCCCCCCCCNCC1=CC(=C(OC(=O)CC(CC)CCC)C(=C1)OC(=O)CC(CC)CCC)OC(=O)CC(CC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
290,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,169.6 °æ 4.5,0.19 °æ 0.12,12.8 °æ 0.7,86.8 °æ 1.9,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 88)",C14PEG2K,7-A3-7b,DOPE,cholesterol,CCCCCN(CCC)NCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
291,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,201.5 °æ 4.4,0.24 °æ 0.06,2.3 °æ 0.9,82.4 °æ 3.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 89)",C14PEG2K,9-A3-7b,DOPE,cholesterol,CCCCCCCC(CCCN)NCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
292,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,162.3 °æ 4.1,0.22 °æ 0.06,'-1.7 °æ 0.6,83.2 °æ 4.1,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 90)",C14PEG2K,6-A3-7b2,DOPE,cholesterol,CN(CCCC)NCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
293,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,143.2 °æ 6.9,0.27 °æ 0.11,1.5 °æ 2.6,75.9 °æ 5.4,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 91)",C14PEG2K,8-A3-7b2,DOPE,cholesterol,CCCCCCCC(CCNCC1=CC(=C(OC(=O)CC(CC)CCCC)C(=C1)OC(=O)CC(CC)CCCC)OC(=O)CC(CC)CCCC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
294,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,126.7 °æ 5.9,0.21 °æ 0.09,'-1.2 °æ 2.7,85.5 °æ 4.5,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 92)",C14PEG2K,5-A3-8b,DOPE,cholesterol,CN(C)CCNCC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
295,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,113.9 °æ 5.0,0.13 °æ 0.05,'-3.1 °æ 2.1,73.8 °æ 4.0,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 93)",C14PEG2K,7-A3-8b,DOPE,cholesterol,CCCCCN(CCC)NCC1=CC(=C(OC(=O)CC(CC)CCCCC)C(=C1)OC(=O)CC(CC)CCCCC)OC(=O)CC(CC)CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
296,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,115.4 °æ 7.1,0.16 °æ 0.08,6.7 °æ 4.5,75.1 °æ 2.6,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 94)",C14PEG2K,5-A3-9b2,DOPE,cholesterol,CN(C)CCNCC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
297,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,109.2 °æ 5.2,0.25 °æ 0.05,'-3.0 °æ 4.1,80.4 °æ 4.3,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 95)",C14PEG2K,7-A3-9b2,DOPE,cholesterol,CCCCCN(CCC)NCC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; gene_expression_result: Liver-enriched delivery; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
298,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,114.1 °æ 6.7,0.16 °æ 0.04,2.1 °æ 1.6,84.9 °æ 4.8,OTHER:b-DNA:FLuc mRNA weight ratio 10:1,mRNA,"firefly_luciferase, barcode(dna barcode 96)",C14PEG2K,10-A3-9b2,DOPE,cholesterol,NCCCCCCCCCCNCC1=CC(=C(OC(=O)CCC(CC)CCCCCC)C(=C1)OC(=O)CCC(CC)CCCCCC)OC(=O)CCC(CC)CCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing or pipette mixing; device_used: Microfluidic device with staggered herringbone features; total_flow_rate_ml_min: 2.4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: Ethanol with lipids; mixing_time_sec: ; temperature_condition: Room temperature; post_processing: Dialysis in 1x PBS for 2h, filtration through 0.45 •Ïm filter; sterilization: 0.45 •Ïm filtration; storage_buffer: 1x PBS","cell_line: HeLa; animal_model: C57BL/6J female mice; administration_route: intravenous (IV); dose: 1.0 mg/kg total nucleic acid; biodistribution_result: Measured by deep sequencing in heart, liver, spleen, lungs, kidneys; toxicity_profile: Cell viability >85%","High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models","['Lulu Xue', 'Alex G. Hamilton', 'Gan Zhao', 'Zebin Xiao', 'Rakan El-Mayta', 'Xuexiang Han', 'Ningqiang Gong', 'Xinhong Xiong', 'Junchao Xu', 'Christian G. Figueroa-Espada', 'Sarah J. Shepherd', 'Alvin J. Mukalel', 'Mohamad-Gabriel Alameh', 'Jiaxi Cui', 'Karin Wang', 'Andrew E. Vaughan', 'Drew Weissman', 'Michael J. Mitchell']",https://doi.org/10.1038/s41467-024-45422-9,Nature Communications,2024
509,SM-102,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,71.48 °æ 4.33,0.106 °æ 0.016,,92.3 °æ 0.71,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,"firefly_luciferase, epo, cre_recombinase",DMG-PEG 2000,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice, C57BL/6 mice, LSL-tdTomato mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg, 0.01 mg/kg; gene_expression_result: 84.5% protein expression maintained at second administration (hEPO); biodistribution_result: Primarily liver; cytokine_response: Anti-PEG IgM: 639.6 °æ 131.2 U/ml, Complement C5a: 236.1 °æ 52.4 pg/ml",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
510,SM-102,C16-Ceramide-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,82.84 °æ 4.86,0.079 °æ 0.052,,92.9 °æ 0.42,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,"firefly_luciferase, epo, cre_recombinase",C16-PEG 2000 ceramide,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice, C57BL/6 mice, LSL-tdTomato mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg, 0.01 mg/kg; gene_expression_result: 43.4% protein expression maintained at second administration (hEPO); biodistribution_result: Primarily liver; cytokine_response: Anti-PEG IgM: 1817.7 °æ 398.7 U/ml, Complement C5a: 348.7 °æ 89.2 pg/ml, MCP-1: 340.8 °æ 15.6 pg/ml",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
511,244-cis,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:20:52:1.5,69.41 °æ 2.71,0.077 °æ 0.008,,91.7 °æ 2.12,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,"firefly_luciferase, epo, cre_recombinase",C16-PEG 2000 ceramide,244-cis,DOPE,cholesterol,CCCCCC/C=C\COC(=O)CCCCCCCCN1CCN(CC1)CCN(CCCCCCCCC(=O)OC/C=C\CCCCCC)CCCCCCCCC(=O)OC/C=C\CCCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice, C57BL/6 mice, LSL-tdTomato mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg, 0.01 mg/kg; gene_expression_result: 22.2% protein expression maintained at second administration (hEPO), 41.2% (fLuc); biodistribution_result: Primarily liver; cytokine_response: Anti-PEG IgM: 1817.7 °æ 398.7 U/ml, Complement C5a: 348.7 °æ 89.2 pg/ml, MCP-1: 187.0 °æ 45.4 pg/ml",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
512,244-cis,DMG-PEG2000,cholesterol,DOPE,26.5:20:52:1.5,68.29 °æ 7.33,0.110 °æ 0.018,,91.1 °æ 1.70,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,"firefly_luciferase, epo, cre_recombinase",DMG-PEG 2000,244-cis,DOPE,cholesterol,CCCCCC/C=C\COC(=O)CCCCCCCCN1CCN(CC1)CCN(CCCCCCCCC(=O)OC/C=C\CCCCCC)CCCCCCCCC(=O)OC/C=C\CCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice, C57BL/6 mice, LSL-tdTomato mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg, 0.01 mg/kg; gene_expression_result: 70.2% protein expression maintained at second administration (hEPO), 88.0% (fLuc); biodistribution_result: Primarily liver; cytokine_response: Anti-PEG IgM: 639.6 °æ 131.2 U/ml, Complement C5a: 236.1 °æ 52.4 pg/ml",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
513,244-cis,DMG-PEG2000,cholesterol,DOPE,26.5:20:52.4:1.1,78.37 °æ 6.19,0.074 °æ 0.006,,89.5 °æ 1.70,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,"firefly_luciferase, epo, cre_recombinase",DMG-PEG 2000,244-cis,DOPE,cholesterol,CCCCCC/C=C\COC(=O)CCCCCCCCN1CCN(CC1)CCN(CCCCCCCCC(=O)OC/C=C\CCCCCC)CCCCCCCCC(=O)OC/C=C\CCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice, C57BL/6 mice, LSL-tdTomato mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg, 0.01 mg/kg; gene_expression_result: 99.0% protein expression maintained at second administration (hEPO), 101.2% (fLuc); biodistribution_result: Primarily liver; cytokine_response: Anti-PEG IgM: 734.5 °æ 165.3 U/ml, Complement C5a: 91.2 °æ 23.4 pg/ml",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
514,244-cis,DMG-PEG2000,cholesterol,DOPE,26.5:20:52.4:1.0,,,,72.5 °æ 3.54,OTHER:10:1 (ionizable lipid:RNA weight ratio),mRNA,epo,DMG-PEG 2000,244-cis,DOPE,cholesterol,CCCCCC/C=C\COC(=O)CCCCCCCCN1CCN(CC1)CCN(CCCCCCCCC(=O)OC/C=C\CCCCCC)CCCCCCCCC(=O)OC/C=C\CCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Ignite, PNI, Canada; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (lipid phase:RNA phase); aqueous_phase_composition: PBS and 10.0 mM citrate buffer (volume ratio 2:1); organic_phase_composition: Ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: 40-fold dilution in 1°ø PBS, ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, UFC9010); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice; administration_route: IV (intravenous); dose: 0.5 mg/kg, 0.1 mg/kg; gene_expression_result: Low encapsulation efficiency, not suitable for repeated administration",Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics,"['Yeji Lee', 'Michaela Jeong', 'Gyeongseok Lee', 'Jeongeun Park', 'Hyein Jung', 'Seongeun Im', 'Hyukjin Lee']",https://doi.org/10.34133/bmr.0017,Biomaterials Research,2024
574,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,105,0.3,'-10.5,65,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C8-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C",cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA); gene_expression_result: ~2°ø10^7 total flux (liver); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed,Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
575,C9-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,120,0.28,5.2,47,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C9-200,DOPE,cholesterol,CCCCCCCC(O)CN(CCN1CCN(CCN(CC(O)CCCCCCC)CC(O)CCCCCCC)CC1)CCN(CC(O)CCCCCCC)CC(O)CCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~3°ø10^8 total flux (liver, FLuc); 35% indels (Cas9); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
576,C10-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,85,0.18,'-4.2,95,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C10-200,DOPE,cholesterol,OC(CN(CCN1CCN(CC1)CCN(CC(O)CCCCCCCC)CC(O)CCCCCCCC)CCN(CC(O)CCCCCCCC)CC(O)CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~1°ø10^9 total flux (liver, FLuc) - 10-fold increase vs C12-200; biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
577,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,90,0.16,7.8,62,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C11-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~1°ø10^8 total flux (liver, FLuc); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
578,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,82,0.22,'-9.8,87,OTHER:10:1 weight ratio (IL:mRNA),mRNA,"firefly_luciferase, epo, cas9",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~1°ø10^8 total flux (liver, FLuc); ~10,000 mU/mL EPO at 6h; 10% indels (Cas9); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
579,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,88,0.19,9.2,74,OTHER:10:1 weight ratio (IL:mRNA),mRNA,"firefly_luciferase, epo",C14-PEG2000,C13-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~1°ø10^8 total flux (liver, FLuc); ~15,000 mU/mL EPO at 6h (similar to C12-200); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
580,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,108,0.33,'-5.1,68,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C14-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.1 mg/kg (EPO mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~5°ø10^7 total flux (liver, FLuc); biodistribution_result: primarily liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
581,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,98,0.24,'-5.2,50,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C15-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: no enhancement relative to PBS negative control (FLuc); <2% indels (Cas9); biodistribution_result: poor liver targeting; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
582,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,95,0.21,'-6.1,58,OTHER:10:1 weight ratio (IL:mRNA),mRNA,firefly_luciferase,C14-PEG2000,C16-200,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic herringbone mixing devices; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer at pH 3; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20 kDa molecular weight cutoff dialysis cassettes for 2 h and sterile filtered through 0.22 •Ïm syringe filters; sterilization: 0.22 •Ïm sterile filtration; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HepG2; animal_model: BALB/cJ female mice (6-8 weeks old); administration_route: IV (lateral tail vein); dose: 0.1 mg/kg (FLuc mRNA), 0.5 mg/kg (Cas9 mRNA); gene_expression_result: ~3°ø10^7 total flux (liver, FLuc); <2% indels (Cas9); biodistribution_result: reduced liver targeting compared to shorter chain ILs; toxicity_profile: no significant cytotoxicity observed",Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length,"['Kaitlin Mrksich', 'Marshall S. Padilla', 'Ryann A. Joseph', 'Emily L. Han', 'Dongyoon Kim', 'Rohan Palanki', 'Junchao Xu', 'Michael J. Mitchell']",10.1002/jbm.a.37705,Journal of Biomedical Materials Research Part A,2024
641,DOTAP,DSG-PEG2000,cholesterol,DOPE,46.3:9.4:41.8:2.5,66.55,0.12,1.34,93.176,NP:10(molar),mRNA,nanoluciferase,DSG,DOTAP,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
642,DOTAP,DMG,cholesterol,DSPE,46.3:9.4:42.7:1.6,78.57,0.107,1.97,92.391,NP:8(molar),mRNA,nanoluciferase,DMG,DOTAP,DSPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
643,DOTAP,DPPE-PEG2000,cholesterol,DMPC,50:10:38.4:1.6,96.95,0.071,2.33,96.439,NP:10(molar),mRNA,nanoluciferase,DPPE,DOTAP,DMPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
644,DOTAP,C16-Ceramide-PEG2000,cholesterol,DOPC,50:10:38.5:1.5,94.42,0.069,3.09,95.558,NP:6(molar),mRNA,nanoluciferase,Ceramide,DOTAP,DOPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
645,DOTAP,C16-Ceramide-PEG2000,cholesterol,DSPC,50:10:38.4:1.6,92.45,0.099,3.26,91.141,NP:6(molar),mRNA,nanoluciferase,Ceramide,DOTAP,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
646,DOTMA,DMG,cholesterol,DLPE,50:10:38.4:1.6,75.26,0.212,0.43,93.162,NP:10(molar),mRNA,nanoluciferase,DMG,DOTMA,DLPE,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN)OC(=O)CCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
647,DOTMA,DPPE-PEG2000,cholesterol,DOPE,50:10:38.5:1.5,77.76,0.208,0.87,91.161,NP:8(molar),mRNA,nanoluciferase,DPPE,DOTMA,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
648,DOTMA,DPPE-PEG2000,cholesterol,DSPE,50:10:38.4:1.6,78.82,0.178,0.96,92.526,NP:6(molar),mRNA,nanoluciferase,DPPE,DOTMA,DSPE,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
649,DOTMA,DSG-PEG2000,cholesterol,DMPC,50:10:38.5:1.5,82.88,0.258,2.09,92.043,NP:6(molar),mRNA,nanoluciferase,DSG,DOTMA,DMPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
650,DOTMA,DSG-PEG2000,cholesterol,DOPC,46.3:9.4:42.7:1.6,69.44,0.222,0.8,90.146,NP:10(molar),mRNA,nanoluciferase,DSG,DOTMA,DOPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
651,DOTMA,C16-Ceramide-PEG2000,cholesterol,DSPC,50:10:37.5:2.5,82.11,0.233,1.74,92.571,NP:8(molar),mRNA,nanoluciferase,Ceramide,DOTMA,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
652,DODAP,DPPE-PEG2000,cholesterol,DLPE,46.3:9.4:41.8:2.5,51.13,0.087,0.47,91.816,NP:6(molar),mRNA,nanoluciferase,DPPE,DODAP,DLPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN)OC(=O)CCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
653,DODAP,DMG,cholesterol,DOPE,46.3:9.4:42.7:1.6,50.99,0.073,0.97,93.363,NP:6(molar),mRNA,nanoluciferase,DMG,DODAP,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
654,DODAP,C16-Ceramide-PEG2000,cholesterol,DSPE,50:10:38.5:1.5,51.89,0.067,0.64,91.361,NP:10(molar),mRNA,nanoluciferase,Ceramide,DODAP,DSPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
655,DODAP,DMG,cholesterol,DMPC,50:10:37.5:2.5,57.25,0.203,0.61,90.261,NP:8(molar),mRNA,nanoluciferase,DMG,DODAP,DMPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
656,DODAP,DMG,cholesterol,DOPC,50:10:37.5:2.5,57,0.211,0.59,93.491,NP:10(molar),mRNA,nanoluciferase,DMG,DODAP,DOPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
657,DODAP,DSG-PEG2000,cholesterol,DSPC,50:10:38.4:1.6,57.13,0.198,1,90.138,NP:8(molar),mRNA,nanoluciferase,DSG,DODAP,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
658,DLin-MC3-DMA,DSG-PEG2000,cholesterol,DLPE,50:10:38.4:1.6,55.88,0.32,0.84,79.216,NP:8(molar),mRNA,nanoluciferase,DSG,MC3,DLPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN)OC(=O)CCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
659,DLin-MC3-DMA,C16-Ceramide-PEG2000,cholesterol,DOPE,50:10:37.5:2.5,57.44,0.374,0.16,74.532,NP:10(molar),mRNA,nanoluciferase,Ceramide,MC3,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
660,DLin-MC3-DMA,DSG-PEG2000,cholesterol,DSPE,50:10:37.5:2.5,56.43,0.331,1.12,84.168,NP:6(molar),mRNA,nanoluciferase,DSG,MC3,DSPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
661,DLin-MC3-DMA,C16-Ceramide-PEG2000,cholesterol,DMPC,46.3:9.4:42.7:1.6,51.82,0.149,0.86,75.923,NP:8(molar),mRNA,nanoluciferase,Ceramide,MC3,DMPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 20; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
662,DLin-MC3-DMA,DPPE-PEG2000,cholesterol,DOPC,50:10:38.4:1.6,56.13,0.156,0.84,80.542,NP:8(molar),mRNA,nanoluciferase,DPPE,MC3,DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 4:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
663,DLin-MC3-DMA,DPPE-PEG2000,cholesterol,DSPC,46.3:8.4:42.8:2.5,51.08,0.146,0.16,77.349,NP:10(molar),mRNA,nanoluciferase,DPPE,MC3,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
664,DLin-MC3-DMA,DMG,cholesterol,DSPC,50:10:38.5:1.5,54.7,0.09,1.12,85.416,NP:6(molar),mRNA,nanoluciferase,DMG,MC3,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Benchtop; total_flow_rate_ml_min: 15; flow_rate_ratio: 5:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.5); organic_phase_composition: ethanol (>99.5%); mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis against 10 mM Tris buffer (pH 7.4) for 24 h, concentrated using centrifuge at 5000 g for 30 min, filtered with PALL capsule (MWCO 300 kD); sterilization: glassware sterilized at 300°∆C for 12 h, equipment treated with RNaseZap; storage_buffer: 10 mM Tris buffer (pH 7.4)",,Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost/Bayesian method and ensemble model approaches,"['Ravi Maharjan', 'Ki Hyun Kim', 'Kyeong Lee', 'Hyo-Kyung Han', 'Seong Hoon Jeong']",https://doi.org/10.1016/j.jpha.2024.100996,Journal of Pharmaceutical Analysis,2024
846,Custom lipid,DMG-PEG2000,cholesterol,DOPE,15:2:25:20,80,0.15,'-8.5,,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DOPE,cholesterol,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: 97.9% liver expression; biodistribution_result: Liver (97.9%), Spleen (1.5%), Lung (0.4%), Heart (0.1%), Kidney (0.1%); toxicity_profile: well tolerated",Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
847,Custom lipid,DMG-PEG2000,cholesterol,DOPE,15:2:25:20,85,0.18,'-8,,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,5Ac1-C12,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver-targeted expression; biodistribution_result: primarily liver; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
848,Custom lipid,DMG-PEG2000,,DOTAP,60:1.2:0:60,115,0.09,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DOTAP,,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
849,Custom lipid,DMG-PEG2000,cholesterol,DOTAP,60:1.2:40:60,120,0.08,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DOTAP,cholesterol,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
850,Custom lipid,DMG-PEG2000,cholesterol,DOPE + DOTAP,15:2:25:20+62,95,0.1,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DOPE + DOTAP,cholesterol,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
851,Custom lipid,DMG-PEG2000,,DDAB,50:0.2:0:40,75,0.13,4.8,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DDAB,,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
852,Custom lipid,DMG-PEG2000,cholesterol,DDAB,50:0.2:50:40,92,0.19,3.5,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C12,DDAB,cholesterol,CCCCCCCCCCCCN(C)C(=O)CCCOC(COC(=O)CCCN(C)CCCCCCCCCCCC)(COC(=O)CCCN(C)CCCCCCCCCCCC)OC(=O)CCCN(C)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
853,Custom lipid,DMG-PEG2000,cholesterol,DOPE,15:2:25:20,82,0.16,'-7.2,,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,2Ac3-C18,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: spleen-specific expression; biodistribution_result: primarily spleen; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
854,SM-102,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,85,0.14,'-6.8,,,mRNA,firefly_luciferase,DMG-PEG2000,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v. and i.m.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver expression (i.v.), muscle expression (i.m.); biodistribution_result: primarily liver (i.v.); toxicity_profile: well tolerated",Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
855,SM-102,DMG-PEG2000,,DOTAP,60:1.2:0:60,110,0.09,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,SM-102,DOTAP,,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
856,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:1.6:42.7:9.4,88,0.13,'-6.5,,,mRNA,firefly_luciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v. and i.m.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver expression (i.v.), muscle expression (i.m.); biodistribution_result: primarily liver (i.v.); toxicity_profile: well tolerated",Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
857,ALC-0315,DMG-PEG2000,,DOTAP,60:1.2:0:60,108,0.09,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,ALC-0315,DOTAP,,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
858,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,92,0.15,'-7,,,mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v. and i.m.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver expression (i.v.), muscle expression (i.m.); biodistribution_result: primarily liver (i.v.); toxicity_profile: well tolerated",Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
859,DLin-MC3-DMA,DMG-PEG2000,,DOTAP,60:1.2:0:60,112,0.1,,~90,WR:20(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DOTAP,,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: lung-specific expression; biodistribution_result: primarily lung; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
860,Custom lipid,DMG-PEG2000,cholesterol,DOPE,15:2:25:20,78,0.14,'-6.2,,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C8,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver-targeted expression; biodistribution_result: primarily liver; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
861,Custom lipid,DMG-PEG2000,cholesterol,DOPE,15:2:25:20,95,0.21,'-9.5,,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,6Ac1-C18,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 10 mM sodium citrate buffer, pH 4.0; organic_phase_composition: 100% ethanol; mixing_time_sec: 900; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 2 h; sterilization: ; storage_buffer: 1°ø PBS",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: i.v.; dose: 0.25 mg/kg mRNA; gene_expression_result: liver-targeted expression; biodistribution_result: primarily liver; toxicity_profile: well tolerated,Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation,"['Kexin Su', 'Lu Shi', 'Tao Sheng', 'Xinxin Yan', 'Lixin Lin', 'Chaoyang Meng', 'Shiqi Wu', 'Yuxuan Chen', 'Yao Zhang', 'Chaorong Wang', 'Zichuan Wang', 'Junjie Qiu', 'Jiahui Zhao', 'Tengfei Xu', 'Yuan Ping', 'Zhen Gu', 'Shuai Liu']",https://doi.org/10.1038/s41467-024-50093-7,Nature Communications,2024
911,SM-102,DMG-PEG2000,cholesterol,DSPC,50:38.5:10:1.5,63.5 °æ 0.6,,,95.0 °æ 2.0,NP:6(molar),mRNA,"firefly_luciferase, gfp",DMG-PEG2000,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoGenerator Flex; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM citrate buffer (pH 4.0); organic_phase_composition: anhydrous ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: ultrafiltration at 3,000 rpm using 100 kDa MWCO Millipore filter; sterilization: ; storage_buffer: Tris buffer (pH 7.4)",cell_line: HEK293T; dose: 20 •ÏL of mRNA-LNP suspension per well; gene_expression_result: 4.0°ø10^8 normalized RLU,Structural Characterization of mRNA Lipid Nanoparticles in the Presence of Intrinsic Drug-free Lipid Nanoparticles,"['Xiaoxia Chen', 'Yongfeng Ye', 'Mengrong Li', 'Taisen Zuo', 'Zhenhua Xie', 'Yubin Ke', 'He Cheng', 'Liang Hong', 'Zhuo Liu']",https://doi.org/10.1101/2024.09.27.614859,bioRxiv,2024
912,SM-102,DMG-PEG2000,cholesterol,DSPC,50:38.5:10:1.5,47.8 °æ 2.0,,,,,empty,empty,DMG-PEG2000,SM-102,DSPC (d70-DSPC for SANS),cholesterol (d7-cholesterol for SANS),CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoGenerator Flex; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 100 mM sodium citrate buffer (pH 4.0); organic_phase_composition: anhydrous ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: ultrafiltration at 3,000 rpm using 30 kDa MWCO Millipore filter; sterilization: ; storage_buffer: Tris buffer (pH 7.4)",,Structural Characterization of mRNA Lipid Nanoparticles in the Presence of Intrinsic Drug-free Lipid Nanoparticles,"['Xiaoxia Chen', 'Yongfeng Ye', 'Mengrong Li', 'Taisen Zuo', 'Zhenhua Xie', 'Yubin Ke', 'He Cheng', 'Liang Hong', 'Zhuo Liu']",https://doi.org/10.1101/2024.09.27.614859,bioRxiv,2024
932,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,77-350,0.05-0.39,,35-98,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision Nanosystems); total_flow_rate_ml_min: 1-4; flow_rate_ratio: 1:1 to 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH with dissolved lipids; mixing_time_sec: ; temperature_condition: 2-8°∆C during dialysis; post_processing: Two-stage dialysis: first against PBS (pH 7.5) for 6h at 2-8°∆C, then against 8% sucrose/20 mM Tris buffer (pH 7.5) overnight at 2-8°∆C. Concentration via ultrafiltration (100 kDa MWCO); sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Luciferase expression varied by particle size, with medium-sized LNPs (105 nm) showing highest expression",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
933,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,83,0.121,,96,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: 4.0; flow_rate_ratio: 25% EtOH (flow rate ratio 3:1); aqueous_phase_composition: 50 mM sodium citrate buffer, pH 4.0; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C (dilution with citrate buffer then dialysis); sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Target ~80 nm particle size achieved via Bayesian optimization",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
934,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,77,0.081,,96,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: 4.0; flow_rate_ratio: 25% EtOH (flow rate ratio 3:1); aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Target ~80 nm particle size achieved via Bayesian optimization",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
935,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,200,0.058,,97,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: 2.5; flow_rate_ratio: 44% EtOH; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Target ~200 nm particle size achieved via Bayesian optimization",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
936,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,186,0.072,,97,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: 2.5; flow_rate_ratio: 45% EtOH; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Target ~200 nm particle size achieved via Bayesian optimization",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
937,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,81,0.109,,96,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Small size category for protein expression studies",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
938,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,109,0.053,,96,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Medium size category showed highest protein expression levels",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
939,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,139,0.057,,92,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Large size category for protein expression studies",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
940,L202,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,199,0.062,,97,WR:0.05(wt/wt)[mRNA:lipi],mRNA,firefly_luciferase,mPEG2000-DMG,L202,DSPC,cholesterol,CCCCCCCCCCC(CCCCCCCCC(=O)OCCC(CCCCC)CCCCC)COC(=O)C1CCN(CC1)C,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer, pH 3.5; organic_phase_composition: EtOH; mixing_time_sec: ; temperature_condition: 2-8°∆C; post_processing: Two-stage dialysis with Method C; sterilization: ; storage_buffer: 8% sucrose/20 mM Tris buffer (pH 7.5)","cell_line: Hep3B, Huh7; dose: 100 ng/mL and 500 ng/mL mRNA; gene_expression_result: Extra-large size category showed lowest protein expression levels",Understanding the Manufacturing Process of Lipid Nanoparticles for mRNA Delivery Using Machine Learning,"['Shinya Sato', 'Syusuke Sano', 'Hiroki Muto', 'Kenji Kubara', 'Keita Kondo', 'Takayuki Miyazaki', 'Yuta Suzuki', 'Yoshifumi Uemoto', 'Koji Ukai']",https://doi.org/10.1248/cpb.c24-00089,Chemical and Pharmaceutical Bulletin,2024
555,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:1.5:42.7:9.5,104,0.012,,90,CONC:0.27(mg/mL)[pDNA],DNA,bnt162b2_pdna,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Batch (pipetting); device_used: Pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer at pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: 50 mM sodium citrate buffer at pH 4,,Formulation of Nucleic Acids by Encapsulation in Lipid Nanoparticles for Continuous Production of mRNA,"['Alina Hengelbrock', 'Axel Schmidt', 'Jochen Strube']",https://doi.org/10.3390/pr11061718,Processes,2023
556,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:1.5:42.7:9.5,96-104,0.012-0.017,,,,empty,empty,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Batch (pipetting); device_used: Pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer at pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: 50 mM sodium citrate buffer at pH 4,,Formulation of Nucleic Acids by Encapsulation in Lipid Nanoparticles for Continuous Production of mRNA,"['Alina Hengelbrock', 'Axel Schmidt', 'Jochen Strube']",https://doi.org/10.3390/pr11061718,Processes,2023
557,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:1.5:42.7:9.5,120,0.027,,32,CONC:0.27(mg/mL)[pDNA],DNA,bnt162b2_pdna,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Batch (pipetting); device_used: Pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM sodium citrate buffer at pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: 50 mM sodium citrate buffer at pH 4,,Formulation of Nucleic Acids by Encapsulation in Lipid Nanoparticles for Continuous Production of mRNA,"['Alina Hengelbrock', 'Axel Schmidt', 'Jochen Strube']",https://doi.org/10.3390/pr11061718,Processes,2023
558,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:1.5:42.7:9.5,71,0.004,,88,,DNA,bnt162b2_pdna,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Continuous (T-mixer); device_used: T-mixer; total_flow_rate_ml_min: 12; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 50 mM sodium citrate buffer at pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: TFF/UF/DF with 9 diavolumes, buffer exchange to 1X PBS pH 7.4; sterilization: ; storage_buffer: 1X PBS pH 7.4",,Formulation of Nucleic Acids by Encapsulation in Lipid Nanoparticles for Continuous Production of mRNA,"['Alina Hengelbrock', 'Axel Schmidt', 'Jochen Strube']",https://doi.org/10.3390/pr11061718,Processes,2023
622,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,106.97 °æ 1.69,0.10 °æ 0.02,,94.84 °æ 3.48,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,"luciferase, mcherry, vegf",C14-PEG2000,A1 (C12 epoxide + polyamine core 1),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; animal_model: Non-pregnant and pregnant mice (E16); administration_route: IV (tail vein injection); dose: 0.6 mg mRNA/kg body mass (luciferase), 1 mg mRNA/kg (mCherry, VEGF); gene_expression_result: Normalized luciferase expression in JEG-3 cells; biodistribution_result: Primarily liver and spleen delivery; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
623,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,100.77 °æ 1.75,0.13 °æ 0.01,,89.74 °æ 2.62,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,A2 (C12 epoxide + polyamine core 2),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
624,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,97.96 °æ 0.78,0.11 °æ 0.01,,88.11 °æ 2.93,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,A3 (C12 epoxide + polyamine core 3),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
625,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,93.44 °æ 1.18,0.16 °æ 0.01,,94.86 °æ 1.59,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,"luciferase, mcherry, vegf",C14-PEG2000,A4 (C12 epoxide + polyamine core 4),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; animal_model: Non-pregnant and pregnant mice (E16); administration_route: IV (tail vein injection); dose: 0.6 mg mRNA/kg body mass (luciferase), 1 mg mRNA/kg (mCherry, VEGF); gene_expression_result: Highest luciferase expression in JEG-3 cells, 4.58% mCherry+ trophoblasts; biodistribution_result: 81% of total luminescent flux from placental delivery, extrahepatic delivery to spleen; toxicity_profile: No significant liver toxicity (ALT/AST levels), minimal placental inflammation; cytokine_response: Elevated cytokines at 6h, resolved by 48h",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
626,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,116.60 °æ 1.77,0.19 °æ 0.02,,93.77 °æ 2.41,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,A5 (C12 epoxide + polyamine core 5),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
627,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,114.57 °æ 2.88,0.13 °æ 0.01,,75.34 °æ 7.00,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,B1 (C14 epoxide + polyamine core 1),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
628,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,96.88 °æ 0.59,0.12 °æ 0.01,,86.34 °æ 4.47,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,B2 (C14 epoxide + polyamine core 2),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Significantly higher luciferase expression than Lipofectamine; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
629,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,94.61 °æ 0.75,0.12 °æ 0.01,,84.45 °æ 3.16,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,B3 (C14 epoxide + polyamine core 3),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
630,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,101.10 °æ 1.71,0.14 °æ 0.01,,77.28 °æ 4.41,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,B4 (C14 epoxide + polyamine core 4),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
631,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,120.03 °æ 2.67,0.20 °æ 0.02,,93.77 °æ 1.79,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,"luciferase, mcherry",C14-PEG2000,B5 (C14 epoxide + polyamine core 5),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; animal_model: Non-pregnant and pregnant mice (E16); administration_route: IV (tail vein injection); dose: 0.6 mg mRNA/kg body mass (luciferase), 1 mg mRNA/kg (mCherry); gene_expression_result: Significantly higher luciferase expression than Lipofectamine; biodistribution_result: 79% of total luminescent flux from placental delivery, extrahepatic delivery to spleen; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
632,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,101.80 °æ 1.41,0.14 °æ 0.01,,74.39 °æ 5.74,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,C2 (C16 epoxide + polyamine core 2),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Significantly higher luciferase expression than Lipofectamine; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
633,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,102.97 °æ 2.21,0.13 °æ 0.01,,73.75 °æ 4.41,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,C3 (C16 epoxide + polyamine core 3),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
634,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,129.77 °æ 4.22,0.24 °æ 0.02,,71.51 °æ 6.32,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,C14-PEG2000,C5 (C16 epoxide + polyamine core 5),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Normalized luciferase expression in JEG-3 cells; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
635,C12-200,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,82.11 °æ 3.28,0.11 °æ 0.01,,88.31 °æ 2.47,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,"luciferase, mcherry, vegf",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; animal_model: Non-pregnant and pregnant mice (E16); administration_route: IV (tail vein injection); dose: 0.6 mg mRNA/kg body mass (luciferase), 1 mg mRNA/kg (mCherry, VEGF); gene_expression_result: Lower than A4 and B5 in JEG-3 cells, 2.44% mCherry+ endothelial cells; biodistribution_result: Primarily liver delivery (44-51% of total flux), 23% placental delivery; toxicity_profile: Significant AST elevation (3.5-fold vs PBS), hepatic toxicity; cytokine_response: Elevated cytokines at 6h, resolved by 48h",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
636,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,92.32 °æ 2.42,0.09 °æ 0.01,,89.45 °æ 2.47,OTHER:10:1 ratio of ionizable lipid: mRNA weight ratio,mRNA,luciferase,DMG-PEG,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 •Ïg luciferase mRNA in 10 mM citrate buffer (pH = 3); organic_phase_composition: Ethanol phase with lipids; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1X PBS with 20 kDa MWCO for 2 h; sterilization: 0.22 •Ïm filter; storage_buffer: Stored at 4°∆C,"cell_line: JEG-3 choriocarcinoma cells; dose: 50 ng mRNA per 25,000 cells; gene_expression_result: Lower luciferase expression compared to top performers; toxicity_profile: No significant decrease in cell viability vs Lipofectamine",Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy,"['Kelsey L. Swingle', 'Hannah C. Safford', 'Hannah C. Geisler', 'Alex G. Hamilton', 'Ajay S. Thatte', 'Margaret M. Billingsley', 'Ryann A. Joseph', 'Kaitlin Mrksich', 'Marshall S. Padilla', 'Aditi A. Ghalsasi', 'Mohamad-Gabriel Alameh', 'Drew Weissman', 'Michael J. Mitchell']",10.1021/jacs.2c12893,Journal of the American Chemical Society,2023
756,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,107,0.02,'-3.3,96,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice (6-8 weeks old, female); administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
757,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:3,97,0.004,'-4.2,96,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
758,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:5,83,0.03,'-8.8,76,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
759,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:10,78,0.05,'-3.1,42,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
760,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:15,77,0.09,'-3.8,26,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
761,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:25,75,0.11,'-2.5,18,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
762,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:50,69,0.15,'-0.7,10,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
763,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:1.5,145,0.1,'-4.3,94,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
764,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:3,113,0.11,'-3.7,92,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
765,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:5,98,0.04,'-4,82,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
766,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:10,78,0.07,'-4.6,45,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
767,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:15,71,0.12,'-5,29,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
768,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:25,67,0.14,'-0.9,19,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
769,AX4,DMG-PEG2000,cholesterol,DOPE,50:10:38.5:50,63,0.09,'-2.3,10,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
770,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:5:5,147,0.12,'-16.6,19,NP:9(molar)/1,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
771,AX4,DMG-PEG2000,cholesterol,DSPC,50:10:100:5,70,0.13,'-7.4,95,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
772,AX4,DMG-PEG2000,cholesterol,DSPC,20:10:100:5,61,0.23,'-3.8,95,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
773,AX4,DMG-PEG2000,cholesterol,DSPC,35:16:46.5:2.5,71,0.05,'-1.6,96,,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4) or 20 mM Tris-HCl (pH 7.4) with trehalose","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Superior luciferase expression after SMI atomization compared to vibrating mesh nebulizer; biodistribution_result: Lung targeting after I.T., liver accumulation after I.M.",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
774,AX4,DMG-PEG2000,cholesterol,DSPC,35:16:46.5:5,62,0.11,'-4.2,95,NP:9(molar)/1,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
775,AX4,DMG-PEG2000,cholesterol,DSPC,35:16:46.5:5,61,0.15,'-3.4,95,NP:18(molar)/1,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
776,AX4,DMG-PEG2000,cholesterol,DSPC,35:16:46.5:5,54,0.07,'-5.7,94,NP:27(molar)/1,mRNA,firefly_luciferase,DMG-PEG2K,AX4,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)C)CCC(OCCCCOC(C(CCCCCC)CCCC)=O)=O)OCCCCOC(C(CCCCCC)CCCC)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)","animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Luciferase expression measured by IVIS imaging; biodistribution_result: Accumulation in liver, spleen, lungs",Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
777,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,,,,,,mRNA,"firefly_luciferase, rbd",DMG-PEG2K,MC3 (Dlin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: INano L, Micro&Nano Technology Inc, China; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (water:oil); aqueous_phase_composition: 10 mM citrate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis with 150 mM PBS (pH 7.4) through 100 kDa MWCO; sterilization: ; storage_buffer: 150 mM PBS (pH 7.4)",animal_model: BALB/c mice; administration_route: I.M. and I.T.; dose: 20 •Ïg mRNA per mouse; gene_expression_result: Compared with AX4-based LNPs for atomization studies; biodistribution_result: Standard reference for comparison,Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA,"['Hao Miao', 'Ke Huang', 'Yingwen Li', 'Renjie Li', 'Xudong Zhou', 'Jingyu Shi', 'Zhenbo Tong', 'Zhenhua Sun', 'Aibing Yu']",https://doi.org/10.1016/j.ijpharm.2023.123050,International Journal of Pharmaceutics,2023
778,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DPPC,60:20:19:1,118.9,0.168,5.5,91.5,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,MC3,DPPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI), 750 ng NLuc mRNA (in vivo); gene_expression_result: ~30,000 RLU (ALI), 4.8°ø10^5 photons/sec/cm©˜/sr (in vivo); biodistribution_result: Distributed across all lung lobes",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
779,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,109.9,0.154,7,92.8,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,MC3,DPPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI), 750 ng NLuc mRNA (in vivo); gene_expression_result: ~120,000 RLU (ALI), 1.4°ø10^6 photons/sec/cm©˜/sr (in vivo); biodistribution_result: Distributed across all lung lobes",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
780,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DPPC,45:5:49:1,112.9,0.152,6.7,93.4,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,MC3,DPPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~80,000 RLU (ALI)",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
781,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,123.3,0.153,1.7,87.2,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMG-PEG 2000,MC3,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI), 750 ng NLuc mRNA (in vivo); gene_expression_result: ~90,000 RLU (ALI), 1.2°ø10^6 photons/sec/cm©˜/sr (in vivo); biodistribution_result: Distributed across all lung lobes",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
782,SM-102,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,109.8,0.162,10.3,93.9,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo (NLuc), 150 ng/•ÏL for Cre, 100 ng/•ÏL for TEM/NGI",mRNA,"nanoluciferase, cre_recombinase",DMPE-PEG 2000,SM-102,DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; animal_model: BALB/c mice (female, 6-8 weeks), Ai9 mice (female, 6-8 weeks); administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI), 750 ng NLuc mRNA (in vivo), 0.5 mg/kg Cre mRNA; gene_expression_result: ~150,000 RLU (ALI), 8.1°ø10^6 photons/sec/cm©˜/sr (in vivo); biodistribution_result: Distributed across all lung lobes with highest expression",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
783,SM-102,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,111.2,0.172,3.8,89.8,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMG-PEG 2000,SM-102,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~50,000 RLU (ALI)",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
784,ALC-0315,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,108.1,0.166,8.7,91.2,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,ALC-0315,DPPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~40,000 RLU (ALI)",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
785,ALC-0315,ALC-0159,cholesterol,DSPC,46.3:9.4:42.7:1.6,113.9,0.174,4.2,88.7,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,ALC-0159,ALC-0315,DSPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCN(CCCCCCCCCC(=O)OC)CC(O)COC(=O)CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~25,000 RLU (ALI)",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
786,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,,,,,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,"SM-102 analog (BP-26399, 3-carbon head)",DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~300,000 RLU (ALI), 2.0-fold increase vs B-1",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
787,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,,,,,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,"SM-102 analog (BP-26367, modified ester position)",DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~200,000 RLU (ALI), 1.3-fold increase vs B-1",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
788,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,,,,,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,"SM-102 analog (BP-26361, modified ester position)",DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~200,000 RLU (ALI), 1.3-fold increase vs B-1",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
789,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,,,,,"NP:5.67(molar), 15 ng/•ÏL for in vitro/vivo, 100 ng/•ÏL for TEM/NGI",mRNA,nanoluciferase,DMPE-PEG 2000,"SM-102 analog (BP-26371, modified alkyl tail)",DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixer (Precision Nanosystems); total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS pH 7.4 overnight using 10-kDa MWCO Slide-A-Lyzer G2 Dialysis Cassettes; sterilization: ; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: ALI Calu-3 cells; administration_route: Intratracheal (after aerosolization); dose: 1000 ng NLuc mRNA (ALI); gene_expression_result: ~60,000 RLU (ALI), no significant difference vs B-1",Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles,"['Mae M. Lewis', 'Melissa R. Soto', 'Esther Y. Maier', 'Steven D. Wulfe', 'Sandy Bakheet', 'Hannah Obregon', 'Debadyuti Ghosh']",10.1002/btm2.10580,Bioengineering & Translational Medicine,2023
875,SM-102,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,78.7,,,88,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,SM-102,DPPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 6.0°ø10^7 RLU (HEK293T), 3.0°ø10^7 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
876,ALC-0315,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,92.16,,,84,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,ALC-0315,DPPC,cholesterol,CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCO,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 6.0°ø10^7 RLU (HEK293T), 1.0°ø10^7 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
877,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,85.05,,,93,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,BP 114 (SM-102 analog with 9-carbon single chain tail),DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 6.0°ø10^7 RLU (HEK293T), 3.0°ø10^7 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
878,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,81.65,,,91,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,BP 113 (SM-102 analog with 7-carbon single chain tail),DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 6.0°ø10^7 RLU (HEK293T), 3.0°ø10^6 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
879,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,93.4,,,93,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,BP 142 (SM-102 analog with 3-carbon head),DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 7.0°ø10^7 RLU (HEK293T), 2.0°ø10^7 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
880,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,87.39,,,90,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,BP 223 (ALC-0315 analog with 5-carbon head),DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 4.0°ø10^7 RLU (HEK293T), 2.0°ø10^6 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
881,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,87.48,,,90,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,BP 226 (ALC-0315 analog with 2-carbon head),DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 2.0°ø10^7 RLU (HEK293T), 5.0°ø10^6 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
882,Custom lipid,DMPE-PEG2000,cholesterol,DPPC,45:20:34:1,62.6,,,78,"NP:5.67(molar), mRNA concentration 10 ng/•ÏL",mRNA,nanoluciferase,DMPE-PEG 2000,"BP 227 (ALC-0315 analog with 2-carbon head, 8-carbon tails)",DPPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium citrate buffer (pH 3.0); organic_phase_composition: 100% EtOH; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1x PBS for 4 hours using 10 kDa MWCO; sterilization: ; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HEK293T, A549; dose: 100 ng mRNA per well; gene_expression_result: 5.0°ø10^6 RLU (HEK293T), 6.0°ø10^7 RLU (A549)",Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNA,"['Mae M. Lewis', 'Travis J. Beck', 'Debadyuti Ghosh']",https://doi.org/10.1101/2023.11.09.565872,bioRxiv,2023
913,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:35:5,52 °æ 2 (TDA); 93 °æ 3 (DLS),0.004 °æ 0.002 (TDA); 0.148 °æ 0.041 (DLS),,79 (TDA with RiboGreen); 75 (SpectraMax i3k),"OTHER:12.3 •Ïg/mL free mRNA, 60.7 •Ïg/mL total mRNA",mRNA,firefly_luciferase,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4, mRNA at 0.25 g/L; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
914,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,86 °æ 3 (TDA); 128 °æ 2 (DLS),0.011 °æ 0.007 (TDA); 0.112 °æ 0.045 (DLS),,,,mRNA,firefly_luciferase,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4, mRNA at 0.25 g/L; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
915,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:39.5:0.5,216 °æ 4 (TDA); 239 °æ 3 (DLS),0.017 °æ 0.005 (TDA); 0.099 °æ 0.048 (DLS),,95 (TDA with RiboGreen); 94 (SpectraMax i3k),"OTHER:3.2 •Ïg/mL free mRNA, 62.1 •Ïg/mL total mRNA",mRNA,firefly_luciferase,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4, mRNA at 0.25 g/L; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
916,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,83 °æ 5 (TDA); 85 °æ 2 (DLS),0.011 °æ 0.007 (TDA); 0.152 °æ 0.036 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 6; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
917,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,97 °æ 4 (TDA); 117 °æ 2 (DLS),0.009 °æ 0.003 (TDA); 0.171 °æ 0.012 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
918,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,114 °æ 3 (TDA); 144 °æ 1 (DLS),0.015 °æ 0.015 (TDA); 0.166 °æ 0.022 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 2; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
919,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,121 °æ 5 (TDA); 191 °æ 6 (DLS),0.032 °æ 0.023 (TDA); 0.151 °æ 0.035 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 1; flow_rate_ratio: 3:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
920,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,79 °æ 4 (TDA); 91 °æ 3 (DLS),0.001 °æ 0.001 (TDA); 0.156 °æ 0.024 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 5:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
921,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,100 °æ 5 (TDA); 132 °æ 2 (DLS),0.064 °æ 0.006 (TDA); 0.141 °æ 0.008 (DLS),,,,empty,empty,DMG-PEG-2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr IgniteTM; total_flow_rate_ml_min: 4; flow_rate_ratio: 2:1; aqueous_phase_composition: 50 mM citrate buffer, pH 4; organic_phase_composition: absolute ethanol with lipids; mixing_time_sec: ; temperature_condition: 25°∆C; post_processing: dialysis overnight against 500 mL 50 mM citrate buffer pH 4, then two successive dialysis against 500 mL PBS pH 7.4; sterilization: filtered using 0.2 or 0.45 micrometer filters; storage_buffer: PBS pH 7.4, stored at +5°∆C",,Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines,"['Camille Malburet', 'Laurent Leclercq', 'Jean-Francois Cotte', 'Jerome Thiebaud', 'Emilie Bazin', 'Marie Garinot', 'Herve Cottet']",https://doi.org/10.1038/s41434-022-00370-1,Gene Therapy,2023
922,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~70,,,>85,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,firefly_luciferase,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 1x chip; total_flow_rate_ml_min: 1.1-1.2; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA (74 •Ïg/mL) in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS in 20-kDa MWCO dialysis cassettes for 2h, filtered by 0.22-•Ïm PES filters; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HepG2 cells; animal_model: C57BL/6 mice; administration_route: intramuscular; dose: 50 ng per 5,000 cells (in vitro), 5 •Ïg per mouse (in vivo); gene_expression_result: normalized luminescence ~150 (HepG2); biodistribution_result: injection site and inguinal lymph nodes, some liver transfection",Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
923,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~70,,,>85,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,firefly_luciferase,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 10x chip; total_flow_rate_ml_min: 0.72; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA (diluted 3x) in 10 mM citrate buffer; organic_phase_composition: lipids (diluted 3x) in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS in 20-kDa MWCO dialysis cassettes for 2h, filtered by 0.22-•Ïm PES filters; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HepG2 cells; animal_model: C57BL/6 mice; administration_route: intramuscular; dose: 50 ng per 5,000 cells (in vitro), 5 •Ïg per mouse (in vivo); gene_expression_result: normalized luminescence ~150 (HepG2); biodistribution_result: injection site and inguinal lymph nodes, some liver transfection",Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
924,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~57.5,,,~90,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,sars_cov2_spike,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 1x chip; total_flow_rate_ml_min: 1.1-1.2; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA (74 •Ïg/mL) in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS in 20-kDa MWCO dialysis cassettes for 2h, filtered by 0.22-•Ïm PES filters; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; dose: 1 •Ïg mRNA per mouse; gene_expression_result: S1-specific IgG titers (10^6 to 10^8),Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
925,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~52,,,~90,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,sars_cov2_spike,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 10x chip; total_flow_rate_ml_min: 0.72; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA (diluted 3x) in 10 mM citrate buffer; organic_phase_composition: lipids (diluted 3x) in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS in 20-kDa MWCO dialysis cassettes for 2h, filtered by 0.22-•Ïm PES filters; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; dose: 1 •Ïg mRNA per mouse; gene_expression_result: S1-specific IgG titers (10^6 to 10^8),Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
926,C12-200,DMG-PEG2000,cholesterol,DOPE,50:1.5:38.5:10,~70,,,,,empty,empty,DMG-PEG 2000,C12-200,"DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)",cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: SCALAR 256x chip; total_flow_rate_ml_min: 17000 mL/h (17 L/h); flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,,Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
927,C12-200,DMG-PEG2000,cholesterol,DOPE,50:1.5:38.5:10,~58,,,~85,,empty,empty,DMG-PEG 2000,C12-200,"DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)",cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: SCALAR 256x chip; total_flow_rate_ml_min: 17000 mL/h (17 L/h); flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: polyA in citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,,Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
928,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,,,,>85,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,mcherry,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 1x chip (reuse experiment); total_flow_rate_ml_min: 1.1-1.2; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS, filtered, chip cleaned with 1% triton X 100; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: Jurkat cells; dose: 60 ng per 60,000 cells; gene_expression_result: mCherry positive cells ~100%",Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
929,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,,,,>85,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,gfp,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 1x chip (reuse experiment); total_flow_rate_ml_min: 1.1-1.2; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS, filtered, chip cleaned with 1% triton X 100; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: Jurkat cells; dose: 60 ng per 60,000 cells; gene_expression_result: GFP positive cells ~100%",Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
930,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~80,,,~95,,empty,empty,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: SCALAR 1x chip (reuse experiment); total_flow_rate_ml_min: 1.1-1.2; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: polyA in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1x PBS, filtered, chip cleaned with 1% triton X 100 between runs; sterilization: 0.22-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C",,Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
931,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,~160,,,~60,OTHER:ionizable lipid to mRNA weight ratio 10:1,mRNA,firefly_luciferase,DMG-PEG 2000,D-Lin-MC3-DMA (MC3),"DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing (bulk mixed); device_used: Eppendorf Xplorer Electronic Pipette; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA (74 •Ïg/mL) in 10 mM citrate buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: 50 cycles at maximum speed; temperature_condition: ; post_processing: dialyzed against 1x PBS, filtered by 0.45-•Ïm PES filter; sterilization: 0.45-•Ïm PES filtration; storage_buffer: 1x PBS, stored at 4°∆C","cell_line: HepG2 cells; dose: 50 ng per 5,000 cells; gene_expression_result: normalized luminescence ~80 (significantly lower than microfluidic)",Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines,"['Sarah J. Shepherd', 'Xuexiang Han', 'Alvin J. Mukalel', 'Rakan El-Mayta', 'Ajay S. Thatte', 'Jingyu Wu', 'Marshall S. Padilla', 'Mohamad-Gabriel Alameh', 'Neha Srikumar', 'Daeyeon Lee', 'Drew Weissman', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1073/pnas.2303567120,PNAS,2023
501,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,199 °æ 18.1,0.32 °æ 0.07,'-3.21 °æ 0.86,82.64 °æ 0.11,NP:1(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-MC3-DMA (MC3),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 70.19% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
502,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,95.8 °æ 5.3,0.27 °æ 0.032,'-1.32 °æ 0.2,94.37 °æ 0.051,NP:3(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-MC3-DMA (MC3),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 76.80% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
503,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,85.2 °æ 1.61,0.25 °æ 0.037,'-1.34 °æ 1.35,99.43 °æ 0.099,NP:6(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-MC3-DMA (MC3),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 77.42% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
504,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,175 °æ 51.7,0.38 °æ 0.11,'-1.5 °æ 1.5,65.75 °æ 0.49,NP:1(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-KC2-DMA (KC2),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 69.46% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
505,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,90.6 °æ 1.87,0.25 °æ 0.024,'-1.95 °æ 0.92,91.95 °æ 0.33,NP:3(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-KC2-DMA (KC2),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 81.58% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
506,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,90.1 °æ 1.36,0.26 °æ 0.011,'-0.91 °æ 0.72,98.94 °æ 0.23,NP:6(molar),siRNA,similip(5'-GGUAACAUAGAGACCCUAUTT-3'),DMG-PEG2000,DLin-KC2-DMA (KC2),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; dose: 50 nM; gene_expression_result: 81.06% knockdown efficiency,Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
507,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,201 °æ 13.4,0.45 °æ 0.027,0.96 °æ 0.44,,,empty,empty,DMG-PEG2000,DLin-MC3-DMA (MC3),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; gene_expression_result: Control (no knockdown),Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
508,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPC,50:10:38:2,217 °æ 56.2,0.54 °æ 0.061,'-0.073 °æ 0.2,,,empty,empty,DMG-PEG2000,DLin-KC2-DMA (KC2),DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr Ignite; total_flow_rate_ml_min: 11; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: 50 mM acetate buffer (pH 4); organic_phase_composition: ethanol phase with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: 1:4 dilution with PBS, washed 3 times with PBS using 100 kDa Amicon ultra-4 centrifugal filter units at 3,000 °ø g for 10 min; sterilization: ; storage_buffer: PBS (pH 7.4)",cell_line: A549; gene_expression_result: Control (no knockdown),Development of in silico methodology for siRNA lipid nanoparticle formulations,"['Haoshi Gao', 'Stanislav Kan', 'Zhuyifan Ye', 'Yuchen Feng', 'Lei Jin', 'Xudong Zhang', 'Jiayin Deng', 'Ging Chan', 'Yuanjia Hu', 'Yongjun Wang', 'Dongsheng Cao', 'Yuanhui Ji', 'Mingtao Liang', 'Haifeng Li', 'Defang Ouyang']",https://doi.org/10.1016/j.cej.2022.136310,Chemical Engineering Journal,2022
515,Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),89.3,0.17,,94,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: Baseline control,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
516,BP-Lipid-135,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),89.1,0.16,,75.2,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
517,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),93.2,0.18,,63.1,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((4-hydroxybutyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCCO)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 1.9x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
518,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),102.4,0.12,,81.9,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-acetamidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
519,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),84.5,0.12,,94.6,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-(methylsulfonamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNS(=O)(=O)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
520,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),93.4,0.07,,63.4,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
521,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),91.3,0.08,,78.6,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylthioureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=S)N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.8x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
522,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),88.1,0.07,,90.9,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-(3-methylureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)NC)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
523,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),84.3,0.23,,94.5,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-(3-methylthioureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=S)NC)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.3x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
524,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),52.8,0.15,,100.3,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((methylcarbamoyl)oxy)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCOC(=O)NC)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
525,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),96.7,0.21,,51.6,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCN)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: No significant expression,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
526,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),69.7,0.18,,99.5,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl (E)-8-((3-(2-cyanoguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCC/N(CCCN/C(=N\C#N)N)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
527,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),94.2,0.16,,97.7,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl (E)-8-((3-(2-cyano-3-methylguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCC/N(CCCN/C(=N\C#N)NC)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
528,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),98.8,0.13,,78.3,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl (Z)-8-((3-(2-cyano-3,3-dimethylguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCN\C(=N/C#N)N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.3x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
529,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),53.4,0.16,,98.6,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl (E)-8-((3-(3,3-dimethyl-2-nitroguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCC/N(CCCN/C(=N\[N+](=O)[O-])N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
530,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),75.4,0.24,,99.5,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 4-imino-9-(8-(nonyloxy)-8-oxooctyl)-2-oxa-3,5,9-triazaheptadecan-17-oate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN1CCCOC(=N)N(CCCCCCCC(=O)OCCCCCCCCC)CC1,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
531,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),59.9,0.25,,98.8,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl (Z)-8-((3-(3,3-dimethyl-2-sulfamoylguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCN\C(=N/S(=O)(=O)N)N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
532,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),109,0.15,,98.7,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((1-amino-2-nitrovinyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=C([N+](=O)[O-]))N)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
533,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),94.8,0.15,,96.8,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl (E)-8-((3-((1-(methylamino)-2-nitrovinyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCC/N(CCCNC(=C([N+](=O)[O-]))/NC)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
534,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),60.9,0.33,,98.9,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl (E)-8-((3-((1-(dimethylamino)-2-nitrovinyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCC/N(CCCNC(=C([N+](=O)[O-]))/N(C)C)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.1x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
535,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),69.3,0.23,,100.2,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((8-(nonyloxy)-8-oxooctyl)(3-(thiazol-2-ylamino)propyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNc1nccs1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.2x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
536,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),123.9,0.2,,75.1,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-((2-amino-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC1=C(N)C(=O)C1=O)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.6x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
537,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),102.2,0.17,,93.5,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC1=C(NC)C(=O)C1=O)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.9x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
538,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),84.4,0.17,,89.6,NP:3.4(molar),mRNA,epo,PEG-lipid,"7-((3-(3,3-dimethylthioureido)propyl)(8-(heptadecan-9-yloxy)-8-oxooctyl)amino)heptyl decanoate",DSPC,cholesterol,CCCCCCCCCCC(=O)OCCCCCCCN(CCCNC(=S)N(C)C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 10.5x fold change vs Lipid 1,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
539,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),78.1,0.43,,77.9,NP:3.4(molar),mRNA,epo,PEG-lipid,"7-((8-(heptadecan-9-yloxy)-8-oxooctyl)(3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)amino)heptyl decanoate",DSPC,cholesterol,CCCCCCCCCCC(=O)OCCCCCCCN(CCCNC1=C(NC)C(=O)C1=O)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
540,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),77.1,0.19,,95.1,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylthioureido)propyl)(8-((2-methylnonyl)oxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=S)N(C)C)CCCCCCCC(=O)OCC(C)CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
541,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),63.4,0.22,,83,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-((2-methylnonyl)oxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC1=C(NC)C(=O)C1=O)CCCCCCCC(=O)OCC(C)CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
542,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),98.8,0.2,,93.8,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylthioureido)propyl)(8-oxo-8-(undecan-3-yloxy)octyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=S)N(C)C)CCCCCCCC(=O)OCC(CC)CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
543,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),67,0.11,,90.4,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-oxo-8-(undecan-3-yloxy)octyl)amino)octanoate",DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C","animal_model: CD-1 mice, cynomolgus monkeys; administration_route: IV; dose: 0.5 mg/kg (mice), 0.1 mg/kg (NHP); gene_expression_result: 10.5x fold change vs Lipid 1 (mice), 2x higher Emax and 6x higher AUEC vs Lipid 1 (NHP); biodistribution_result: primarily hepatic expression",Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
544,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),73.2,0.37,,97.6,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylthioureido)propyl)(8-((2,2-dimethylundecyl)oxy)-8-oxooctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=S)N(C)C)CCCCCCCC(=O)OCC(C)(C)CCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
545,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),83.2,0.11,,96,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(2-naphthyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccc2ccccc2c1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.5x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
546,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),98.7,0.16,,98.1,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(phenyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccccc1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.5x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
547,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),96.3,0.16,,97.5,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(4-fluorophenyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccc(F)cc1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.5x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
548,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),60.4,0.11,,99,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(4-chlorophenyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccc(Cl)cc1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.7x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
549,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),92,0.16,,97.6,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(4-methoxyphenyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccc(OC)cc1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.7x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
550,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),104.4,0.18,,95.3,NP:3.4(molar),mRNA,epo,PEG-lipid,Heptadecan-9-yl 8-((3-((3-(4-nitrophenyl)ureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)Nc1ccc([N+](=O)[O-])cc1)CCCCCCCC(=O)OCCCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.5x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
551,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),75.8,0.08,,95,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(10-oxodecyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)N(C)C)CCCCCCCCC(=O)C,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 2.0x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
552,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),57.6,0.07,,83,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(6-oxododecyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)N(C)C)CCCCCC(=O)CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.1x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
553,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),89.4,0.16,,99,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(3,7-dimethyloctyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)N(C)C)CCC(C)CCC(C)CCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.1x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
554,Custom lipid,PEG-lipid,cholesterol,DSPC,50:38.5:10:1.5 (Estimated molar ratio 45-55:0-5:35-50:0-10),65.9,0.2,,99,NP:3.4(molar),mRNA,epo,PEG-lipid,"Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(3,7,11-trimethyldodecyl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCNC(=O)N(C)C)CCC(C)CCC(C)CCC(C)CCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol-drop nanoprecipitation; device_used: high-efficiency mixer; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: acetate buffer, pH 5.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: buffer exchange into PBS, pH 7.2; sterilization: ; storage_buffer: PBS, pH 7.2, stored at 5°∆C",animal_model: CD-1 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: 0.1x fold change vs Lipid 29,Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA,"['Mark Cornebise', 'Elisabeth Narayanan', 'Yan Xia', 'Edward Acosta', 'Lei Ci', 'Hillary Koch', 'Jaclyn Milton', 'Staci Sabnis', 'Timothy Salerno', 'Kerry E. Benenato']",10.1002/adfm.202106727,Advanced Functional Materials,2022
637,C12-200,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, epo, cre_recombinase",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic device; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (ethanol:aqueous phase); aqueous_phase_composition: 10 mM sodium citrate buffer (pH 3); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS for 1 h; sterilization: ; storage_buffer: PBS,"cell_line: RAW Blue cells; animal_model: C57BL/6 mice, Ai9 mice; administration_route: IV (tail vein); dose: 0.75 mg/kg mRNA; gene_expression_result: 6-fold increase in overall Luc expression with m1•˜ modification, 54-fold increase in spleen; biodistribution_result: predominantly liver (>60%), spleen, kidneys, lungs; cytokine_response: 30% reduction in SEAP levels with m1•˜ modification",Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery,"['Jilian R. Melamed', 'Khalid A. Hajj', 'Namit Chaudhary', 'Daria Strelkova', 'Mariah L. Arral', 'Norbert Pardi', 'Mohamad-Gabriel Alameh', 'Jason B. Miller', 'Lukas Farbiak', 'Daniel J. Siegwart', 'Drew Weissman', 'Kathryn A. Whitehead']",https://doi.org/10.1016/j.jconrel.2021.11.022,Journal of Controlled Release,2022
638,cKK-E12,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, epo, cre_recombinase",C14-PEG2000,cKK-E12 (MD-1),DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic device; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (ethanol:aqueous phase); aqueous_phase_composition: 10 mM sodium citrate buffer (pH 3); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS for 1 h; sterilization: ; storage_buffer: PBS,"cell_line: RAW Blue cells; animal_model: C57BL/6 mice, Ai9 mice; administration_route: IV (tail vein); dose: 0.75 mg/kg mRNA; gene_expression_result: no statistically significant increase with modifications, but 8-fold increase in spleen with m1•˜; biodistribution_result: predominantly liver (>60%), spleen, kidneys, lungs; cytokine_response: no significant reduction in SEAP levels with modifications",Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery,"['Jilian R. Melamed', 'Khalid A. Hajj', 'Namit Chaudhary', 'Daria Strelkova', 'Mariah L. Arral', 'Norbert Pardi', 'Mohamad-Gabriel Alameh', 'Jason B. Miller', 'Lukas Farbiak', 'Daniel J. Siegwart', 'Drew Weissman', 'Kathryn A. Whitehead']",https://doi.org/10.1016/j.jconrel.2021.11.022,Journal of Controlled Release,2022
639,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, epo, cre_recombinase",C14-PEG2000,200Oi10,DOPE,cholesterol,CCCCCCCC(C)COC(=O)CCN1CCN(CCNCCN(CCC(=O)OCC(C)CCCCCCCC)CCC(=O)OCC(C)CCCCCCCC)CC1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Rapid mixing; device_used: pulse vortexing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 volume ratio; aqueous_phase_composition: 10 mM sodium citrate buffer (pH 3); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS for 1 h; sterilization: ; storage_buffer: PBS,"cell_line: RAW Blue cells; animal_model: C57BL/6 mice, Ai9 mice; administration_route: IV (tail vein); dose: 0.75 mg/kg mRNA; gene_expression_result: 11-fold increase in overall Luc expression with m1•˜ modification, 37-fold increase in spleen; biodistribution_result: liver (64%), spleen (21%), lungs (13%); cytokine_response: 40% reduction in SEAP levels with m1•˜ modification",Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery,"['Jilian R. Melamed', 'Khalid A. Hajj', 'Namit Chaudhary', 'Daria Strelkova', 'Mariah L. Arral', 'Norbert Pardi', 'Mohamad-Gabriel Alameh', 'Jason B. Miller', 'Lukas Farbiak', 'Daniel J. Siegwart', 'Drew Weissman', 'Kathryn A. Whitehead']",https://doi.org/10.1016/j.jconrel.2021.11.022,Journal of Controlled Release,2022
640,ZA3-Ep10,DMG-PEG2000,cholesterol,,50:38.5:0.5,,,,,WR:7.5(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, epo, cre_recombinase",DMG-PEG2000,ZA3-Ep10,,cholesterol,CCCCCCCCC(CN(CCC(=O)NCC[N+](C)(C)CCCS(=O)(=O)[O-])CCN(CCN(CC(CCCCCCCC)O)CC(CCCCCCCC)O)CCN(CC(CCCCCCCC)O)CC(CCCCCCCC)O)O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: microfluidic mixing device; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (ethanol:aqueous phase); aqueous_phase_composition: 10 mM sodium citrate (pH 3); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS for 1 h; sterilization: ; storage_buffer: PBS,"cell_line: RAW Blue cells; animal_model: C57BL/6 mice, Ai9 mice; administration_route: IV (tail vein); dose: 0.375 mg/kg mRNA; gene_expression_result: 3-fold increase in overall Luc expression with m1•˜ modification, 13-fold increase in spleen; biodistribution_result: predominantly lungs (70%), liver, spleen; cytokine_response: 70% reduction in SEAP levels with m1•˜ modification",Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery,"['Jilian R. Melamed', 'Khalid A. Hajj', 'Namit Chaudhary', 'Daria Strelkova', 'Mariah L. Arral', 'Norbert Pardi', 'Mohamad-Gabriel Alameh', 'Jason B. Miller', 'Lukas Farbiak', 'Daniel J. Siegwart', 'Drew Weissman', 'Kathryn A. Whitehead']",https://doi.org/10.1016/j.jconrel.2021.11.022,Journal of Controlled Release,2022
790,4A3-SC8,DMG-PEG2000,cholesterol,DOPE,38.5:1.5:30:30,95,0.17,'-1.7,93,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,DOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: High luciferase expression in liver; biodistribution_result: Liver predominant targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
791,4A3-SC8,DMG-PEG2000,cholesterol,POPE,38.5:1.5:30:30,102,0.1,'-4.5,65,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,POPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN)OC(=O)CCCCCCC=CCCCCCCCC,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: High luciferase expression in liver; biodistribution_result: Liver predominant targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
792,4A3-SC8,DMG-PEG2000,cholesterol,BMP,38.5:1.5:30:30,133,0.08,'-3.5,88,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,"BMP(S,R)",cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Spleen predominant targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
793,4A3-SC8,DMG-PEG2000,cholesterol,BMP,38.5:1.5:30:30,167,0.07,'-4,84,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,"BMP(S,S)",cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Mixed targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
794,4A3-SC8,DMG-PEG2000,cholesterol,4ME,38.5:1.5:30:30,85,0.1,'-3,82,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,4ME,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: High luciferase expression in liver; biodistribution_result: Liver predominant targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
795,4A3-SC8,DMG-PEG2000,cholesterol,DSPC,38.5:1.5:30:30,115,0.13,'-2,72,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,DSPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Low luciferase expression; biodistribution_result: Limited targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
796,4A3-SC8,DMG-PEG2000,cholesterol,CL,38.5:1.5:30:30,147,0.07,'-4.5,48,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,CL,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Low luciferase expression; biodistribution_result: Mixed targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
797,4A3-SC8,DMG-PEG2000,cholesterol,SOPE,38.5:1.5:30:30,126,0.13,'-2.5,67,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,SOPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Moderate targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
798,4A3-SC8,DMG-PEG2000,cholesterol,DEPE,38.5:1.5:30:30,130,0.17,'-2.5,70,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,DEPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Moderate targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
799,4A3-SC8,DMG-PEG2000,cholesterol,DPPE,38.5:1.5:30:30,135,0.13,'-2.5,68,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,DPPE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN)OC(=O)CCCCCCCCCCCCCCC,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Moderate targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
800,4A3-SC8,DMG-PEG2000,cholesterol,C16-18:1 PE,38.5:1.5:30:30,122,0.17,'-2.5,69,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,C16-18:1 PE,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Moderate luciferase expression; biodistribution_result: Moderate targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
801,4A3-SC8,DMG-PEG2000,cholesterol,SOPC,38.5:1.5:30:30,128,0.09,'-0.5,57,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,SOPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Low luciferase expression; biodistribution_result: Limited targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
802,4A3-SC8,DMG-PEG2000,cholesterol,POPC,38.5:1.5:30:30,232,0.21,'-0.5,78,OTHER:23:1 weight ratio (4A3-SC8:mRNA),mRNA,firefly_luciferase,DMG-PEG2000,4A3-SC8,POPC,cholesterol,O=C(CCN(CCCN(CCCN(CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)C)CCC(OCCOC(C(CSCCCCCCCC)C)=O)=O)OCCOC(C(CSCCCCCCCC)C)=O,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC=CCCCCCCCC,synthesis_method: Rapid hand mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 100 mM citrate buffer pH 3.0; organic_phase_composition: Ethanol solution; mixing_time_sec: 30; temperature_condition: Room temperature; post_processing: Dialysis in sterile PBS with 3.5 kDa cut-off for 2 hours; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T, HeLa; animal_model: C57BL/6 female mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: Low luciferase expression; biodistribution_result: Limited targeting",Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA),"['Ester Alvarez-Benedicto', 'Lukas Farbiak', 'Martha Marquez Ramirez', 'Xu Wang', 'Lindsay T. Johnson', 'Osamah Mian', 'Erick D. Guerrero', 'Daniel J. Siegwart']",10.1039/d1bm01454d,Biomaterials Science,2022
803,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,120.5 °æ 6.0,,'-6.3 °æ 1.3,94.2 °æ 3.6,"29 •Ïg mRNA per •Ïmol total lipid, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC (18:0 PC),cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis against 25 mM sodium acetate buffer (pH 4.0) or PBS (pH 7.4) for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)","animal_model: Balb/cJ mice (female, 8 weeks old); administration_route: intravenous (i.v.); dose: 0.5 mg mRNA/kg; gene_expression_result: luciferase expression measured by IVIS imaging at 12h post-injection; biodistribution_result: primarily liver and spleen distribution",Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
804,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:0.25:38.75:10.5,210,,,,"mRNA concentration 20 •Ïg/mL, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
805,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:0.5:38.5:10.5,180,,,,"mRNA concentration 20 •Ïg/mL, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
806,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:1.0:38.0:10.5,150,,,,"mRNA concentration 20 •Ïg/mL, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
807,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:1.5:38.5:10.5,120.5 °æ 6.0,,'-6.3 °æ 1.3,94.2 °æ 3.6,"mRNA concentration 20 •Ïg/mL, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",animal_model: Balb/cJ mice; administration_route: intravenous; dose: 0.5 mg mRNA/kg; gene_expression_result: luciferase expression measured; biodistribution_result: liver and spleen distribution,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
808,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:3.0:35.5:10.5,100,,,,"mRNA concentration 20 •Ïg/mL, NP:6(molar)",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
809,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,variable based on N/P:1.5:38.5:10.5,120-180,,,,"NP:1(molar), 2, 3, 4.5, 6, 12",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",animal_model: Balb/cJ mice; administration_route: intravenous; dose: 0.5 mg mRNA/kg; gene_expression_result: luciferase expression varies with N/P ratio; biodistribution_result: liver and spleen distribution,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
810,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:1.5:38.5:10.5,,,,,"CONC:5(•Ïg/mL)[mRNA], 20, 50, 100 •Ïg/mL",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
811,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC + TMR-PC,50:1.5:38.5:10.5,,,,,OTHER:doubled_mRNA_copies,mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC + TMR-PC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
812,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,113.0 °æ 1.4,,'-3.2 °æ 1.4,95.6 °æ 0.6,"NP:6(molar), mRNA concentration 20 •Ïg/mL",mRNA,luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC (non-fluorescent),cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction microfluidic mixing; device_used: T-junction (IDEX Health and Science); total_flow_rate_ml_min: 4.0; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate buffer (pH 4.0); organic_phase_composition: pure ethanol; mixing_time_sec: ; temperature_condition: 4°∆C during dialysis; post_processing: dialysis for 12h using MWCO 3,500; sterilization: ; storage_buffer: PBS (pH 7.4)",,Payload distribution and capacity of mRNA lipid nanoparticles,"['Sixuan Li', 'Yizong Hu', 'Andrew Li', 'Jinghan Lin', 'Kuangwen Hsieh', 'Zachary Schneiderman', 'Pengfei Zhang', 'Yining Zhu', 'Chenhu Qiu', 'Efrosini Kokkoli', 'Tza-Huei Wang', 'Hai-Quan Mao']",https://doi.org/10.1038/s41467-022-33157-4,Nature Communications,2022
813,DLin-MC3-DMA,DMPE-PEG550,cholesterol,DSPC,40:1:49:10,189.5,,,~85,NP:2(molar),ASO,aso,DMPE (C14:0)-PEG-0.55k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.25",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
814,DLin-MC3-DMA,DMPE-PEG1000,cholesterol,DSPC,40:1:49:10,151.3,,,~85,NP:2(molar),ASO,aso,DMPE (C14:0)-PEG-1k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.25",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
815,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,40:1:49:10,101.7,,,~85,NP:2(molar),ASO,aso,DMPE (C14:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.5",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
816,DLin-MC3-DMA,DPPE-PEG1000,cholesterol,DSPC,40:1:49:10,173.8,,,~85,NP:2(molar),ASO,aso,DPPE (C16:0)-PEG-1k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.75",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
817,DLin-MC3-DMA,DPPE-PEG2000,cholesterol,DSPC,40:1:49:10,103.2,,,~85,NP:2(molar),ASO,aso,DPPE (C16:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.9",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
818,DLin-MC3-DMA,DSPE-PEG550,cholesterol,DSPC,40:1:49:10,211.9,,,~85,NP:2(molar),ASO,aso,DSPE (C18:0)-PEG-0.55k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.9",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
819,DLin-MC3-DMA,DSPE-PEG1000,cholesterol,DSPC,40:1:49:10,156.7,,,~85,NP:2(molar),ASO,aso,DSPE (C18:0)-PEG-1k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~1.0",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
820,DLin-MC3-DMA,DSPE-PEG2000,cholesterol,DSPC,40:3:47:10,98.4,,,~85,NP:2(molar),ASO,aso,DSPE (C18:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~1.0",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
821,DLin-MC3-DMA,DSPE-2armPEG2000,cholesterol,DSPC,40:1:49:10,107.2,,,~85,NP:2(molar),ASO,aso,DSPE (C18:0)-2arm-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)(COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~1.0",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
822,DLin-MC3-DMA,DOPE-PEG550,cholesterol,DSPC,40:1:49:10,212.1,,,~85,NP:2(molar),ASO,aso,DOPE (C18:1)-PEG-0.55k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCC=CCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCC=CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~1.0",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
823,DLin-MC3-DMA,DOPE-PEG1000,cholesterol,DSPC,40:1:49:10,132.2,,,~85,NP:2(molar),ASO,aso,DOPE (C18:1)-PEG-1k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCC=CCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCC=CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.8",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
824,DLin-MC3-DMA,DOPE-PEG2000,cholesterol,DSPC,40:1:49:10,104.6,,,~85,NP:2(molar),ASO,aso,DOPE (C18:1)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCC=CCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCC=CCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.8",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
825,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,40:1:49:10,116.9,,,~85,NP:2(molar),ASO,aso,DMG (C14:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.2",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
826,DLin-MC3-DMA,DSG-PEG2000,cholesterol,DSPC,40:1:49:10,114.7,,,~85,NP:2(molar),ASO,aso,DSG (C18:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.4",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
827,DLin-MC3-DMA,C8-Ceramide-PEG750,cholesterol,DSPC,40:1:49:10,147.7,,,~85,NP:2(molar),ASO,aso,Ceramide (C8)-PEG-0.75k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.25",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
828,DLin-MC3-DMA,C8-Ceramide-PEG2000,cholesterol,DSPC,40:3:47:10,114.7,,,~85,NP:2(molar),ASO,aso,Ceramide (C8)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.25",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
829,DLin-MC3-DMA,C16-Ceramide-PEG750,cholesterol,DSPC,40:1:49:10,195.8,,,~85,NP:2(molar),ASO,aso,Ceramide (C16)-PEG-0.75k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.7",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
830,DLin-MC3-DMA,C16-Ceramide-PEG2000,cholesterol,DSPC,40:1:49:10,115.6,,,~85,NP:2(molar),ASO,aso,Ceramide (C16)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: High-throughput screening (HTS); device_used: TECAN Freedom EVO robotic liquid handler; total_flow_rate_ml_min: ; flow_rate_ratio: 1:3 (ethanol:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0); organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: 10 cycles of mixing with 0.1 mL volume per cycle; temperature_condition: ; post_processing: diluted in phosphate-buffered saline (PBS, pH 7.4); sterilization: ; storage_buffer: PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 50 nM ASO per well; gene_expression_result: relative mRNA expression ~0.2",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
831,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,40:1:49:10,~120,,,~85,NP:2(molar),ASO,aso,DMG (C14:0)-PEG-2k,MC3 (DLin-MC3-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr¢‚ Benchtop; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: citrate buffer (25 mM, pH 4.0), ASO 93.9 •Ïg/mL; organic_phase_composition: ethanol with total lipid concentration of 4 mM; mixing_time_sec: ; temperature_condition: ; post_processing: centrifugal ultrafiltration (MWCO 10 kDa) at 2000g for 30 min, buffer exchange to RNase-free PBS; sterilization: ; storage_buffer: RNase-free PBS","cell_line: primary murine cortical neurons, primary murine microglia; animal_model: C57BL/6N mice; administration_route: in vitro; dose: 0.2-100 nM ASO concentration range; gene_expression_result: EC50 = 3.6 nM in cortical neurons",Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing,"['Apoorva Sarode', 'Yuchen Fan', 'Amy E. Byrnes', 'Michal Hammel', 'Greg L. Hura', 'Yige Fu', 'Ponien Kou', 'Chloe Hu', 'Flora I. Hinz', 'Jasmine Roberts', 'Stefan G. Koenig', 'Karthik Nagapudi', 'Casper C. Hoogenraad', 'Tao Chen', 'Dennis Leung', 'Chun-Wan Yen']",10.1039/d1na00712b,Nanoscale Advances,2022
51,Custom lipid,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:1.5:52:20,66 °æ 14,0.083,'-0.694 °æ 0.31,,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,C16-PEG2000 ceramide,244C10,DOPE,cholesterol,,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,cell_line: HeLa; animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.1 mg/kg mRNA; gene_expression_result: moderate luciferase expression; biodistribution_result: liver-specific,Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
52,Custom lipid,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:1.5:52:20,70 °æ 12,0.104,'-1.54 °æ 0.42,,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,C16-PEG2000 ceramide,245C10,DOPE,cholesterol,CCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCCN1CCN(CC(O)CCCCCCCCCC)CC1CC(O)CCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,cell_line: HeLa; animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.1 mg/kg mRNA; gene_expression_result: moderate luciferase expression; biodistribution_result: liver-specific,Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
53,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:1.5:52:20,68 °æ 15,0.079,'-0.997 °æ 0.17,,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,C16-PEG2000 ceramide,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: C57BL/6 mice, LSL-tdTomato mice; administration_route: intravenous; dose: 0.1 mg/kg mRNA (mFLuc), 0.5 mg/kg mRNA (mCre); gene_expression_result: highest luciferase expression, significant tdTomato expression in hepatocytes (80%); biodistribution_result: liver-specific, primarily hepatocytes",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
54,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:1.0:52:20,97 °æ 17,0.064,,88.3 °æ 7,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,cre_recombinase,C16-PEG2000 ceramide,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: LSL-tdTomato mice; administration_route: intravenous; dose: 0.5 mg/kg mRNA; gene_expression_result: tdTomato expression in hepatocytes (43°æ10%) and LSECs (54°æ8%); biodistribution_result: liver, both hepatocytes and LSECs",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
55,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:1.5:51.5:20,68 °æ 15,0.127,,90.1 °æ 5,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,cre_recombinase,C16-PEG2000 ceramide,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: LSL-tdTomato mice; administration_route: intravenous; dose: 0.5 mg/kg mRNA; gene_expression_result: tdTomato expression primarily in hepatocytes (80%); biodistribution_result: liver, primarily hepatocytes",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
56,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:3.0:50.5:20,58 °æ 8,0.196,,80.1 °æ 8,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,cre_recombinase,C16-PEG2000 ceramide,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: LSL-tdTomato mice; administration_route: intravenous; dose: 0.5 mg/kg mRNA; gene_expression_result: reduced tdTomato expression in all liver cells due to reduced ApoE adsorption; biodistribution_result: liver, reduced overall uptake",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
57,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:3.0:50.5:20,101 °æ 11,0.188,,,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,"firefly_luciferase, cre_recombinase",C16-PEG2000 ceramide + mannose-PEG lipid,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"cell_line: HepG2; animal_model: C57BL/6 mice, LSL-tdTomato mice; administration_route: intravenous; dose: 0.1 mg/kg mRNA (mFLuc), 0.5 mg/kg mRNA (mCre); gene_expression_result: selective targeting to LSECs (70% tdTomato+), reduced hepatocyte targeting (15% tdTomato+); biodistribution_result: liver-specific, selective for LSECs via mannose receptor (CD206)",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
58,246C10,C16-Ceramide-PEG2000,cholesterol,DOPE,26.5:3.0:50.5:20,103 °æ 14,0.063,,,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,C16-PEG2000 ceramide + galactose-PEG lipid,246C10,DOPE,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 10 mM citrate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"cell_line: HepG2; animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.1 mg/kg mRNA; gene_expression_result: control group - no selective targeting; biodistribution_result: liver, similar to PEG-only LNPs",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
59,246C10,C16-Ceramide-PEG2000,cholesterol,DSPC,42.5:1.5:43:13,65 °æ 6,,,,WR:7.5(wt/wt)[ionizable_lipid:siRNA],siRNA,factor_vii,C16-PEG2000 ceramide,246C10,DSPC,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium acetate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.5 mg/kg siRNA; gene_expression_result: moderate FVIII gene silencing; biodistribution_result: liver, primarily hepatocytes",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
60,246C10,C16-Ceramide-PEG2000,cholesterol,DSPC,42.5:3.0:41.5:13,101 °æ 10,,,,WR:7.5(wt/wt)[ionizable_lipid:siRNA],siRNA,factor_vii,C16-PEG2000 ceramide + mannose-PEG lipid,246C10,DSPC,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium acetate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.5 mg/kg siRNA; gene_expression_result: enhanced FVIII gene silencing in LSECs; biodistribution_result: liver, selective for LSECs",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
61,246C10,C16-Ceramide-PEG2000,cholesterol,DSPC,42.5:1.5:43:13,59 °æ 7,,,,WR:7.5(wt/wt)[ionizable_lipid:siRNA],siRNA,factor_vii,C16-PEG2000 ceramide,246C10,DSPC,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium acetate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.2 mg/kg siRNA; gene_expression_result: FVII gene silencing primarily in hepatocytes; biodistribution_result: liver, primarily hepatocytes",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
62,246C10,C16-Ceramide-PEG2000,cholesterol,DSPC,42.5:3.0:41.5:13,109 °æ 10,,,,WR:7.5(wt/wt)[ionizable_lipid:siRNA],siRNA,factor_vii,C16-PEG2000 ceramide + mannose-PEG lipid,246C10,DSPC,cholesterol,CCCCCCCCCCC(CN(CCCN1CCN(CC1)CCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O,CCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic-based system; total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 50 mM sodium acetate; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS using 3500 MWCO dialysis cassettes overnight; sterilization: ; storage_buffer: PBS,"animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.2 mg/kg siRNA; gene_expression_result: reduced FVII gene silencing in hepatocytes (selective for LSECs); biodistribution_result: liver, reduced hepatocyte uptake",Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,"['M. Kim', 'M. Jeong', 'S. Hur', 'Y. Cho', 'J. Park', 'H. Jung', 'Y. Seo', 'H. A. Woo', 'K. T. Nam', 'K. Lee', 'H. Lee']",10.1126/sciadv.abf4398,Science Advances,2021
299,C12-200,PEG1000,cholesterol,DOPE,40:1.5:48.5:10,64.91,0.177,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
300,C12-200,PEG1000,cholesterol,DOPE,40:1.5:48.5:10,91.96,0.148,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
301,C12-200,PEG2000,cholesterol,DOPE,40:1.5:48.5:10,109.9,0.163,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
302,C12-200,PEG2000,cholesterol,DOPE,40:1.5:48.5:10,114.2,0.181,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
303,C12-200,PEG3000,cholesterol,DOPE,40:1.5:48.5:10,135.8,0.071,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
304,C12-200,PEG3000,cholesterol,DOPE,40:1.5:48.5:10,140.1,0.077,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
305,C12-200,PEG5000,cholesterol,DOPE,40:1.5:48.5:10,124.1,0.189,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
306,C12-200,PEG5000,cholesterol,DOPE,40:1.5:48.5:10,128.2,0.019,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
307,C12-200,PEG1000,cholesterol,DOPE,40:10:40:10,107,0.172,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
308,C12-200,PEG1000,cholesterol,DOPE,40:10:40:10,118.6,0.017,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
309,C12-200,PEG2000,cholesterol,DOPE,40:10:40:10,148.9,0.045,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
310,C12-200,PEG2000,cholesterol,DOPE,40:10:40:10,130.5,0.161,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
311,C12-200,PEG3000,cholesterol,DOPE,40:10:40:10,152.2,0.052,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
312,C12-200,PEG3000,cholesterol,DOPE,40:10:40:10,146.9,0.08,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
313,C12-200,PEG5000,cholesterol,DOPE,40:10:40:10,144.1,0.011,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
314,C12-200,PEG5000,cholesterol,DOPE,40:10:40:10,129.3,0.165,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
315,C12-200,PEG1000,cholesterol,DOPE,40:20:30:10,131.6,0.186,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
316,C12-200,PEG1000,cholesterol,DOPE,40:20:30:10,108.8,0.185,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
317,C12-200,PEG2000,cholesterol,DOPE,40:20:30:10,139.4,0.118,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
318,C12-200,PEG2000,cholesterol,DOPE,40:20:30:10,139,0.146,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
319,C12-200,PEG3000,cholesterol,DOPE,40:20:30:10,152.9,0.078,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
320,C12-200,PEG3000,cholesterol,DOPE,40:20:30:10,154.4,0.029,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
321,C12-200,PEG5000,cholesterol,DOPE,40:20:30:10,130.2,0.095,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
322,C12-200,PEG5000,cholesterol,DOPE,40:20:30:10,131.7,0.006,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
323,C12-200,PEG1000,cholesterol,DOPE,40:30:20:10,130.3,0.129,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
324,C12-200,PEG1000,cholesterol,DOPE,40:30:20:10,121.7,0.141,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
325,C12-200,PEG2000,cholesterol,DOPE,40:30:20:10,153.9,0.002,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
326,C12-200,PEG2000,cholesterol,DOPE,40:30:20:10,148,0.023,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
327,C12-200,PEG3000,cholesterol,DOPE,40:30:20:10,154.7,0.106,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
328,C12-200,PEG3000,cholesterol,DOPE,40:30:20:10,154.5,0.09,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
329,C12-200,PEG5000,cholesterol,DOPE,40:30:20:10,153.3,0.085,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
330,C12-200,PEG5000,cholesterol,DOPE,40:30:20:10,146.3,0.019,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
331,C12-200,PEG1000,cholesterol,DOPE,40:40:10:10,144.4,0.13,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
332,C12-200,PEG1000,cholesterol,DOPE,40:40:10:10,138,0.094,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
333,C12-200,PEG2000,cholesterol,DOPE,40:40:10:10,150.6,0.073,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
334,C12-200,PEG2000,cholesterol,DOPE,40:40:10:10,155.6,0.114,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
335,C12-200,PEG3000,cholesterol,DOPE,40:40:10:10,163.9,0.115,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
336,C12-200,PEG3000,cholesterol,DOPE,40:40:10:10,160.9,0.085,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
337,C12-200,PEG5000,cholesterol,DOPE,40:40:10:10,150.1,0.038,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
338,C12-200,PEG5000,cholesterol,DOPE,40:40:10:10,159,0.03,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
339,C12-200,PEG1000,cholesterol,DOPE,40:48.5:1.5:10,180.6,0.145,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
340,C12-200,PEG1000,cholesterol,DOPE,40:48.5:1.5:10,170.5,0.074,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; 0.2 mg kg?©ˆ mRNA (luciferase study); 5 •Ïg siRNA (Cy3-siRNA study); gene_expression_result: Luciferase: ~7°ø10? p/sec/cm©˜/sr liver bioluminescence; 2-fold higher mRNA delivery to liver vs LNP90; 3-fold higher liver transfection vs LNP90; biodistribution_result: Preferential liver accumulation; DOPE-containing LNPs accumulated significantly higher in liver compared to DSPC-containing LNPs (****P < 0.0001); Lower spleen accumulation compared to DSPC-containing LNPs; Stronger ApoE interaction (-350 Hz QCM-D frequency shift),Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
341,C12-200,PEG2000,cholesterol,DOPE,40:48.5:1.5:10,162.8,0.043,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
342,C12-200,PEG2000,cholesterol,DOPE,40:48.5:1.5:10,166.1,0.094,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
343,C12-200,PEG3000,cholesterol,DOPE,40:48.5:1.5:10,170.7,0.063,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
344,C12-200,PEG3000,cholesterol,DOPE,40:48.5:1.5:10,166.1,0.111,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
345,C12-200,PEG5000,cholesterol,DOPE,40:48.5:1.5:10,171.4,0.061,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
346,C12-200,PEG5000,cholesterol,DOPE,40:48.5:1.5:10,173,0.104,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
347,C12-200,PEG1000,cholesterol,DSPC,40:1.5:48.5:10,,,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: excluded from injected pool based on DLS analysis,Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
348,C12-200,PEG1000,cholesterol,DSPC,40:1.5:48.5:10,88.87,0.106,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
349,C12-200,PEG2000,cholesterol,DSPC,40:1.5:48.5:10,90.47,0.261,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
350,C12-200,PEG2000,cholesterol,DSPC,40:1.5:48.5:10,91.93,0.19,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
351,C12-200,PEG3000,cholesterol,DSPC,40:1.5:48.5:10,117.7,0.016,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
352,C12-200,PEG3000,cholesterol,DSPC,40:1.5:48.5:10,128.5,0.035,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
353,C12-200,PEG5000,cholesterol,DSPC,40:1.5:48.5:10,115.1,0.079,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
354,C12-200,PEG5000,cholesterol,DSPC,40:1.5:48.5:10,,,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: excluded from injected pool based on DLS analysis,Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
355,C12-200,PEG1000,cholesterol,DSPC,40:10:40:10,94.74,0.191,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
356,C12-200,PEG1000,cholesterol,DSPC,40:10:40:10,122.8,0.013,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
357,C12-200,PEG2000,cholesterol,DSPC,40:10:40:10,118.6,0.043,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
358,C12-200,PEG2000,cholesterol,DSPC,40:10:40:10,125.4,0.03,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
359,C12-200,PEG3000,cholesterol,DSPC,40:10:40:10,120,0.093,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
360,C12-200,PEG3000,cholesterol,DSPC,40:10:40:10,148.4,0.037,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
361,C12-200,PEG5000,cholesterol,DSPC,40:10:40:10,123.1,0.059,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
362,C12-200,PEG5000,cholesterol,DSPC,40:10:40:10,118.6,0.114,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
363,C12-200,PEG1000,cholesterol,DSPC,40:20:30:10,107.9,0.208,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
364,C12-200,PEG1000,cholesterol,DSPC,40:20:30:10,73.25,0.216,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
365,C12-200,PEG2000,cholesterol,DSPC,40:20:30:10,131,0.039,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
366,C12-200,PEG2000,cholesterol,DSPC,40:20:30:10,126.8,0.067,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
367,C12-200,PEG3000,cholesterol,DSPC,40:20:30:10,138.9,0.104,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
368,C12-200,PEG3000,cholesterol,DSPC,40:20:30:10,134,0.078,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
369,C12-200,PEG5000,cholesterol,DSPC,40:20:30:10,122.5,0.077,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
370,C12-200,PEG5000,cholesterol,DSPC,40:20:30:10,132.8,0.007,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
371,C12-200,PEG1000,cholesterol,DSPC,40:30:20:10,120.9,0.153,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
372,C12-200,PEG1000,cholesterol,DSPC,40:30:20:10,111.6,0.13,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
373,C12-200,PEG2000,cholesterol,DSPC,40:30:20:10,132.2,0.118,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
374,C12-200,PEG2000,cholesterol,DSPC,40:30:20:10,134.9,0.097,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
375,C12-200,PEG3000,cholesterol,DSPC,40:30:20:10,144.6,0.064,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
376,C12-200,PEG3000,cholesterol,DSPC,40:30:20:10,136,0.074,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
377,C12-200,PEG5000,cholesterol,DSPC,40:30:20:10,143.6,0.103,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
378,C12-200,PEG5000,cholesterol,DSPC,40:30:20:10,148.2,0.042,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
379,C12-200,PEG1000,cholesterol,DSPC,40:40:10:10,141.3,0.103,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
380,C12-200,PEG1000,cholesterol,DSPC,40:40:10:10,124.2,0.087,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
381,C12-200,PEG2000,cholesterol,DSPC,40:40:10:10,134.8,0.116,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
382,C12-200,PEG2000,cholesterol,DSPC,40:40:10:10,131.4,0.113,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
383,C12-200,PEG3000,cholesterol,DSPC,40:40:10:10,154.9,0.076,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
384,C12-200,PEG3000,cholesterol,DSPC,40:40:10:10,157.8,0.091,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
385,C12-200,PEG5000,cholesterol,DSPC,40:40:10:10,156.1,0.061,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
386,C12-200,PEG5000,cholesterol,DSPC,40:40:10:10,154.2,0.087,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
387,C12-200,PEG1000,cholesterol,DSPC,40:48.5:1.5:10,173.2,0.098,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
388,C12-200,PEG1000,cholesterol,DSPC,40:48.5:1.5:10,167.2,0.111,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG1000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; 0.2 mg kg?©ˆ mRNA (luciferase study); 5 •Ïg siRNA (Cy3-siRNA study); gene_expression_result: Luciferase: ~2°ø10^-9 p/sec/cm©˜/sr liver bioluminescence; 5-fold higher mRNA delivery to spleen vs LNP42; 2-fold higher Cy3-siRNA delivery to spleen vs LNP42; biodistribution_result: Preferential spleen accumulation; DSPC-containing LNPs accumulated significantly higher in spleen compared to DOPE-containing LNPs (**P = 0.0027); Lower liver accumulation compared to DOPE-containing LNPs; Weaker ApoE interaction (-200 Hz QCM-D frequency shift),Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
389,C12-200,PEG2000,cholesterol,DSPC,40:48.5:1.5:10,165.9,0.106,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
390,C12-200,PEG2000,cholesterol,DSPC,40:48.5:1.5:10,164.5,0.069,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
391,C12-200,PEG3000,cholesterol,DSPC,40:48.5:1.5:10,172,0.096,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
392,C12-200,PEG3000,cholesterol,DSPC,40:48.5:1.5:10,168.3,0.105,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG3000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
393,C12-200,PEG5000,cholesterol,DSPC,40:48.5:1.5:10,162.9,0.093,,,WR:5(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
394,C12-200,PEG5000,cholesterol,DSPC,40:48.5:1.5:10,158.4,0.08,,,WR:10(wt/wt)[ionizable_lipid:bDNA],DNA,barcode(61 nucleotides with unique barcode region),PEG5000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Pipette mixing; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 10 mM pH 4.0 citrate buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against PBS in 96-well microdialysis plate (10,000 MWCO) for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein); dose: 0.4 •Ïg per b-DNA; biodistribution_result: measured by deep sequencing in liver, spleen, kidney, small intestine, colon, stomach, cecum, feces",Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,"['Rui Zhang', 'Rakan El-Mayta', 'Timothy J. Murdoch', 'Claude C. Warzecha', 'Margaret M. Billingsley', 'Sarah J. Shepherd', 'Ningqiang Gong', 'Lili Wang', 'James M. Wilson', 'Daeyeon Lee', 'Michael J. Mitchell']",10.1039/d0bm01609h,Biomaterials Science,2021
607,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,92.3 °æ 6.0,<0.3,,88,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 1 + C12 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C","animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: High luciferase expression in fetal liver; biodistribution_result: Primarily liver, some lung and intestines; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation",Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
608,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,64.6 °æ 3.2,<0.3,,96.7,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 1 + C14 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Moderate luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
609,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,92.9 °æ 1.7,<0.3,,97.5,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 1 + C16 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
610,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,96.5 °æ 7.1,<0.3,,84.6,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 2 + C12 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
611,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,135.2 °æ 14.6,>0.3,,87.9,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 2 + C14 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
612,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,102.8 °æ 11.0,<0.3,,89.8,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 2 + C16 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
613,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,116 °æ 5.3,<0.3,,81.3,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,"luciferase, epo, gfp",C14-PEG2000,Polyamine core 3 + C12 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C","animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA) or 190-760 ng EPO mRNA; gene_expression_result: Highest luciferase expression; 1.1% GFP+ liver cells; ~100 mIU/mL EPO; biodistribution_result: Liver, lungs, intestines; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation",Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
614,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,115.5 °æ 0.8,<0.3,,86.3,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 3 + C14 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C","animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: High luciferase expression; biodistribution_result: Liver, lungs, intestines; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation",Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
615,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,82.5 °æ 10.1,<0.3,,86.2,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 3 + C16 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
616,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,85.8 °æ 6.2,<0.3,,96,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 4 + C12 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Moderate luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
617,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,94.1 °æ 12.7,<0.3,,95,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,"luciferase, epo, gfp",C14-PEG2000,Polyamine core 4 + C14 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C","animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA) or 190-760 ng EPO mRNA; gene_expression_result: High luciferase expression; 0.17% GFP+ liver cells; ~50 mIU/mL EPO; biodistribution_result: Liver, lungs, intestines; toxicity_profile: >90% fetal survival; cytokine_response: Elevated KC and MIP-2 in Balb/c mice",Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
618,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,118.6 °æ 6.9,<0.3,,96.1,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 4 + C16 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
619,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,105.4 °æ 7.2,<0.3,,74,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 5 + C12 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
620,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,102.3 °æ 4.8,<0.3,,92.6,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,Polyamine core 5 + C14 epoxide-terminated alkyl tail,DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C",animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Low luciferase expression; biodistribution_result: Primarily liver; toxicity_profile: >90% fetal survival; cytokine_response: No significant cytokine elevation,Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
621,DLin-MC3-DMA,C14-PEG2000,cholesterol,DOPE,35:46.5:16:2.5,,,,,CONC:25(•Ïg/337.5•ÏL)[mRNA],mRNA,luciferase,C14-PEG2000,DLin-MC3-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device with herringbone features; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol phase with lipid components; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed against PBS for 2 hours; sterilization: 0.2 •Ïm sterile filtration; storage_buffer: PBS, stored at 4°∆C","animal_model: E16 mouse fetuses (Balb/c); administration_route: Vitelline vein injection; dose: 5 •ÏL (38.4 ng/•ÏL mRNA); gene_expression_result: Moderate luciferase expression (3.5-fold lower than LNP A-3); biodistribution_result: Primarily liver, minimal lung/intestine delivery; toxicity_profile: 72.4% fetal survival; cytokine_response: Elevated KC and IL-6 in maternal plasma",Ionizable lipid nanoparticles for in utero mRNA delivery,"['Rachel S. Riley', 'Meghana V. Kashyap', 'Margaret M. Billingsley', 'Brandon White', 'Mohamad-Gabriel Alameh', 'Sourav K. Bose', 'Philip W. Zoltick', 'Hiaying Li', 'Rui Zhang', 'Andrew Y. Cheng', 'Drew Weissman', 'William H. Peranteau', 'Michael J. Mitchell']",10.1126/sciadv.aba1028,Science Advances,2021
665,9A1P9,DMG-PEG2000,cholesterol,MDOA,25:1:30:30,~150,~0.2,~-5,,"OTHER:iPhos:mRNA molar ratio 11622:1, weight ratio ~18:1",mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,MDOA,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 4.4; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Diluted 3-fold with 1°ø PBS buffer; sterilization: ; storage_buffer: 1°ø PBS buffer","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.1-0.25 mg/kg mRNA; gene_expression_result: High luciferase expression in liver; biodistribution_result: Liver-selective delivery; toxicity_profile: Negligible cytotoxicity, well tolerated",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
666,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:1:30:30,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 4.4; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.05-0.25 mg/kg mRNA; gene_expression_result: ~10^8 photons/s/cm©˜/sr in liver; biodistribution_result: Liver-selective delivery; toxicity_profile: Well tolerated, no significant liver/kidney function changes",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
667,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:0.4:30:40,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 4.4; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: ~10^8 photons/s/cm©˜/sr in lung; biodistribution_result: Lung-selective delivery; toxicity_profile: Well tolerated, no obvious tissue injury",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
668,Custom lipid,DMG-PEG2000,cholesterol,MDOA,25:1:30:30,~200,,~-5 to -10,,WR:11.5(wt/wt)[10A1P16:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,10A1P16,MDOA,cholesterol,CCCCCCCCC[N+](CCCC)(CCO[P-](=O)OCCCCCCCCCCCCCCCC)CCO[P-](=O)OCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 4.4; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer","cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: High luciferase expression in spleen; biodistribution_result: Spleen-selective delivery; toxicity_profile: Well tolerated, no significant toxicity",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
669,9A1P9,DMG-PEG2000,cholesterol,DOPE,55:0.2:45:30,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DOPE,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 4.4; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer",cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: Moderate luciferase expression in spleen; biodistribution_result: Spleen-selective delivery; toxicity_profile: Well tolerated,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
670,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:1:30:30,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:RNA],mRNA,cas9,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 3.2; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer",animal_model: Ai9 mice (Cre-reporter mice); administration_route: IV; dose: 0.75 mg/kg total RNA; gene_expression_result: ~91% tdTomato editing in hepatocytes; biodistribution_result: Liver-selective gene editing; toxicity_profile: Well tolerated,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
671,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:0.4:40:30,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:RNA],mRNA,cas9,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 3.2; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer","animal_model: Ai9 mice (Cre-reporter mice); administration_route: IV; dose: 0.75 mg/kg total RNA; gene_expression_result: ~34% endothelial cells, ~20% epithelial cells, ~13% immune cells edited; biodistribution_result: Lung-selective gene editing; toxicity_profile: Well tolerated",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
672,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:1:30:30,~150,~0.2,~-5,,WR:18(wt/wt)[9A1P9:RNA],mRNA,cas9,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Ethanol dilution; device_used: Manual pipette mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 3.2; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: Rapid mixing by pipette, 15 min incubation; temperature_condition: ; post_processing: Dialyzed against 1°ø PBS in Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1°ø PBS buffer",animal_model: C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg total RNA; gene_expression_result: Efficient PTEN gene editing in liver (T7E1 assay); biodistribution_result: Liver-selective gene editing; toxicity_profile: Well tolerated,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
673,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:1:30:30,77.2,,,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr microfluidic mixing system; total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 3.2; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: N/A (continuous flow); temperature_condition: ; post_processing: Dialyzed against 1°ø PBS, 0.3 mL waste collection at start, 0.1 mL at end; sterilization: ; storage_buffer: 1°ø PBS buffer",animal_model: C57BL/6 mice; administration_route: IV; dose: 0.05-0.25 mg/kg mRNA; gene_expression_result: High efficacy and organ selectivity retained; biodistribution_result: Liver-selective delivery maintained; toxicity_profile: Well tolerated,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
674,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:0.4:40:30,108.1,,,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],"synthesis_method: Microfluidic mixing; device_used: NanoAssemblr microfluidic mixing system; total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer, pH 3.2; organic_phase_composition: Ethanol with lipid mixture; mixing_time_sec: N/A (continuous flow); temperature_condition: ; post_processing: Dialyzed against 1°ø PBS, 0.3 mL waste collection at start, 0.1 mL at end; sterilization: ; storage_buffer: 1°ø PBS buffer",animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: High efficacy and organ selectivity retained; biodistribution_result: Lung-selective delivery maintained; toxicity_profile: Well tolerated,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
675,9A1P9,DMG-PEG2000,cholesterol,MDOA,25:30:30:1,~150,~0.2,~-5,,OTHER:iPhos:mRNA molar ratio 11622:1,mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,MDOA,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 4.4); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: 3-fold dilution with 1x PBS; sterilization: ; storage_buffer: 1x PBS,cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.1 mg/kg mRNA; gene_expression_result: High luciferase expression in liver; biodistribution_result: Liver-specific delivery; toxicity_profile: Negligible cytotoxicity,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
676,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:30:30:1,~150,,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.05 mg/kg mRNA; gene_expression_result: ~10^8 photons s^-1 cm^-2 sr^-1 in liver; biodistribution_result: Liver-selective delivery; toxicity_profile: Well tolerated, no significant organ injury",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
677,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:30:40:0.4,~150,,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: ~10^8 photons s^-1 cm^-2 sr^-1 in lung; biodistribution_result: Lung-selective delivery; toxicity_profile: Well tolerated, no significant organ injury",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
678,9A1P9,DMG-PEG2000,cholesterol,DOPE,55:30:45:0.2,~150,,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DOPE,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: mRNA expression in spleen; biodistribution_result: Spleen-selective delivery,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
679,Custom lipid,DMG-PEG2000,cholesterol,MDOA,25:30:30:1,~200,,,,WR:11.5(wt/wt)[10A1P16:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,10A1P16,MDOA,cholesterol,CCCCCCCCC[N+](CCCC)(CCO[P-](=O)OCCCCCCCCCCCCCCCC)CCO[P-](=O)OCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: High mRNA expression in spleen; biodistribution_result: Spleen-selective delivery; toxicity_profile: Well tolerated, no significant difference from PBS control",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
680,9A1P9,DMG-PEG2000,cholesterol,DODAP,25:30:30:1,~150,,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DODAP,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)CN(C)C,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: mRNA expression in liver; biodistribution_result: Liver-selective delivery,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
681,9A1P9,DMG-PEG2000,cholesterol,DOTAP,60:30:40:0.4,~150,,~-5,,WR:18(wt/wt)[9A1P9:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DOTAP,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,cell_line: IGROV1; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: mRNA expression in lung; biodistribution_result: Lung-selective delivery,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
682,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:30:30:1,~150,,~-5,,"WR:4(wt/wt)[Cas9:sgRNA], total RNA dose 0.75 mg/kg",mRNA,cas9,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,animal_model: Ai9 mice; administration_route: IV; dose: 0.75 mg/kg total RNA; gene_expression_result: tdTomato expression in liver after Cre-mediated recombination; biodistribution_result: Liver-specific gene editing,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
683,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:30:40:0.4,~150,,~-5,,"WR:4(wt/wt)[Cas9:sgRNA], total RNA dose 0.75 mg/kg",mRNA,cas9,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Ethanol dilution; device_used: Manual pipetting; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,animal_model: Ai9 mice; administration_route: IV; dose: 0.75 mg/kg total RNA; gene_expression_result: tdTomato expression in lung after Cre-mediated recombination; biodistribution_result: Lung-specific gene editing,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
684,9A1P9,DMG-PEG2000,cholesterol,5A2-SC8,25:30:30:1,77.2,,,,,mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,5A2-SC8,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixing system; total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation post-mixing; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"animal_model: C57BL/6 mice; administration_route: IV; dose: 0.05 mg/kg mRNA; gene_expression_result: High efficacy retained, liver-specific; biodistribution_result: Liver-selective delivery maintained",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
685,9A1P9,DMG-PEG2000,cholesterol,DDAB,60:30:40:0.4,108.1,,,,,mRNA,firefly_luciferase,DMG-PEG2000,9A1P9,DDAB,cholesterol,CCCCCCCCCOP(=O)(O)OCCN(CCCCCCCC)CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixing system; total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation post-mixing; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: High efficacy retained, lung-specific; biodistribution_result: Lung-selective delivery maintained",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
686,Custom lipid,DMG-PEG2000,cholesterol,MDOA,25:30:30:1,96.1,,,,,mRNA,firefly_luciferase,DMG-PEG2000,10A1P16,MDOA,cholesterol,CCCCCCCCC[N+](CCCC)(CCO[P-](=O)OCCCCCCCCCCCCCCCC)CCO[P-](=O)OCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: NanoAssemblr microfluidic mixing system; total_flow_rate_ml_min: 9; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citric acid/sodium citrate buffer (pH 3.2); organic_phase_composition: 100% ethanol; mixing_time_sec: 15 min incubation post-mixing; temperature_condition: Room temperature; post_processing: Dialysis against 1x PBS using Pur-A-Lyzer midi dialysis chambers; sterilization: ; storage_buffer: 1x PBS,"animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 mg/kg mRNA; gene_expression_result: High efficacy retained, spleen-specific; biodistribution_result: Spleen-selective delivery maintained",Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
687,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,,,,,,mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Standard LNP formulation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: ; organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,animal_model: C57BL/6 mice; administration_route: IV; dose: 0.05 mg/kg mRNA; gene_expression_result: 13-fold lower efficacy compared to 9A1P9-5A2-SC8 iPLNPs; biodistribution_result: Liver delivery,Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR?Cas gene editing,"['Shuai Liu', 'Qiang Cheng', 'Tuo Wei', 'Xueliang Yu', 'Lindsay T. Johnson', 'Lukas Farbiak', 'Daniel J. Siegwart']",https://doi.org/10.1038/s41563-020-00886-0,Nature Materials,2021
883,C12-200,PE-PEG2000,cholesterol,DOPE,50:1.5:38.5:10,~70,,,,WR:10(wt/wt)[C12-200:RNA],siRNA,firefly_luciferase,PEG2000-PE,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Parallelized Microfluidic Device (PMD) or single channel; total_flow_rate_ml_min: 0.06-1.26; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: RNA in buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS for two hours, filtered by 0.22 •Ïm filters; sterilization: 0.22 •Ïm filtration; storage_buffer: 1X PBS",cell_line: HeLa cells (firefly luciferase expressing); dose: 1-10 nM siRNA; gene_expression_result: >80% luciferase knockdown at 5 nM; toxicity_profile: No significant cytotoxicity at 10 nM,Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device,"['Sarah J. Shepherd', 'Claude C. Warzecha', 'Sagar Yadavali', 'Rakan El-Mayta', 'Mohamad-Gabriel Alameh', 'Lili Wang', 'Drew Weissman', 'James M. Wilson', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1021/acs.nanolett.1c01353,Nano Letters,2021
884,C12-200,PE-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,67.3-82.2 (microfluidic); 124.4 (bulk mixed),0.066-0.068 (microfluidic); 0.083 (bulk mixed),,95.0-95.6,WR:5(wt/wt)[C12-200:RNA],siRNA,factor_vii,PEG2000-PE,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Parallelized Microfluidic Device (PMD), single row PMD, or single channel; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: siRNA in buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS for two hours, concentrated using 50K MWCO centrifugal filters, filtered by 0.22 •Ïm filters; sterilization: 0.22 •Ïm filtration; storage_buffer: 1X PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.2 mg/kg; gene_expression_result: >90% Factor VII knockdown (microfluidic), ~20% (bulk mixed); biodistribution_result: Hepatic targeting; toxicity_profile: No significant differences in liver histopathology between formulations",Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device,"['Sarah J. Shepherd', 'Claude C. Warzecha', 'Sagar Yadavali', 'Rakan El-Mayta', 'Mohamad-Gabriel Alameh', 'Lili Wang', 'Drew Weissman', 'James M. Wilson', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1021/acs.nanolett.1c01353,Nano Letters,2021
885,C12-200,PE-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,77.3-82.4 (microfluidic); 145.1 (bulk mixed),0.089-0.108 (microfluidic); 0.085 (bulk mixed),,81.1-83.5 (microfluidic); 61.5 (bulk mixed),WR:10(wt/wt)[C12-200:RNA],mRNA,firefly_luciferase,PEG2000-PE,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Parallelized Microfluidic Device (PMD), single row PMD, or single channel; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: mRNA in buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS for two hours, concentrated using 50K MWCO centrifugal filters, filtered by 0.22 •Ïm filters; sterilization: 0.22 •Ïm filtration; storage_buffer: 1X PBS","animal_model: C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.2 mg/kg; gene_expression_result: 5-fold increase in luciferase expression compared to bulk mixed; biodistribution_result: Hepatic expression; toxicity_profile: No clinically significant differences in liver enzymes (AST, ALT, ALP)",Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device,"['Sarah J. Shepherd', 'Claude C. Warzecha', 'Sagar Yadavali', 'Rakan El-Mayta', 'Mohamad-Gabriel Alameh', 'Lili Wang', 'Drew Weissman', 'James M. Wilson', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1021/acs.nanolett.1c01353,Nano Letters,2021
886,C12-200,PE-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,~50,,,,WR:10(wt/wt)[C12-200:DNA],DNA,not_specified,PEG2000-PE,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Single row PMD; total_flow_rate_ml_min: 0.1-1.26; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: ssDNA in buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS for two hours, filtered; sterilization: ; storage_buffer: 1X PBS",,Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device,"['Sarah J. Shepherd', 'Claude C. Warzecha', 'Sagar Yadavali', 'Rakan El-Mayta', 'Mohamad-Gabriel Alameh', 'Lili Wang', 'Drew Weissman', 'James M. Wilson', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1021/acs.nanolett.1c01353,Nano Letters,2021
887,C12-200,PE-PEG2000,cholesterol,DOPE,50:1.5:38.5:10,~130,,,,WR:10(wt/wt)[C12-200:RNA],siRNA,firefly_luciferase,PEG2000-PE,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Bulk mixing; device_used: Electronic pipette at maximum flow rate; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: siRNA in buffer; organic_phase_composition: lipids in ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS for two hours, filtered by 0.45 •Ïm filters; sterilization: 0.45 •Ïm filtration; storage_buffer: 1X PBS",cell_line: HeLa cells (firefly luciferase expressing); dose: 1-10 nM siRNA; gene_expression_result: Equivalent knockdown to microfluidic formulations in vitro; toxicity_profile: No significant cytotoxicity,Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device,"['Sarah J. Shepherd', 'Claude C. Warzecha', 'Sagar Yadavali', 'Rakan El-Mayta', 'Mohamad-Gabriel Alameh', 'Lili Wang', 'Drew Weissman', 'James M. Wilson', 'David Issadore', 'Michael J. Mitchell']",https://doi.org/10.1021/acs.nanolett.1c01353,Nano Letters,2021
1029,7C1,C18-PEG2000,cholesterol,DOTAP,35:55:5:5,~80-120,0.2,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C18PEG2000,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (citrate:ethanol); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter; storage_buffer: 1°ø PBS, stored at 4°∆C","cell_line: lung epithelial cells (ciliated, club, alveolar type I and II); animal_model: BALB/c mice; administration_route: nebulization (inhalation); dose: 13.5-50 •Ïg mRNA per mouse; gene_expression_result: Significant lung luminescence, >28-fold higher than worst performing LNPs; biodistribution_result: broad delivery throughout lung sections, uniform punctate pattern, higher density at periphery; toxicity_profile: well tolerated, only 6 of 547 inflammatory genes significantly increased >2-fold; cytokine_response: minimal inflammatory response compared to LPS control",Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1030,7C1,C14-PEG2000,cholesterol,DOPE,60:10:2:28,243.1,,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1; aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter (failed QC); storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; dose: 43 •Ïg mRNA per mouse (pooled); gene_expression_result: Failed quality control - not tested in vivo,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1031,7C1,C14-PEG2000,cholesterol,DOTAP,60:10:25:5,123.3,,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1; aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; dose: 43 •Ïg mRNA per mouse (pooled in Group D); gene_expression_result: Moderate lung luminescence as part of Group D,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1032,7C1,C14-PEG2000,cholesterol,DOPE,60:5:30:5,73.6,0.203,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1; aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter; storage_buffer: 1°ø PBS,"animal_model: BALB/c mice; administration_route: nebulization; dose: 43 •Ïg mRNA per mouse (pooled in Group E); gene_expression_result: Highest lung luminescence among Groups D, E, F",Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1033,7C1,C14-PEG2000,cholesterol,DOTAP,60:25:10:5,~80-120,<0.2,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C14PEG2000,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1; aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; dose: 15 •Ïg mRNA per mouse; gene_expression_result: High delivery efficiency with 25% PEG molarity,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1034,7C1,C18-PEG2000,cholesterol,DOPE,60:15:20:5,~100-150,<0.3,,,WR:10(wt/wt)[LNP:mRNA],mRNA,nanoluciferase,C18PEG2000,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1; aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis in 20 kD dialysis cassettes; sterilization: 0.22 •Ïm filter; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; dose: 13.5 •Ïg mRNA per mouse; gene_expression_result: High delivery with neutral lipids and low PEG,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1035,7C1,C14-PEG2000,cholesterol,DOPE,60:30:5:5,45.4,0.199,,,"Lipid:RNA ratio 10, NP:5.5(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1036,7C1,C14-PEG2000,cholesterol,DOPE,55:35:5:5,56.6,0.201,,,"Lipid:RNA ratio 10, NP:5.1(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1037,7C1,C14-PEG2000,cholesterol,DOPE,45:45:5:5,54.2,0.187,,,"Lipid:RNA ratio 10, NP:4.3(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1038,7C1,C14-PEG2000,cholesterol,DOPE,35:55:5:5,50.7,0.308,,,"Lipid:RNA ratio 10, NP:3.5(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1039,7C1,C14-PEG2000,cholesterol,DOPE,30:60:5:5,40.8,0.143,,,"Lipid:RNA ratio 10, NP:3.0(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1040,7C1,C18-PEG2000,cholesterol,DOPE,60:30:5:5,165.5,,,,"Lipid:RNA ratio 10, NP:5.4(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1041,7C1,C18-PEG2000,cholesterol,DOPE,55:35:5:5,45.6,0.201,,,"Lipid:RNA ratio 10, NP:5.1(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1042,7C1,C18-PEG2000,cholesterol,DOPE,45:45:5:5,197.1,0.201,,,"Lipid:RNA ratio 10, NP:4.3(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1043,7C1,C18-PEG2000,cholesterol,DOPE,35:55:5:5,41.7,0.24,,,"Lipid:RNA ratio 10, NP:3.4(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1044,7C1,C18-PEG2000,cholesterol,DOPE,30:60:5:5,53.1,0.259,,,"Lipid:RNA ratio 10, NP:3.0(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1045,7C1,C14-PEG2000,cholesterol,DOPE,60:25:10:5,94.9,0.329,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1046,7C1,C14-PEG2000,cholesterol,DOPE,50:6.5:23.5:20,96.9,0.362,,,"Lipid:RNA ratio 10, NP:6.3(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1047,7C1,C14-PEG2000,cholesterol,DOPE,35:2.5:18:44.5,209.4,0.527,,,"Lipid:RNA ratio 10, NP:5.6(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1048,7C1,C14-PEG2000,cholesterol,DOPE,20:15:37.5:27.5,50.6,0.18,,,"Lipid:RNA ratio 10, NP:3.8(molar)",mRNA,empty,C14PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1049,7C1,C18-PEG2000,cholesterol,DOPE,60:25:10:5,64.9,0.218,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1050,7C1,C18-PEG2000,cholesterol,DOPE,50:6.5:23.5:20,475.9,0.241,,,"Lipid:RNA ratio 10, NP:6.2(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1051,7C1,C18-PEG2000,cholesterol,DOPE,35:2.5:18:44.5,103.2,,,,"Lipid:RNA ratio 10, NP:5.6(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1052,7C1,C18-PEG2000,cholesterol,DOPE,20:15:37.5:27.5,72.5,0.339,,,"Lipid:RNA ratio 10, NP:3.7(molar)",mRNA,empty,C18PEG2K,7C1,DOPE,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1053,7C1,C14-PEG2000,cholesterol,DSPC,60:25:10:5,52.2,0.397,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1054,7C1,C14-PEG2000,cholesterol,DSPC,50:6.5:23.5:20,254.8,0.466,,,"Lipid:RNA ratio 10, NP:6.2(molar)",mRNA,empty,C14PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1055,7C1,C14-PEG2000,cholesterol,DSPC,35:2.5:18:44.5,442.2,,,,"Lipid:RNA ratio 10, NP:5.6(molar)",mRNA,empty,C14PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1056,7C1,C14-PEG2000,cholesterol,DSPC,20:15:37.5:27.5,93.3,0.414,,,"Lipid:RNA ratio 10, NP:3.7(molar)",mRNA,empty,C14PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1057,7C1,C18-PEG2000,cholesterol,DSPC,60:25:10:5,52.4,0.238,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C18PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1058,7C1,C18-PEG2000,cholesterol,DSPC,50:6.5:23.5:20,110.6,0.532,,,"Lipid:RNA ratio 10, NP:6.2(molar)",mRNA,empty,C18PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1059,7C1,C18-PEG2000,cholesterol,DSPC,35:2.5:18:44.5,614.6,,,,"Lipid:RNA ratio 10, NP:5.5(molar)",mRNA,empty,C18PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1060,7C1,C18-PEG2000,cholesterol,DSPC,20:15:37.5:27.5,77.4,0.238,,,"Lipid:RNA ratio 10, NP:3.7(molar)",mRNA,empty,C18PEG2K,7C1,DSPC,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1061,7C1,C14-PEG2000,cholesterol,DOTAP,60:30:5:5,179.6,0.341,,,"Lipid:RNA ratio 10, NP:5.5(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1062,7C1,C14-PEG2000,cholesterol,DOTAP,55:35:5:5,68.5,0.292,,,"Lipid:RNA ratio 10, NP:5.1(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1063,7C1,C14-PEG2000,cholesterol,DOTAP,45:45:5:5,95.2,0.561,,,"Lipid:RNA ratio 10, NP:4.3(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1064,7C1,C14-PEG2000,cholesterol,DOTAP,35:55:5:5,65.5,0.305,,,"Lipid:RNA ratio 10, NP:3.5(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1065,7C1,C14-PEG2000,cholesterol,DOTAP,30:60:5:5,193.8,,,,"Lipid:RNA ratio 10, NP:3.0(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1066,7C1,C14-PEG2000,cholesterol,DOTAP,60:25:10:5,68.8,0.162,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1067,7C1,C14-PEG2000,cholesterol,DOTAP,50:6.5:23.5:20,173.1,0.304,,,"Lipid:RNA ratio 10, NP:6.3(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1068,7C1,C14-PEG2000,cholesterol,DOTAP,35:2.5:18:44.5,145.5,0.269,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1069,7C1,C14-PEG2000,cholesterol,DOTAP,20:15:37.5:27.5,149.1,0.529,,,"Lipid:RNA ratio 10, NP:3.8(molar)",mRNA,empty,C14PEG2K,7C1,DOTAP,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1070,7C1,C14-PEG2000,cholesterol,DOTMA,60:30:5:5,106.9,,,,"Lipid:RNA ratio 10, NP:5.5(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1071,7C1,C14-PEG2000,cholesterol,DOTMA,55:35:5:5,141.1,0.568,,,"Lipid:RNA ratio 10, NP:5.1(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1072,7C1,C14-PEG2000,cholesterol,DOTMA,45:45:5:5,103.4,0.389,,,"Lipid:RNA ratio 10, NP:4.3(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1073,7C1,C14-PEG2000,cholesterol,DOTMA,35:55:5:5,69.4,0.268,,,"Lipid:RNA ratio 10, NP:3.5(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1074,7C1,C14-PEG2000,cholesterol,DOTMA,30:60:5:5,96.2,,,,"Lipid:RNA ratio 10, NP:3.0(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1075,7C1,C14-PEG2000,cholesterol,DOTMA,60:25:10:5,355.7,,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1076,7C1,C14-PEG2000,cholesterol,DOTMA,50:6.5:23.5:20,163.2,0.353,,,"Lipid:RNA ratio 10, NP:6.3(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1077,7C1,C14-PEG2000,cholesterol,DOTMA,35:2.5:18:44.5,152.6,0.202,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1078,7C1,C14-PEG2000,cholesterol,DOTMA,20:15:37.5:27.5,81.9,0.377,,,"Lipid:RNA ratio 10, NP:3.8(molar)",mRNA,empty,C14PEG2K,7C1,DOTMA,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1079,7C1,C14-PEG2000,cholesterol,DDAB,60:30:5:5,60.2,0.412,,,"Lipid:RNA ratio 10, NP:5.5(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1080,7C1,C14-PEG2000,cholesterol,DDAB,55:35:5:5,89.8,0.455,,,"Lipid:RNA ratio 10, NP:5.1(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1081,7C1,C14-PEG2000,cholesterol,DDAB,45:45:5:5,79.5,0.376,,,"Lipid:RNA ratio 10, NP:4.3(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1082,7C1,C14-PEG2000,cholesterol,DDAB,35:55:5:5,72.2,0.45,,,"Lipid:RNA ratio 10, NP:3.5(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1083,7C1,C14-PEG2000,cholesterol,DDAB,30:60:5:5,81.5,,,,"Lipid:RNA ratio 10, NP:3.0(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1084,7C1,C14-PEG2000,cholesterol,DDAB,60:25:10:5,65.4,0.345,,,"Lipid:RNA ratio 10, NP:5.7(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1085,7C1,C14-PEG2000,cholesterol,DDAB,50:6.5:23.5:20,206,,,,"Lipid:RNA ratio 10, NP:6.3(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1086,7C1,C14-PEG2000,cholesterol,DDAB,35:2.5:18:44.5,130,0.209,,,"Lipid:RNA ratio 10, NP:5.8(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: included in study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
1087,7C1,C14-PEG2000,cholesterol,DDAB,20:15:37.5:27.5,125.5,,,,"Lipid:RNA ratio 10, NP:3.9(molar)",mRNA,empty,C14PEG2K,7C1,DDAB,cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Br-],synthesis_method: Microfluidic; device_used: microfluidic device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed in 20 kD dialysis cassettes; sterilization: ; storage_buffer: 1°ø PBS,animal_model: BALB/c mice; administration_route: nebulization; gene_expression_result: excluded from study,Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs,"['Melissa P. Lokugamage', 'Daryll Vanover', 'Jared Beyersdorf', 'Marine Z.C. Hatit', 'Lauren Rotolo', 'Elisa Schrader Echeverri', 'Hannah E. Peck', 'Huanzhen Ni', 'Jeong-Kee Yoon', 'YongTae Kim', 'Phillip J. Santangelo', 'James E. Dahlman']",10.1038/s41551-021-00786-x,Nature Biomedical Engineering,2021
174,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,100,0.23,,,,mRNA,"firefly_luciferase, base_editor",DMG-PEG2000,TT3,DOPE,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice, hemophilia A mice, Balb/c mice; administration_route: IV; dose: 0.5 mg/kg (screening), 2 mg/kg (hFVIII), 0.15-1.5 mg/kg (base editing); gene_expression_result: Reference control for comparison; biodistribution_result: Liver, spleen, lung, kidney, heart; toxicity_profile: Well tolerated",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
175,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,105,0.28,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT1,DOPE,cholesterol,CCCCCCCC=CC=CCCCCCCCCN(CCCCCCCC=CC=CCCCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCCC=CC=CCCCCCCCCC)CCCCCCCC=CC=CCCCCCCCCC)cc(C(=O)NCCCN(CCCCCCCC=CC=CCCCCCCCCC)CCCCCCCC=CC=CCCCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~1.0 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
176,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,94,0.17,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT2,DOPE,cholesterol,CCCCCCCCCCOC(=O)CCCCCCCCCN(CCCCCCCCCCOC(=O)CCCCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCCCCCOC(=O)CCCCCCCCCC)CCCCCCCCCCOC(=O)CCCCCCCCCC)cc(C(=O)NCCCN(CCCCCCCCCCOC(=O)CCCCCCCCCC)CCCCCCCCCCOC(=O)CCCCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~1.3 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
177,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,107,0.13,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT3,DOPE,cholesterol,CCC(CC)OC(=O)CCCCCCCCCN(CCC(CC)OC(=O)CCCCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCC(CC)OC(=O)CCCCCCCCCC)CCC(CC)OC(=O)CCCCCCCCCC)cc(C(=O)NCCCN(CCC(CC)OC(=O)CCCCCCCCCC)CCC(CC)OC(=O)CCCCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~1.0 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
178,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,103,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT4,DOPE,cholesterol,CC(CCC)CCCOC(=O)CCCCCCCN(CC(CCC)CCCOC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CC(CCC)CCCOC(=O)CCCCCCCC)CC(CCC)CCCOC(=O)CCCCCCCC)cc(C(=O)NCCCN(CC(CCC)CCCOC(=O)CCCCCCCC)CC(CCC)CCCOC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~0.9 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
179,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,86,0.25,'-11,91,,mRNA,"firefly_luciferase, base_editor",DMG-PEG2000,FTT5,DOPE,cholesterol,CCC(CCCC)COC(=O)CCCCCCCN(CCC(CCCC)COC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCC(CCCC)COC(=O)CCCCCCCC)CCC(CCCC)COC(=O)CCCCCCCC)cc(C(=O)NCCCN(CCC(CCCC)COC(=O)CCCCCCCC)CCC(CCCC)COC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice, hemophilia A mice, Balb/c mice; administration_route: IV; dose: 0.5 mg/kg (screening), 2 mg/kg (hFVIII), 0.125-1 mg/kg (base editing); gene_expression_result: ~2.0 fold vs TT3 in liver, >140 ng/ml hFVIII protein, 90% hFVIII activity, ~60% base editing efficiency; biodistribution_result: Primarily liver targeting; toxicity_profile: Well tolerated, no pathological changes",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
180,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,92,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT6,DOPE,cholesterol,CCCCCCCC(C)OC(=O)CCCCCCCN(CCCCCCCC(C)OC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCCC(C)OC(=O)CCCCCCCC)CCCCCCCC(C)OC(=O)CCCCCCCC)cc(C(=O)NCCCN(CCCCCCCC(C)OC(=O)CCCCCCCC)CCCCCCCC(C)OC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~0.7 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
181,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,93,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT7,DOPE,cholesterol,CCCCCCC=CCOC(=O)CCCCCCCN(CCCCCCC=CCOC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCC=CCOC(=O)CCCCCCCC)CCCCCCC=CCOC(=O)CCCCCCCC)cc(C(=O)NCCCN(CCCCCCC=CCOC(=O)CCCCCCCC)CCCCCCC=CCOC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~1.0 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
182,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,95,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT8,DOPE,cholesterol,CCCCCCC=CCCOC(=O)CCCCCCCN(CCCCCCC=CCCOC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCC=CCCOC(=O)CCCCCCCC)CCCCCCC=CCCOC(=O)CCCCCCCC)cc(C(=O)NCCCN(CCCCCCC=CCCOC(=O)CCCCCCCC)CCCCCCC=CCCOC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~1.1 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
183,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,98,0.14,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT9,DOPE,cholesterol,CCCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCCCCOC(=O)CCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCCCCCCCCCOC(=O)CCCCCCCC)CCCCCCCCCCOC(=O)CCCCCCCC)cc(C(=O)NCCCN(CCCCCCCCCCOC(=O)CCCCCCCC)CCCCCCCCCCOC(=O)CCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~0.2 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
184,Custom lipid,DMG-PEG2000,cholesterol,DOPE,20:0.75:40:30,100,0.15,,,,mRNA,firefly_luciferase,DMG-PEG2000,FTT10,DOPE,cholesterol,CCC=CCOC(=O)CCCCCCCCN(CCC=CCOC(=O)CCCCCCCCC)CCCNC(=O)c1cc(C(=O)NCCN(CCC=CCOC(=O)CCCCCCCCC)CCC=CCOC(=O)CCCCCCCCC)cc(C(=O)NCCCN(CCC=CCOC(=O)CCCCCCCCC)CCC=CCOC(=O)CCCCCCCCC)c1,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: NanoAssemblr benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate acid buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,"cell_line: Hep3B; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.5 mg/kg; gene_expression_result: ~0.1 fold vs TT3 in liver; biodistribution_result: Liver, spleen, lung, kidney, heart",Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing,"['Xinfu Zhang', 'Weiyu Zhao', 'Giang N. Nguyen', 'Chengxiang Zhang', 'Chunxi Zeng', 'Jingyue Yan', 'Shi Du', 'Xucheng Hou', 'Wenqing Li', 'Justin Jiang', 'Binbin Deng', 'David W. McComb', 'Robert Dorkin', 'Aalok Shah', 'Luis Barrera', 'Francine Gregoire', 'Manmohan Singh', 'Delai Chen', 'Denise E. Sabatino', 'Yizhou Dong']",10.1126/sciadv.abc2315,Science Advances,2020
395,Custom lipid,,,,100:0:0:0,85,,28,,,empty,empty,,76-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
396,Custom lipid,,,,100:0:0:0,175,,'-8,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,76-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
397,Custom lipid,,,,100:0:0:0,95,,25,,,empty,empty,,77-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
398,Custom lipid,,,,100:0:0:0,150,,'-12,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,77-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
399,Custom lipid,,,,100:0:0:0,110,,28,,,empty,empty,,80-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
400,Custom lipid,,,,100:0:0:0,165,,'-15,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,80-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
401,Custom lipid,,,,100:0:0:0,190,,22,,,empty,empty,,87-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
402,Custom lipid,,,,100:0:0:0,270,,'-18,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,87-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
403,Custom lipid,,,,100:0:0:0,200,,20,,,empty,empty,,93-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
404,Custom lipid,,,,100:0:0:0,265,,'-22,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,93-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
405,Custom lipid,,,,100:0:0:0,220,,18,,,empty,empty,,113-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
406,Custom lipid,,,,100:0:0:0,300,,'-42,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,113-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: high GFP silencing (>53.5%),Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
407,Custom lipid,,,,100:0:0:0,235,,5,,,empty,empty,,113-O12B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
408,Custom lipid,,,,100:0:0:0,325,,'-35,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,113-O12B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
409,Custom lipid,,,,100:0:0:0,215,,8,,,empty,empty,,113-O14B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
410,Custom lipid,,,,100:0:0:0,355,,'-35,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,113-O14B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: high GFP silencing (>LPF 2000); toxicity_profile: high cell viability (>76.4%),Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
411,Custom lipid,,,,100:0:0:0,220,,8,,,empty,empty,,113-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
412,Custom lipid,,,,100:0:0:0,245,,'-25,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,113-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
413,Custom lipid,,,,100:0:0:0,155,,5,,,empty,empty,,113-O18B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
414,Custom lipid,,,,100:0:0:0,240,,'-22,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,113-O18B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
415,Custom lipid,,,,100:0:0:0,235,,5,,,empty,empty,,200-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
416,Custom lipid,,,,100:0:0:0,390,,'-25,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,200-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
417,Custom lipid,,,,100:0:0:0,285,,12,,,empty,empty,,304-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
418,Custom lipid,,,,100:0:0:0,350,,'-25,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,304-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
419,Custom lipid,,,,100:0:0:0,140,,28,,,empty,empty,,306-O12B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
420,Custom lipid,,,,100:0:0:0,275,,'-32,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,306-O12B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: highest GFP silencing (81.5% GFP-negative cells); toxicity_profile: high cell viability (>76.4%),Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
421,Custom lipid,,,,100:0:0:0,195,,20,,,empty,empty,,306-O14B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
422,Custom lipid,,,,100:0:0:0,280,,'-28,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,306-O14B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
423,Custom lipid,,,,100:0:0:0,200,,20,,,empty,empty,,306-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
424,Custom lipid,,,,100:0:0:0,210,,'-25,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,306-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
425,Custom lipid,,,,100:0:0:0,220,,18,,,empty,empty,,306-O18B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
426,Custom lipid,,,,100:0:0:0,320,,'-25,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,306-O18B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: moderate GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
427,Custom lipid,,,,100:0:0:0,240,,15,,,empty,empty,,400-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: brief sonication; temperature_condition: room temperature; post_processing: dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
428,Custom lipid,,,,100:0:0:0,340,,'-12,,PCT:1°æ15(%),ASO,"aso(gfp, 5'-TTGCCGGTGGTGCAGATAAA-3')",,400-O16B,,,,,,,"synthesis_method: Direct dissolution; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (25 mM, pH 5.2); organic_phase_composition: ; mixing_time_sec: 15 min incubation at room temperature; temperature_condition: room temperature; post_processing: brief sonication and dialysis; sterilization: ; storage_buffer: sodium acetate buffer (25 mM, pH 5.2)",cell_line: GFP-HEK cells; dose: 0.1 mg/mL ASO concentration; gene_expression_result: minimal GFP silencing,Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo,"['Liu Yang', 'Feihe Ma', 'Fang Liu', 'Jinjin Chen', 'Xuewei Zhao', 'Qiaobing Xu']",https://doi.org/10.1016/j.omtn.2020.01.018,Molecular Therapy: Nucleic Acids,2020
946,cKK-E12,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,86.7 °æ 0.5 (Fluc mRNA); 82.5 °æ 1.8 (hEPO mRNA),0.17 (Fluc mRNA); 0.13 (hEPO mRNA),'-5.5 °æ 1.2,65.5 °æ 3.8 (Fluc mRNA); 56.5 °æ 3.3 (hEPO mRNA),,mRNA,"firefly_luciferase, epo, cre_recombinase",C14-PEG2000,cKK-E12,DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer (pH 3.5); organic_phase_composition: ethanol with dissolved lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1°øPBS in 20,000 MWCO cassette at 4°∆C for 2 h; sterilization: ; storage_buffer: 1°øPBS","cell_line: primary hepatocytes, HeLa cells; animal_model: C57BL/6 mice; administration_route: intravenous (IV); dose: 0.75 mg/kg mRNA; gene_expression_result: hEPO: ~14,000 ng/mL at 6h, Fluc: ~10^6 p/s/cm©˜/sr; biodistribution_result: primarily liver, followed by spleen; toxicity_profile: dose-dependent increase in AST, ALT, BUN, total bilirubin at °√2.25 mg/kg; cytokine_response: elevation of IFN, IL6, TNF•·, groAlpha, MCP1",Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver,"['Lei Miao', 'Jiaqi Lin', 'Yuxuan Huang', 'Linxian Li', 'Derfogail Delcassian', 'Yifan Ge', 'Yunhua Shi', 'Daniel G. Anderson']",https://doi.org/10.1038/s41467-020-16248-y,Nature Communications,2020
947,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,85 °æ 1.2 (Fluc mRNA); 78.2 °æ 2.1 (hEPO mRNA),0.10 (Fluc mRNA); 0.16 (hEPO mRNA),'-1.1 °æ 0.8,75.2 °æ 3.1 (Fluc mRNA); 81.5 °æ 2.5 (hEPO mRNA),,mRNA,"firefly_luciferase, epo",C14-PEG2000,A6 (biodegradable alkyne lipid),DOPE,cholesterol,,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer (pH 3.5); organic_phase_composition: ethanol with dissolved lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1°øPBS in 20,000 MWCO cassette at 4°∆C for 2 h; sterilization: ; storage_buffer: 1°øPBS","cell_line: primary hepatocytes, HeLa cells; animal_model: C57BL/6 mice; administration_route: intravenous (IV); dose: 0.75 mg/kg mRNA; gene_expression_result: moderate protein expression, enhanced fusion capability; biodistribution_result: primarily liver; toxicity_profile: lower toxicity compared to cKK-E12, minimal immune stimulation; cytokine_response: reduced inflammatory cytokines compared to cKK-E12",Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver,"['Lei Miao', 'Jiaqi Lin', 'Yuxuan Huang', 'Linxian Li', 'Derfogail Delcassian', 'Yifan Ge', 'Yunhua Shi', 'Daniel G. Anderson']",https://doi.org/10.1038/s41467-020-16248-y,Nature Communications,2020
948,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,99.5 °æ 0.3 (Fluc mRNA); 91.2 °æ 0.5 (hEPO mRNA),0.07 (Fluc mRNA); 0.13 (hEPO mRNA),'-2.1 °æ 1.3,72.5 °æ 2.2 (Fluc mRNA); 71.2 °æ 3.2 (hEPO mRNA),,mRNA,"firefly_luciferase, epo, cre_recombinase",C14-PEG2000,cKK-E12:A6 (7:3 molar ratio),DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 10 mM citrate buffer (pH 3.5); organic_phase_composition: ethanol with dissolved lipids; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1°øPBS in 20,000 MWCO cassette at 4°∆C for 2 h; sterilization: ; storage_buffer: 1°øPBS","cell_line: primary hepatocytes, HeLa cells; animal_model: C57BL/6 mice, renal anemia mouse model; administration_route: intravenous (IV); dose: 0.75 mg/kg mRNA, 0.015-0.25 mg/kg for repeated dosing; gene_expression_result: 5.69-fold higher Fluc expression than cKK-E12, 2.52-fold higher hEPO than cKK-E12; biodistribution_result: primarily liver (73.4% hepatocytes expressing), spleen; toxicity_profile: improved tolerability, lower AST levels after repeated dosing; cytokine_response: reduced inflammatory cytokines compared to cKK-E12",Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver,"['Lei Miao', 'Jiaqi Lin', 'Yuxuan Huang', 'Linxian Li', 'Derfogail Delcassian', 'Yifan Ge', 'Yunhua Shi', 'Daniel G. Anderson']",https://doi.org/10.1038/s41467-020-16248-y,Nature Communications,2020
1088,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,80,0.05,,95,WR:20(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Nanoassemblr Benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 100 mM pH 4 citrate buffer (3-fold excess by volume compared to lipid solution); organic_phase_composition: ethanol containing lipids at total concentration of 5.5 mM; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed twice against 3 L of pH 7 PBS buffer and concentrated using appropriate centrifuge filters; sterilization: ; storage_buffer: pH 7 PBS buffer,cell_line: HeLa; dose: 50-200 ng mRNA; gene_expression_result: baseline (normalized to 1),Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery,"['Yulia Eygeris', 'Siddharth Patel', 'Antony Jozic', 'Gaurav Sahay']",https://dx.doi.org/10.1021/acs.nanolett.0c01386,Nano Letters,2020
1089,DLin-MC3-DMA,DMG-PEG2000,•‚-sitosterol,DSPC,50:1.5:38.5:10,90,0.08,,92,WR:20(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,•‚-sitosterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Nanoassemblr Benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 100 mM pH 4 citrate buffer (3-fold excess by volume compared to lipid solution); organic_phase_composition: ethanol containing lipids at total concentration of 5.5 mM; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed twice against 3 L of pH 7 PBS buffer and concentrated using appropriate centrifuge filters; sterilization: ; storage_buffer: pH 7 PBS buffer,cell_line: HeLa; dose: 50-200 ng mRNA; gene_expression_result: ~10-fold improvement compared to cholesterol LNPs,Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery,"['Yulia Eygeris', 'Siddharth Patel', 'Antony Jozic', 'Gaurav Sahay']",https://dx.doi.org/10.1021/acs.nanolett.0c01386,Nano Letters,2020
1090,DLin-MC3-DMA,DMG-PEG2000,fucosterol,DSPC,50:1.5:38.5:10,85,0.07,,90,WR:20(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,fucosterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C/C=C(\CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)/C(C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Nanoassemblr Benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 100 mM pH 4 citrate buffer (3-fold excess by volume compared to lipid solution); organic_phase_composition: ethanol containing lipids at total concentration of 5.5 mM; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed twice against 3 L of pH 7 PBS buffer and concentrated using appropriate centrifuge filters; sterilization: ; storage_buffer: pH 7 PBS buffer,cell_line: HeLa; dose: 50-200 ng mRNA; gene_expression_result: ~2-fold improvement compared to cholesterol LNPs,Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery,"['Yulia Eygeris', 'Siddharth Patel', 'Antony Jozic', 'Gaurav Sahay']",https://dx.doi.org/10.1021/acs.nanolett.0c01386,Nano Letters,2020
1091,DLin-MC3-DMA,DMG-PEG2000,campesterol,DSPC,50:1.5:38.5:10,95,0.1,,88,WR:20(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,campesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CC[C@@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Nanoassemblr Benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 100 mM pH 4 citrate buffer (3-fold excess by volume compared to lipid solution); organic_phase_composition: ethanol containing lipids at total concentration of 5.5 mM; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed twice against 3 L of pH 7 PBS buffer and concentrated using appropriate centrifuge filters; sterilization: ; storage_buffer: pH 7 PBS buffer,cell_line: HeLa; dose: 50-200 ng mRNA; gene_expression_result: ~5-fold improvement compared to cholesterol LNPs,Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery,"['Yulia Eygeris', 'Siddharth Patel', 'Antony Jozic', 'Gaurav Sahay']",https://dx.doi.org/10.1021/acs.nanolett.0c01386,Nano Letters,2020
1092,DLin-MC3-DMA,DMG-PEG2000,stigmastanol,DSPC,50:1.5:38.5:10,100,0.12,,85,WR:20(wt/wt)[ionizable_lipid:mRNA],mRNA,firefly_luciferase,DMG-PEG2000,DLin-MC3-DMA,DSPC,stigmastanol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Nanoassemblr Benchtop; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 100 mM pH 4 citrate buffer (3-fold excess by volume compared to lipid solution); organic_phase_composition: ethanol containing lipids at total concentration of 5.5 mM; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed twice against 3 L of pH 7 PBS buffer and concentrated using appropriate centrifuge filters; sterilization: ; storage_buffer: pH 7 PBS buffer,cell_line: HeLa; dose: 50-200 ng mRNA; gene_expression_result: ~5-fold improvement compared to cholesterol LNPs,Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery,"['Yulia Eygeris', 'Siddharth Patel', 'Antony Jozic', 'Gaurav Sahay']",https://dx.doi.org/10.1021/acs.nanolett.0c01386,Nano Letters,2020
63,DLin-MC3-DMA,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,50-142,,,69-100,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen",PEG lipid,MC3,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg; gene_expression_result: robust titers and protein expression; biodistribution_result: detectable in liver and spleen 24 h post-IM injection; toxicity_profile: mild to moderate local and systemic adverse events; cytokine_response: elevated IL-6 levels",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
64,DOTAP,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,50-142,,,69-100,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen",PEG lipid,"DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium)",DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C",animal_model: BALB/c mice; administration_route: IM; dose: 0.001 mg/kg; gene_expression_result: no detectable protein expression,Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
65,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66-107,,,72,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen, viral_antigen",PEG lipid,Lipid H (proprietary biodegradable ionizable lipid),DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","cell_line: HeLa cells; animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg to 500 •Ïg; gene_expression_result: significantly higher expression than MC3 (p < 0.001); biodistribution_result: rapid clearance from muscle, spleen, and liver; toxicity_profile: best tolerated lipid with no signs of swelling or redness in NHPs, reduced inflammation compared to MC3; cytokine_response: lowest systemic cytokine production (eotaxin, GRO-alpha, IP-10, RANTES, MCP-1)",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
66,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66-107,,,72,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen, viral_antigen",PEG lipid,Lipid M (proprietary biodegradable ionizable lipid),DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg to 500 •Ïg; gene_expression_result: significantly higher expression than MC3 (p = 0.05); biodistribution_result: rapid clearance from muscle, spleen, and liver; toxicity_profile: improved tolerability compared to MC3; cytokine_response: reduced cytokine production compared to MC3",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
67,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66-107,,,72,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen, viral_antigen",PEG lipid,Lipid P (proprietary biodegradable ionizable lipid),DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg to 500 •Ïg; gene_expression_result: comparable to MC3; biodistribution_result: rapid clearance from muscle, spleen, and liver; toxicity_profile: significantly lower than MC3 after first dose (p < 0.01) and second dose (p < 0.001) by HAI titer; cytokine_response: reduced cytokine production compared to MC3",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
68,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66-107,,,72,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen, viral_antigen",PEG lipid,Lipid Q (proprietary biodegradable ionizable lipid),DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg to 500 •Ïg; gene_expression_result: lower IgG serum concentrations than MC3; biodistribution_result: rapid clearance from muscle, spleen, and liver but did not return to baseline levels by 48 h; toxicity_profile: improved tolerability compared to MC3; cytokine_response: reduced cytokine production compared to MC3",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
69,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66-107,,,72,NP:5.67(molar),mRNA,"firefly_luciferase, influenza_antigen, viral_antigen",PEG lipid,Lipid N (proprietary biodegradable ionizable lipid),DSPC,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixer; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 50 mM sodium citrate (pH 4.0) or 25 mM sodium acetate (pH 5.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.2) or 20 mM Tris (pH 7.4) with 8% sucrose for at least 18 h, concentrated using Amicon ultra-centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: PBS at 4°∆C or 20 mM Tris-8% sucrose at -20°∆C","animal_model: BALB/c mice, CD-1 mice, cynomolgus monkeys, Sprague-Dawley rats; administration_route: IM; dose: 0.001 mg/kg to 500 •Ïg; gene_expression_result: higher IgG serum concentrations than MC3 (p < 0.05); biodistribution_result: rapid clearance from muscle, spleen, and liver; toxicity_profile: improved tolerability compared to MC3, lowest muscle fiber necrosis scores; cytokine_response: reduced cytokine production compared to MC3",Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines,"['Kimberly J. Hassett', 'Kerry E. Benenato', 'Eric Jacquinet', 'Aisha Lee', 'Angela Woods', 'Olga Yuzhakov', 'Sunny Himansu', 'Jessica Deterling', 'Benjamin M. Geilich', 'Tatiana Ketova', 'Cosmin Mihai', 'Andy Lynn', 'Iain McFadyen', 'Melissa J. Moore', 'Joseph J. Senn', 'Matthew G. Stanton', 'Orn Almarsson', 'Giuseppe Ciaramella', 'Luis A. Brito']",https://doi.org/10.1016/j.omtn.2019.01.013,Molecular Therapy: Nucleic Acids,2019
450,C12-200,C14-PEG2000,cholesterol,DOPE,40:2.5:53.5:4,82.4,0.198,'-14.7,67.5,OTHER:2.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
451,C12-200,C14-PEG2000,cholesterol,DOPE,60:0.5:29.5:10,90.77,0.226,'-16.7,33.7,OTHER:2.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
452,C12-200,C14-PEG2000,cholesterol,DOPE,40:3.5:28.5:28,78.53,0.224,'-2.65,48.9,OTHER:7.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
453,C12-200,C14-PEG2000,cholesterol,DOPE,40:2.5:29.5:28,81.49,0.202,'-5.76,92.8,OTHER:10:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
454,C12-200,C14-PEG2000,cholesterol,DOPE,40:3.0:35.0:22,74.42,0.226,'-2.1,95.7,OTHER:12.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
455,C12-200,C14-PEG2000,cholesterol,DOPE,35:3.0:40.0:22,82.03,0.221,'-3.39,90.7,OTHER:7.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
456,C12-200,C14-PEG2000,cholesterol,DOPE,35:3.5:39.5:22,79.23,0.212,'-4.34,49.9,OTHER:10:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
457,C12-200,C14-PEG2000,cholesterol,DOPE,30:3.0:51.0:16,83.25,0.205,'-5.08,91.3,OTHER:10:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
458,C12-200,C14-PEG2000,cholesterol,DOPE,30:2.5:51.5:16,81.4,0.174,'-9.04,92.7,OTHER:5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
459,C12-200,C14-PEG2000,cholesterol,DOPE,40:1.5:42.5:16,75.58,0.208,'-8.16,89.1,OTHER:7.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
460,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,83.55,0.203,'-11.7,89.8,OTHER:5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
461,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,88.09,0.224,'-7.53,88.4,OTHER:7.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; biodistribution_result: liver, spleen, lung, brain, kidney, heart, pancreas, muscle",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
462,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,83.36,0.204,'-3.77,87.4,OTHER:10:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS",cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; gene_expression_result: Higher luciferase expression compared to F01; biodistribution_result: Higher delivery to liver and spleen compared to F01,Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
463,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,77.32,0.214,'-4.23,76.6,OTHER:12.5:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; gene_expression_result: High delivery to most tissues; biodistribution_result: Higher b-mRNA delivery to liver, spleen, brain, heart, kidney, and pancreas",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
464,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,84.71,0.233,'-4.22,88.7,OTHER:15:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; gene_expression_result: High delivery to most tissues; biodistribution_result: Higher b-mRNA delivery to liver, spleen, brain, heart, kidney, and pancreas",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
465,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,80.85,0.223,'-4.01,86.1,OTHER:25:1 ionizable lipid:mRNA weight ratio,mRNA,"luciferase, barcode(luciferase mrna with barcode and umi)",C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3.0); organic_phase_composition: ethanol containing lipids; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialyzed against PBS for 2 hours, 0.22 •Ïm filtration; sterilization: 0.22 •Ïm sterile filter; storage_buffer: PBS","cell_line: bEnd.3; animal_model: C57BL/6 mice; administration_route: IV; dose: 0.25 •Ïg b-mRNA per formulation; gene_expression_result: High delivery to most tissues, highest luciferase expression; biodistribution_result: Higher b-mRNA delivery to liver, spleen, brain, heart, kidney, and pancreas",Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,"['Pedro P. Guimaraes', 'Rui Zhang', 'Roman Spektor', 'Mingchee Tan', 'Amanda Chung', 'Margaret M. Billingsley', 'Rakan El-Mayta', 'Rachel S. Riley', 'Lili Wang', 'James M. Wilson', 'Michael J. Mitchell']",10.1016/j.jconrel.2019.10.028,Journal of Controlled Release,2019
559,DLin-KC2-DMA,PEG-DSPE (PEG2000-DSPE),cholesterol,DSPC,50:10:39:1,17 (pH 4); 45 (pH 7.4),,,,,empty,empty,PEG-DSPE (PEG2000-DSPE),"KC2 (2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane)","DSPC (1,2-distearoyl-sn-glycero-3-phosphorylcholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic, 15:5 mL/min); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1000-fold volume of pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4",,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
560,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:37.5:2.5,17 (pH 4); 31.9 (pH 7.4),,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1000-fold volume buffer; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
561,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39.5:0.5,17 (pH 4); 58.1 (pH 7.4),,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1000-fold volume buffer; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
562,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,17 (pH 4); 40 (pH 7.4),,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 1000-fold volume buffer; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
563,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,19 (liposomes pH 4); 39.4 (electron-dense pH 4); 55.6 (pH 7.4),,,>85,NP:6(molar),mRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with mRNA (0.029 mg/•Ïmol lipid, N/P=6); organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4",,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
564,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,18.5 (liposomes pH 4); 47.6 (electron-dense pH 4); 68 (pH 7.4),,,>85,NP:6(molar),DNA,minicircle_dna,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with mcDNA (0.029 mg/•Ïmol lipid, N/P=6); organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4",,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
565,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,17.2 (liposomes pH 4); 56.3 (electron-dense pH 4); 67.8 (pH 7.4),,,>85,NP:6(molar),DNA,minicircle_dna,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with mcDNA (0.029 mg/•Ïmol lipid, N/P=6); organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4",,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
566,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,22.9 (liposomes pH 4); 47.3 (electron-dense pH 4); 59.4 (pH 7.4),,,>85,NP:6(molar) (1.68°ø10^4 ionizable lipids per pDNA),DNA,plasmid_dna,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with pDNA (0.029 mg/•Ïmol lipid, N/P=6); organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4",,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
567,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,30 (pH 4); 53 (pH 7.4),,,~80 loaded particles at pH 7.4,OTHER:constant GNP surface area-to-lipid ratio of 1.73°ø10^15 nm©˜/•Ïmol lipid,gold_nanoparticles,gold_nanoparticles,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with 2.2°ø10^13 GNP/•Ïmol lipid; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
568,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:10:39:1,21 (pH 4); 52 (pH 7.4),,,~35 loaded particles at pH 7.4,OTHER:constant GNP surface area-to-lipid ratio of 1.73°ø10^15 nm©˜/•Ïmol lipid,gold_nanoparticles,gold_nanoparticles,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with 3.82°ø10^12 GNP/•Ïmol lipid; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
569,Custom lipid,DSPE-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,,,,>85,NP:1(molar)-3,siRNA,firefly_luciferase,PEG-DSPE,"MC3 (heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate)",DSPC,cholesterol,,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection/rapid-mixing; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4.0 buffer with siRNA; organic_phase_composition: ethanol with 10-15 mM total lipid; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against pH 4 buffer or PBS pH 7.4; sterilization: ; storage_buffer: 25 mM sodium acetate pH 4.0 or PBS pH 7.4,,Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Roy van der Meel', 'Josh Zaifman', 'Maria M. Darjuan', 'Hiu Man Grisch-Chan', 'Beat Thony', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/C9NR02004G,Nanoscale,2019
595,C12-200,,cholesterol,DOPE,35:0:49:16,~200,~0.2,8,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^6 RLU (in vitro), ~10^6 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
596,C12-200,,cholesterol,DOPE,35:0:49:16,~200,~0.2,'-10,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^4 RLU (in vitro), ~10^4 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
597,,,cholesterol,DOPE,0:0:49:16,~150,~0.2,25,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^5 RLU (in vitro), ~10^5 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
598,,,cholesterol,DOPE,0:0:49:16,~150,~0.2,15,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^6 RLU (in vitro), ~10^6 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
599,,,cholesterol,DOPE,0:0:49:16,~200,~0.2,30,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: PBS,"cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^5 RLU (in vitro), ~10^5 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
600,,,cholesterol,DOPE,0:0:49:16,~200,~0.2,8,,NP:12(molar):1,mRNA,"firefly_luciferase, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","cell_line: HEK293T.17; animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 100 ng saRNA per well (in vitro), 5 •Ïg saRNA per leg (in vivo); gene_expression_result: ~10^5 RLU (in vitro), ~10^5 RLU (in vivo); biodistribution_result: IM injection sites",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
601,C12-200,,cholesterol,DOPE,35:0:49:16,~200,~0.2,8,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: 1x PBS,"animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: HIV-1 Env gp140-specific IgG antibody response measured by ELISA",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
602,C12-200,,cholesterol,DOPE,35:0:49:16,~200,~0.2,'-10,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: No detectable HIV-1 Env gp140-specific IgG antibody response",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
603,,,cholesterol,DOPE,0:0:49:16,~150,~0.2,25,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: 1x PBS,"animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: HIV-1 Env gp140-specific IgG antibody response measured by ELISA",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
604,,,cholesterol,DOPE,0:0:49:16,~150,~0.2,15,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: Peak HIV-1 Env gp140-specific IgG antibody response after single injection",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
605,,,cholesterol,DOPE,0:0:49:16,~200,~0.2,30,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: citrate buffer (pH 3); organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS in 3500 MWCO dialysis cartridge for 4 h; sterilization: ; storage_buffer: 1x PBS,"animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: HIV-1 Env gp140-specific IgG antibody response measured by ELISA",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
606,,,cholesterol,DOPE,0:0:49:16,~200,~0.2,8,,NP:12(molar):1,mRNA,"viral_antigen, veev_replicon",,,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic (exterior complexation); device_used: •ÏEncapsulator 1 System (Dolomite Bio); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: naive citrate buffer, then saRNA in citrate buffer (pH 3) added post-production; organic_phase_composition: 90% EtOH with lipids at 1.5 mg/mL total concentration; mixing_time_sec: ; temperature_condition: chip T = 70°∆C; post_processing: dialyzed against PBS, then saRNA added 30-45 min prior to experiment; sterilization: ; storage_buffer: pH 7 PBS","animal_model: BALB/c mice (female, 6-8 weeks); administration_route: IM; dose: 5 •Ïg saRNA per injection; biodistribution_result: IM injection sites; cytokine_response: Peak HIV-1 Env gp140-specific IgG antibody response after single injection",Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA,"['Anna K. Blakney', 'Paul F. McKay', 'Barbara Ibarzo Yus', 'Yoann Aldon', 'Robin J. Shattock']",https://doi.org/10.1038/s41434-019-0095-2,Gene Therapy,2019
742,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,94:1:2.5:2.5,135,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
743,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,79:1:10:10,90,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
744,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,59:1:20:20,47,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
745,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,39:1:30:30,42,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
746,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,19:1:40:40,52,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
747,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:0.5:24.75:24.75,58,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
748,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:1:24.5:24.5,45,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
749,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:1.5:24.25:24.25,39,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
750,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,50:2.5:23.75:23.75,32,,,,,empty,empty,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
751,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,94:1:2.5:2.5,190,,,40,NP:1(molar),siRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer containing siRNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
752,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,79:1:10:10,175,,,75,NP:1(molar),siRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer containing siRNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
753,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,59:1:20:20,125,,,78,NP:1(molar),siRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer containing siRNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
754,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,39:1:30:30,78,,,80,NP:1(molar),siRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer containing siRNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
755,DLin-KC2-DMA,DSPE-PEG2000,cholesterol,DSPC,19:1:40:40,65,,,79,NP:1(molar),siRNA,firefly_luciferase,PEG-DSPE,KC2,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer containing siRNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS pH 7.4; sterilization: ; storage_buffer: PBS pH 7.4,,On the role of helper lipids in lipid nanoparticle formulations of siRNA,"['Jayesh A. Kulkarni', 'Dominik Witzigmann', 'Jerry Leung', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1039/c9nr09347h,Nanoscale,2019
888,DLinDMA,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,132,0.12,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,DLinDMA (1),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 0.653 nM (in vitro); biodistribution_result: 52% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
889,DODMA,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,123,0.14,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,DODMA (2),DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; gene_expression_result: IC50 18.4 nM (in vitro),Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
890,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,121,0.15,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,DPalDMA (3),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 4.23 nM (in vitro); biodistribution_result: 81% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
891,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,140,0.11,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,"R,R-4 (PYR core with linoleyl chains)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 1.01 nM (in vitro); biodistribution_result: 44% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
892,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,136,0.15,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,cis-4 (PYR core with linoleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; gene_expression_result: IC50 28.8 nM (in vitro),Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
893,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,129,0.13,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,"S,S-4 (PYR core with linoleyl chains)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; gene_expression_result: IC50 5.67 nM (in vitro),Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
894,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,161,0.091,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,"R,R-5 (PYR core with oleyl chains)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; gene_expression_result: IC50 16.4 nM (in vitro),Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
895,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,139,0.13,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,"R,R-6 (PYR core with palmitoleyl chains)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; gene_expression_result: IC50 0.561 nM (in vitro),Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
896,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,154,0.12,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,7 (DEA core with linoleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 25.4 nM (in vitro); biodistribution_result: 86% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
897,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,152,0.045,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,8 (DEA core with oleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 0.922 nM (in vitro); biodistribution_result: 64% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
898,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,127,0.086,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,9 (DEA core with palmitoleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 0.667 nM (in vitro); biodistribution_result: 42% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
899,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,156,0.081,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,"10 (SST-01, DA core with linoleyl chains)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 5.96 nM (in vitro); biodistribution_result: 37% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
900,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,163,0.073,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,11 (DA core with oleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 7.30 nM (in vitro); biodistribution_result: 82% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
901,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,123,0.15,,,CONC:1.5(mg/mL)[siRNA],siRNA,apob,PEG-DMPE,12 (DA core with palmitoleyl chains),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: SNALP-like one-step method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citrate buffer (pH 5.0); organic_phase_composition: 90 vol% ethanol/water; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.2 •Ïm filter; storage_buffer: DPBS",cell_line: HepG2; animal_model: Balb/c mice; administration_route: IV; dose: 3 mg/kg; gene_expression_result: IC50 0.839 nM (in vitro); biodistribution_result: 42% relative serum cholesterol level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
902,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,143,0.14,,,,siRNA,factor_vii,PEG-DMPE,"13 (N,N-dilinoleyl-2,3-dihydroxypropanamine)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: One-step SNALP-like method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citric acid buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: DPBS",animal_model: male Balb/c mice; administration_route: IV; dose: 0.3 mg/kg; gene_expression_result: 91% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
903,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,174,0.1,,,,siRNA,factor_vii,PEG-DMPE,14 (ethyl 3-(dilinoleylamino)propanoate),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: One-step SNALP-like method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citric acid buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: DPBS",animal_model: male Balb/c mice; administration_route: IV; dose: 0.3 mg/kg; gene_expression_result: 96% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
904,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,137,0.19,,,,siRNA,factor_vii,PEG-DMPE,15 (3-(dilinoleylamino)propionamide),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: One-step SNALP-like method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citric acid buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: DPBS",animal_model: male Balb/c mice; administration_route: IV; dose: 0.3 mg/kg; gene_expression_result: 95% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
905,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,124 (one-step); 88 (two-step),0.16 (one-step); 0.12 (two-step),,,,siRNA,factor_vii,PEG-DMPE,"16 (SST-02, (3-hydroxylpropyl)dilinoleylamine)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: One-step SNALP-like method / Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 2 mM Tris-EDTA buffer, 20 mM citric acid buffer, pH 4.0 (one-step) / 24 mg/mL FVII-siRNA (two-step); organic_phase_composition: ethanol / 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: DPBS (one-step) / saline (two-step)","animal_model: male Balb/c mice, male Sprague-Dawley rats; administration_route: IV; dose: 0.3 mg/kg (one-step), 0.03-0.1 mg/kg (two-step), 1-5 mg/kg (toxicity); gene_expression_result: 12% relative serum factor VII protein level (one-step), ID50 = 0.02 mg/kg (two-step); toxicity_profile: No body weight loss up to 5 mg/kg, decreased AST at 5 mg/kg",Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
906,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,99,0.18,,,,siRNA,factor_vii,PEG-DMPE,"17 (N,N-dilinoleyl-2-hydroxyethanamine)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 24 mg/mL FVII-siRNA; organic_phase_composition: 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: saline,animal_model: male Balb/c mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: 25% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
907,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,96,0.15,,,,siRNA,factor_vii,PEG-DMPE,"18 (N,N-dilinoleyl-4-hydroxybutanamine)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 24 mg/mL FVII-siRNA; organic_phase_composition: 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: saline,animal_model: male Balb/c mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: 34% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
908,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,96,0.18,,,,siRNA,factor_vii,PEG-DMPE,"19 (N,N-dilinoleyl-5-hydroxypentan amine)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 24 mg/mL FVII-siRNA; organic_phase_composition: 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: saline,animal_model: male Balb/c mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: 65% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
909,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,92,0.11,,,,siRNA,factor_vii,PEG-DMPE,20 (3-hydroxylpropyl)dioleylamine),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 24 mg/mL FVII-siRNA; organic_phase_composition: 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: saline,animal_model: male Balb/c mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: 82% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
910,Custom lipid,PEG-DMPE,cholesterol,DSPC,30.4:3.7:46.5:19.4,93,0.15,,,,siRNA,factor_vii,PEG-DMPE,21 ((3-hydroxylpropyl)dipalmitoleylamine),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Two-step WS method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 24 mg/mL FVII-siRNA; organic_phase_composition: 20 vol% ethanol/water containing 0.06 mol/L HCl; mixing_time_sec: ; temperature_condition: 37°∆C; post_processing: ultrafiltration with Amicon Ultra (MWCO 100 kDa); sterilization: 0.20 •Ïm filter; storage_buffer: saline,animal_model: male Balb/c mice; administration_route: IV; dose: 0.03 mg/kg; gene_expression_result: 66% relative serum factor VII protein level,Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles,"['Takeshi Kuboyama', 'Kaori Yagi', 'Tomoyuki Naoi', 'Tomohiro Era', 'Nobuhiro Yagi', 'Yoshisuke Nakasato', 'Hayato Yabuuchi', 'Saori Takahashi', 'Fumikazu Shinohara', 'Hiroto Iwai', 'Ayumi Koubara-Yamada', 'Kazumasa Hasegawa', 'Atsushi Miwa']",10.1021/acsmedchemlett.8b00652,ACS Medicinal Chemistry Letters,2019
949,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,99.9,0.145,4.36,77.0 °æ 2.6 (Luc mRNA); 68.4 °æ 3.2 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova, trp2",C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs, B16F10, B16-OVA; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 6.88°æ0.08E+04 RLU (in vitro macrophage), 1.8°æ0.4E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 31.7°æ5.6 IU/L, ALT: 132.3°æ22.4 IU/L, Histology: OK; cytokine_response: CTL lysis: 53.3°æ12.6%, ELISpot: 159.7°æ56.2 spots, Antibody titer: 200.3°æ25.7 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
950,A12-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,87.9,0.135,4.85,68.4 °æ 2.8 (Luc mRNA); 76.1 °æ 2.5 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A12-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN(C)C)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 5.01°æ0.80E+04 RLU (in vitro macrophage), 1.6°æ0.3E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 31.3°æ2.8 IU/L, ALT: 113.7°æ8.5 IU/L, Histology: OK; cytokine_response: CTL lysis: 27.2°æ1.7%, ELISpot: 14.7°æ2.5 spots, Antibody titer: 49.5°æ19.8 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
951,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,86.9,0.205,8.37,61.2 °æ 3.7 (Luc mRNA); 85.8 °æ 6.7 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A13-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN1CCCCC1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 1.54°æ0.12E+05 RLU (in vitro macrophage), 2.0°æ0.2E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 29.6°æ8.1 IU/L, ALT: 124.3°æ52.4 IU/L, Histology: OK; cytokine_response: CTL lysis: 81.4°æ3.3%, ELISpot: 357.3°æ48.7 spots, Antibody titer: 258.3°æ62.8 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
952,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,89.6,0.159,4.54,63.4 °æ 4.6 (Luc mRNA); 67.3 °æ 3.5 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A17-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN1CC(C)CCC1CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 7.92°æ1.69E+04 RLU (in vitro macrophage), 2.7°æ0.4E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 31.5°æ4.0 IU/L, ALT: 128.3°æ13.3 IU/L, Histology: OK; cytokine_response: CTL lysis: 96.6°æ2.1%, ELISpot: 854.3°æ60.3 spots, Antibody titer: 457.2°æ22.2 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
953,A18-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,95.9,0.166,6.41,67.6 °æ 5.1 (Luc mRNA); 70.3 °æ 4.6 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova, e7, trp2",C14-PEG2000,A18-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2C(CCCC2)CC)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs, B16F10, TC-1, B16-OVA; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 4.01°æ0.60E+05 RLU (in vitro macrophage), 4.4°æ0.6E+08 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 29.5°æ1.5 IU/L, ALT: 134.3°æ4.3 IU/L, Histology: OK; cytokine_response: CTL lysis: 88.7°æ3.5%, ELISpot: 745.0°æ13.8 spots, Antibody titer: 379.4°æ23.2 RLU, strong STING pathway activation",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
954,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,97.9,0.125,4.37,61.2 °æ 4.6 (Luc mRNA); 70.2 °æ 6.3 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A21-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN1CCCCCC1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 3.08°æ0.51E+05 RLU (in vitro macrophage), 1.6°æ0.05E+08 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 25.5°æ0.5 IU/L, ALT: 105.5°æ5.5 IU/L, Histology: OK; cytokine_response: CTL lysis: 93.2°æ2.8%, ELISpot: 478.0°æ71.2 spots, Antibody titer: 406.2°æ95.1 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
955,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,92.4,0.176,5.51,67.2 °æ 2.9 (Luc mRNA); 64.3 °æ 3.7 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A24-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN(CC)CC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 3.41°æ0.22E+04 RLU (in vitro macrophage), 1.2°æ0.1E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 31.5°æ0.5 IU/L, ALT: 117.5°æ6.5 IU/L, Histology: OK; cytokine_response: CTL lysis: 20.9°æ1.3%, ELISpot: 39.3°æ7.4 spots, Antibody titer: 116.3°æ73.2 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
956,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,95.9,0.21,6.41,67.5 °æ 6.5 (Luc mRNA); 64.1 °æ 4.5 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova, trp2",C14-PEG2000,A25-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN(CCCC)CCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 9.71°æ1.45E+04 RLU (in vitro macrophage), 1.4°æ0.2E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 27.5°æ2.5 IU/L, ALT: 124.5°æ5.5 IU/L, Histology: OK; cytokine_response: CTL lysis: 11.5°æ4.5%, ELISpot: 5.3°æ0.6 spots, Antibody titer: 30.2°æ1.9 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
957,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,92.3,0.197,5.36,67.8 °æ 2.4 (Luc mRNA); 68.5 °æ 2.7 (OVA mRNA),WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova",C14-PEG2000,A26-Iso5-2DC18,DOPE,cholesterol,CCOC(=O)C1=NC(CCCCCCCCC=CCCCCCCCC)(CCCCCCCCC=CCCCCCCCC)CN1CCCN(CCC)CCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: Macrophages, HeLa, BMDCs, BMDMs; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: 1.43°æ0.05E+05 RLU (in vitro macrophage), 1.1°æ0.02E+07 (in vivo s.c. 0.5mg/kg); biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: AST: 39.3°æ5.8 IU/L, ALT: 122.7°æ10.5 IU/L, Histology: OK; cytokine_response: CTL lysis: 26.5°æ2.9%, ELISpot: 36.3°æ2.5 spots, Antibody titer: 40.3°æ1.8 RLU",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
958,DLin-MC3-DMA,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:16,80-150,<0.3,,50-70,WR:10(wt/wt)[lipid:mRNA],mRNA,"firefly_luciferase, ova, e7, trp2",C14-PEG2000,MC3,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, BMDCs, BMDMs, B16F10, TC-1, B16-OVA; animal_model: C57BL/6 mice; administration_route: subcutaneous; dose: 15 •Ïg mRNA per mouse; gene_expression_result: control lipid for comparison; biodistribution_result: local injection site and draining lymph nodes; toxicity_profile: no observable toxicity; cytokine_response: minimal immune activation compared to cyclic lipids",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
959,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,45:2.5:42.5:10,87.6,0.2,,45.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS in 20,000 MWCO cassette at 4°∆C for 1h; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: subcutaneous; gene_expression_result: 6.0E+07 (optimized formulation),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
960,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:25,99.9,0.1,,61.3,WR:15(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.9E+07 RLU (in vivo i.m.), 2.2E+07 RLU (HeLa), 2.0E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
961,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,76.9,0.2,,55.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.5E+07 RLU (in vivo i.m.), 1.7E+07 RLU (HeLa), 2.0E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
962,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:2.9:31.1:16,101,0.2,,60.6,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 5.9E+07 RLU (in vivo i.m.), 6.9E+06 RLU (HeLa), 1.3E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
963,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,259.6,0.3,,25.5,WR:2.9(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.1E+07 RLU (in vivo i.m.), 1.2E+07 RLU (HeLa), 2.2E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
964,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:0.5:57.5:7,115.9,0.3,,64.7,WR:5(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 7.5E+06 RLU (in vivo i.m.), 1.2E+07 RLU (HeLa), 6.1E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
965,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,65:0.5:27.5:7,137.9,0.2,,57.9,WR:15(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 7.9E+06 RLU (in vivo i.m.), 1.4E+04 RLU (HeLa), 4.8E+03 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
966,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,65:2.5:7.5:25,167.9,0.2,,22.5,WR:5(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 1.1E+07 RLU (in vivo i.m.), 4.9E+06 RLU (HeLa), 2.7E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
967,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,122.4,0.3,,96.4,WR:17.1(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 9.6E+06 RLU (in vivo i.m.), 3.5E+06 RLU (HeLa), 9.7E+05 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
968,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,95.9,0.2,,59.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.2E+07 RLU (in vivo i.m.), 1.7E+07 RLU (HeLa), 1.6E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
969,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,71.2:1.5:11.3:16,72.3,0.2,,56.4,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.0E+06 RLU (in vivo i.m.), 4.2E+06 RLU (HeLa), 9.2E+05 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
970,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,94,0.2,,68.1,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.2E+07 RLU (in vivo i.m.), 2.5E+07 RLU (HeLa), 1.6E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
971,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,28.8:1.5:53.7:16,84.9,0.2,,64.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 4.2E+07 RLU (in vivo i.m.), 1.5E+07 RLU (HeLa), 2.0E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
972,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,65:2.5:25.5:7,127.8,0.2,,57.2,WR:5(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 1.9E+07 RLU (in vivo i.m.), 4.0E+06 RLU (HeLa), 5.5E+05 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
973,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,84.9,0.2,,57.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.1E+07 RLU (in vivo i.m.), 1.4E+07 RLU (HeLa), 1.8E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
974,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:55.5:7,108.7,0.1,,65.2,WR:15(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 1.9E+07 RLU (in vivo i.m.), 9.9E+06 RLU (HeLa), 1.7E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
975,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:45.2:3.3,94.9,0.3,,21.7,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.0E+07 RLU (in vivo i.m.), 7.6E+06 RLU (HeLa), 3.8E+05 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
976,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:32.5:16,91.8,0.2,,70.2,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.2E+07 RLU (in vivo i.m.), 1.9E+07 RLU (HeLa), 1.8E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
977,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:0.5:39.5:25,129.4,0.2,,53.9,WR:5(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.2E+06 RLU (in vivo i.m.), 2.0E+07 RLU (HeLa), 3.7E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
978,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:19.8:28.7,83.2,0.3,,41.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 7.7E+06 RLU (in vivo i.m.), 5.2E+06 RLU (HeLa), 8.6E+05 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
979,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,65:0.5:9.5:25,110.7,0.1,,98.9,WR:15(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 9.8E+05 RLU (in vivo i.m.), 1.1E+04 RLU (HeLa), 3.5E+04 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
980,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:0.1:33.9:16,154.9,0.1,,9.4,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.9E+05 RLU (in vivo i.m.), 3.7E+06 RLU (HeLa), 2.2E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
981,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,102.5,0.2,,60.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa, B16F10; animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 5.3E+07 RLU (in vivo i.m.), 6.3E+06 RLU (HeLa), 1.1E+06 RLU (B16F10)",Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
982,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:1.5:23.5:25,119.8,0.3,,79,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.2E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
983,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,102.5,0.2,,60.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 5.5E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
984,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,110.6,0.1,,50.4,WR:15(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.15E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
985,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:37.5:25,105.5,0.2,,60.3,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.13E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
986,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:34.5:28,108.6,0.2,,45.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.58E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
987,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.5:42.5:20,112.5,0.1,,54.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 2.67E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
988,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,50:2.5:37.5:10,94.8,0.1,,75.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 7.70E+06 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
989,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,45:2.5:36.5:16,115.6,0.2,,76.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 1.96E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
990,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,45:2.5:42.5:10,87.6,0.2,,45.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 6.0E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
991,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:1.5:47.5:16,140.6,0.1,,55.5,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 3.04E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
992,A2-Iso5-2DC18,C14-PEG2000,cholesterol,DOPE,35:2.8:46.2:16,88.6,0.2,,65.6,WR:10(wt/wt)[lipid:mRNA],mRNA,firefly_luciferase,C14-PEG2000,A2-Iso5-2DC18,DOPE,cholesterol,CCCCCCCC/C=C\CCCCCCCC1(N(C(N=C1)C(=O)OCC)CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10mM citrate buffer (pH 3.0); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1X PBS; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C",animal_model: C57BL/6 mice; administration_route: intramuscular; gene_expression_result: 4.91E+07 RLU (in vivo i.m.),Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation,"['Lei Miao', 'Linxian Li', 'Yuxuan Huang', 'Derfogail Delcassian', 'Jasdave Chahal', 'Jinsong Han', 'Yunhua Shi', 'Kaitlyn Sadtler', 'Wenting Gao', 'Jiaqi Lin', 'Joshua C. Doloff', 'Robert Langer', 'Daniel G. Anderson']",https://doi.org/10.1038/s41587-019-0247-3,Nature Biotechnology,2019
1005,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5 (ionizable_lipid:cholesterol:DOPE:C14-mPEG2000),149.2,0.106,,31.1,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O6 (3,3'-diamino-N-methyldipropylamine + hexyl acrylate)","DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)",cholesterol,CCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCC)CCC(=O)OCCCCCC)CCC(=O)OCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (lipid solution:mRNA solution); aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate (by volume); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes in 3,500 molecular weight cut-off cassettes; sterilization: ; storage_buffer: PBS","cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.75 mg/kg mRNA; gene_expression_result: minimal luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs (similar to other LNPs)",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1006,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,161.6,0.129,,89.7,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O8 (3,3'-diamino-N-methyldipropylamine + octyl acrylate)",DOPE,cholesterol,CCCCCCCCOC(=O)CCN(CCCN(N)CCCN(CCC(=O)OCCCCCCCC)CCC(=O)OCCCCCCCC)CCC(=O)OCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1007,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,166.6,0.135,,93.6,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O9 (3,3'-diamino-N-methyldipropylamine + nonyl acrylate)",DOPE,cholesterol,CCCCCCCCC(OC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCC)CCC(=O)OCCCCCCCCC)CCC(=O)OCCCCCCCCC),CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1008,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,173.9,0.138,,89.3,WR:10(wt/wt)[lipidoid:mRNA],mRNA,"firefly_luciferase, epo",C14-mPEG2000,"306Oi10 (3,3'-diamino-N-methyldipropylamine + branched decyl acrylate with one-carbon branch)",DOPE,cholesterol,CCCCCCCC(C)COC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCC(C)CCCCCCCC)CCC(=O)OCC(C)CCCCCCCC)CCC(=O)OCC(C)CCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA (dose range tested: 0.25-1.5 mg/kg); gene_expression_result: tenfold more potent than 306O10; ~92% expression in liver; dose-dependent expression; biodistribution_result: liver, spleen, kidneys, lungs; predominantly liver accumulation",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1009,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,160,0.141,,89.7,WR:10(wt/wt)[lipidoid:mRNA],mRNA,"firefly_luciferase, epo",C14-mPEG2000,"306O10 (3,3'-diamino-N-methyldipropylamine + straight decyl acrylate)",DOPE,cholesterol,CCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCC)CCC(=O)OCCCCCCCCCC)CCC(=O)OCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA (dose range tested: 0.25-1.5 mg/kg); gene_expression_result: potent luciferase delivery; ~63% spleen and ~34% liver expression; dose-dependent; biodistribution_result: liver, spleen, kidneys, lungs; higher spleen accumulation than 306Oi10",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1010,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,163.2,0.117,,84.7,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O11 (3,3'-diamino-N-methyldipropylamine + undecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1011,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,138.9,0.19,,88.1,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O12 (3,3'-diamino-N-methyldipropylamine + dodecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1012,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,139.5,0.127,,86.2,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O13 (3,3'-diamino-N-methyldipropylamine + tridecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1013,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,118.5,0.216,,82.1,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O14 (3,3'-diamino-N-methyldipropylamine + tetradecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1014,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,180.7,0.17,,69,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O16 (3,3'-diamino-N-methyldipropylamine + hexadecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
1015,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,190.7,0.324,,64.4,WR:10(wt/wt)[lipidoid:mRNA],mRNA,firefly_luciferase,C14-mPEG2000,"306O18 (3,3'-diamino-N-methyldipropylamine + octadecyl acrylate)",DOPE,cholesterol,CCCCCCCCCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: nanoprecipitation; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1; aqueous_phase_composition: 10 mM sodium citrate buffer; organic_phase_composition: 90% ethanol and 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS for 60-90 minutes; sterilization: ; storage_buffer: PBS,"cell_line: HeLa; animal_model: female C57BL/6 mice; administration_route: IV; dose: 0.75 mg/kg mRNA; gene_expression_result: modest luciferase expression; biodistribution_result: liver, spleen, kidneys, lungs",Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH,"['Khalid A. Hajj', 'Rebecca L. Ball', 'Sarah B. Deluty', 'Shridhar R. Singh', 'Daria Strelkova', 'Christopher M. Knapp', 'Kathryn A. Whitehead']",10.1002/smll.201805097,Small,2019
34,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,20:1.0:47.5:31.5,36.0 °æ 6.0,,,,,empty,empty,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
35,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,40:1.0:47.5:11.5,35.0 °æ 6.0,,,,,empty,empty,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
36,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.0:38.5:10,35.1 °æ 8.2,,,,,empty,empty,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
37,DLin-KC2-DMA,DMG-PEG2000,,DOPC,90:1.5:0:8.5,51.3 °æ 8.9,,,,,empty,empty,PEG-DMG,KC2 (DLin-KC2-DMA),DOPC,0,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
38,DLin-KC2-DMA,DMG-PEG2000,,,98.5:1.5:0:0,90.7 °æ 16.9,,,,,empty,empty,PEG-DMG,KC2 (DLin-KC2-DMA),0,0,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
39,DODMA,PEG-lipid,cholesterol,DSPC,20:1.0:47.0:31.5,38.0 °æ 4.0,,,,,empty,empty,PEG-lipid,DODMA,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
40,DODMA,PEG-lipid,cholesterol,DSPC,40:1.0:47.0:11.5,36.0 °æ 4.0,,,,,empty,empty,PEG-lipid,DODMA,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\CCCCCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
41,DOTMA,DSPE-PEG2000,cholesterol,DSPC,20:1.0:47.5:31.5,60.0 °æ 18.0,,,,,empty,empty,PEG-DSPE,DOTMA,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
42,DOTMA,DSPE-PEG2000,cholesterol,DSPC,40:1.0:47.5:11.5,58.0 °æ 13.0,,,,,empty,empty,PEG-DSPE,DOTMA,DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC/C=C\CCCCCCCC.[Cl-],CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer or PBS pH 7.4; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of appropriate buffer; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
43,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,56.0 °æ 8.0 (N/P=6; pH 7.4),,,,"NP:multiple(6,3,1)(molar)",siRNA,firefly_luciferase,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer with siRNA; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of sodium acetate pH 4 buffer or PBS; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
44,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,45.0 °æ 10.0 (N/P=3; pH 7.4),,,,NP:3(molar),siRNA,firefly_luciferase,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer with siRNA; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of sodium acetate pH 4 buffer or PBS; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
45,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,55.0 °æ 5.0 (N/P=1; pH 7.4),,,,NP:1(molar),siRNA,firefly_luciferase,PEG-DMG,KC2 (DLin-KC2-DMA),DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Rapid mixing/T-junction mixer; device_used: T-junction mixer; total_flow_rate_ml_min: 20; flow_rate_ratio: 3:1 (aqueous:organic); aqueous_phase_composition: 25 mM sodium acetate pH 4 buffer with siRNA; organic_phase_composition: ethanol with 15 mM total lipid; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1000-fold volume of sodium acetate pH 4 buffer or PBS; sterilization: ; storage_buffer: PBS pH 7.4,,On the formation and morphology of lipid nanoparticles containing Ionizable cationic lipids and siRNA,"['Jayesh A. Kulkarni', 'Maria M. Darjuan', 'Joanne E. Mercer', 'Sam Chen', 'Roy van der Meel', 'Jenifer L. Thewalt', 'Yuen Yi C. Tam', 'Pieter R. Cullis']",10.1021/acsnano.8b01516,ACS Nano,2018
113,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,93.8,0.14,,96.9,,mRNA,firefly_luciferase,PEG-lipid,"2-(Di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethan-1-ol",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: 2-fold lower than MC3 LNP control; biodistribution_result: majority of protein expression localized in liver,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
114,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,179.4,0.14,,91.8,,mRNA,firefly_luciferase,PEG-lipid,"Dinonyl 8,8'-((2-hydroxyethyl)azanediyl)dioctanoate",DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCCCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: not efficient mRNA delivery,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
115,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,140.4,0.11,,90.9,,mRNA,firefly_luciferase,PEG-lipid,"Nonyl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate",DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: not efficient mRNA delivery,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
116,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,73.1,0.07,,97.6,,mRNA,firefly_luciferase,PEG-lipid,"Heptadecan-9-yl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: equivalent expression to MC3 LNPs,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
117,Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,86.2,0.04,,97.5,CONC:5(molecules/particle)[mRNA],mRNA,"firefly_luciferase, epo, antibody, influenza_antigen",PEG-lipid,Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C","cell_line: HeLa cells; animal_model: CD-1 mice, Sprague-Dawley rats, cynomolgus monkeys; administration_route: i.v.; dose: 0.5 mg/kg (mice), 0.01-1 mg/kg (primates); gene_expression_result: 3-fold higher than MC3, 5-fold higher in non-human primates; biodistribution_result: liver and spleen had highest levels, significantly lower than MC3; toxicity_profile: no adverse findings in 1-month toxicity study, no liver damage or complement activation; cytokine_response: minimal elevation in MCP-1, no significant change in C5b9 levels",A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
118,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,66.8,0.11,,97,,mRNA,firefly_luciferase,PEG-lipid,"Di(heptadecan-9-yl) 8,8'-((2-hydroxyethyl)azanediyl)dioctanoate",DSPC,cholesterol,CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: lower luciferase activity due to lowered surface pKa,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
119,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,130.1,0.15,,95.2,,mRNA,firefly_luciferase,PEG-lipid,Heptadecan-9-yl 8-((2-(dimethylamino)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN(C)C,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: complete loss of delivery efficiency,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
120,SM-102,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,85.8,0.1,,95.8,,mRNA,"firefly_luciferase, epo",PEG-lipid,Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO  ,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C","animal_model: CD-1 mice, Sprague-Dawley rats; administration_route: i.v.; dose: 0.5 mg/kg (mice), 1 mg/kg (rats); gene_expression_result: higher expression compared to MC3",A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
121,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,91.9,0.16,,97.4,,mRNA,firefly_luciferase,PEG-lipid,Heptadecan-9-yl 8-((2-hydroxyethyl)(4-(nonyloxy)-4-oxobutyl)amino)octanoate,DSPC,cholesterol,CCCCCCCCCOC(=O)CCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C","animal_model: CD-1 mice, Sprague-Dawley rats; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: highest luciferase activity of the series",A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
122,Custom lipid,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,69.6,0.14,,98.3,,mRNA,firefly_luciferase,PEG-lipid,Henicosan-11-yl 6-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)hexanoate,DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCCCCN(CCCCCC(=O)OC(CCCCCCCCCC)CCCCCCCCCC)CCO,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C",animal_model: CD-1 mice; administration_route: i.v.; dose: 0.5 mg/kg mRNA; gene_expression_result: comparable luciferase activity to lipid 9,A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
123,DLin-MC3-DMA,PEG-lipid,cholesterol,DSPC,50:10:38.5:1.5,85.6,0.11,,97.3,CONC:5(molecules/particle)[mRNA],mRNA,"firefly_luciferase, epo",PEG-lipid,"MC3 (DLin-MC3-DMA, control)",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (aqueous:ethanol); aqueous_phase_composition: 6.25 mM sodium acetate buffer (pH 5); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS (pH 7.4) for at least 18 hr, concentrated using Amicon ultra centrifugal filters; sterilization: 0.22-•Ïm filter; storage_buffer: stored at 4°∆C","cell_line: HeLa cells; animal_model: CD-1 mice, Sprague-Dawley rats, cynomolgus monkeys; administration_route: i.v.; dose: 0.5 mg/kg (mice), 0.3 mg/kg (rats); gene_expression_result: control reference; biodistribution_result: liver and spleen contained largest concentrations; toxicity_profile: ALT and AST elevation at 0.3 mg/kg, pathology showed evidence of necrosis",A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,"['Staci Sabnis', 'E. Sathyajith Kumarasinghe', 'Timothy Salerno', 'Cosmin Mihai', 'Tatiana Ketova', 'Joseph J. Senn', 'Andy Lynn', 'Alex Bulychev', 'Iain McFadyen', 'Joyce Chan', 'Orn Almarsson', 'Matthew G. Stanton', 'Kerry E. Benenato']",https://doi.org/10.1016/j.ymthe.2018.03.010,Molecular Therapy,2018
124,7C1,C14-PEG2000,4B-OH Cholesterol,,62:30:8:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
125,7C1,C14-PEG2000,4B-OH Cholesterol,,35:60:5:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
126,7C1,C14-PEG2000,4B-OH Cholesterol,,62:22:16:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
127,7C1,C14-PEG2000,4B-OH Cholesterol,,35:35:30:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
128,7C1,C14-PEG2000,,,80:0:20:0,25-150,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,No Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
129,7C1,C14-PEG2000,4B-OH Cholesterol,,80:15:5:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
130,7C1,C14-PEG2000,4B-OH Cholesterol,POPC,50:40:2:8,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,16:0-18:1 PC,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC=CCCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
131,7C1,C14-PEG2000,4B-OH Cholesterol,POPC,50:29:11:10,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,16:0-18:1 PC,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC=CCCCCCCCC,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
132,7C1,C14-PEG2000,4B-OH Cholesterol,18:1 Lyso PC,50:29:11:10,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,18:1 Lyso PC,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
133,7C1,C14-PEG2000,4B-OH Cholesterol,18:1 Lyso PC,50:40:2:8,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,18:1 Lyso PC,4B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
134,7C1,C14-PEG2000,Cholesteryl Oleate,,62:30:8:0,22-115,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,Cholesteryl Oleate,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
135,7C1,C14-PEG2000,Cholesteryl Oleate,18:1 Lyso PC,50:29:11:10,22-115,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,18:1 Lyso PC,Cholesteryl Oleate,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
136,7C1,C14-PEG2000,Cholesteryl Stearate,,62:22:16:0,30-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,Cholesteryl Stearate,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
137,7C1,C14-PEG2000,7A-OH Cholesterol,,62:30:8:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,7A-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
138,7C1,C14-PEG2000,7B-OH Cholesterol,,62:30:8:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,7B-OH Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
139,7C1,C14-PEG2000,cholesterol,,62:30:8:0,25-175,,,,CONC:0.0045(mg/kg/barcode)[mRNA],DNA,barcode(8 nucleotide barcode sequence),C14PEG2000,7C1,,Cholesterol,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, LDLR?/?, VLDLR?/?; administration_route: IV (intravenous); dose: 0.5 mg/kg total DNA; biodistribution_result: Measured in lung, spleen, liver endothelial cells, macrophages, and hepatocytes","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
140,7C1,C14-PEG2000,Cholesteryl oleate,18:1 Lyso PC,50:29:11:10,22-115,,,,CONC:1.0(mg/kg)[sgRNA]+1.5(mg/kg)[siRNA],"mRNA, siRNA","gfp, icam2, aso",C14PEG2000,7C1,18:1 Lyso PC,Cholesteryl oleate,NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, SpCas9 constitutive mice; administration_route: IV (intravenous); dose: 1.0 mg/kg sgRNA, 1.5 mg/kg siRNA; gene_expression_result: 41% GFP editing in liver endothelial cells, 74% ICAM-2 knockdown; biodistribution_result: 3X more efficient delivery to liver endothelial cells vs hepatocytes; toxicity_profile: Mice gained weight normally, normalized weight 60-140% over 5 days","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
141,7C1,C14-PEG2000,cholesterol,18:1 Lyso PC,50:29:11:10,25-175,,,,CONC:1.0(mg/kg)[sgRNA]+1.5(mg/kg)[siRNA],"mRNA, siRNA","gfp, icam2, aso",C14PEG2000,7C1,18:1 Lyso PC,Cholesterol (unmodified),NCCN(CCNCC(O)CCCCCCCCCCCC)CCNCCN(CCNCCNCC(O)CCCCCCCCCCCC)CCN(CCN(CCN)CCNCC(O)CCCCCCCCCCCC)CCNCCN,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,synthesis_method: Microfluidic; device_used: Microfluidic device; total_flow_rate_ml_min: 0.8; flow_rate_ratio: 3:1 (ethanol:citrate); aqueous_phase_composition: 10 mM citrate buffer; organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: Dialyzed in 1X PBS and sterile filtered; sterilization: 0.22 •Ïm filter; storage_buffer: 1X PBS,"animal_model: C57BL/6J, SpCas9 constitutive mice; administration_route: IV (intravenous); dose: 1.0 mg/kg sgRNA, 1.5 mg/kg siRNA; gene_expression_result: 31% GFP editing in liver endothelial cells, 75% ICAM-2 knockdown; biodistribution_result: Less specific targeting compared to oleate LNP; toxicity_profile: Mice gained weight normally, normalized weight 60-140% over 5 days","Analyzing 2,000 in vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery","['Kalina Paunovska', 'Carmen J. Gil', 'Melissa P. Lokugamage', 'Cory D. Sago', 'Manaka Sato', 'Gwyn N. Lando', 'Marielena Gamboa Castro', 'Anton V. Bryksin', 'James E. Dahlman']",10.1021/acsnano.8b03640,ACS Nano,2018
432,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,111,0.056,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-C9,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~90% knockdown (No ApoE), ~75% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
433,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,93,0.047,,98,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-C9,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: ~0.5°ø10^6 RLU (No ApoE), ~1°ø10^6 RLU (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
434,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,93,0.07,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-C12,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~80% knockdown (No ApoE), ~85% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
435,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,96,0.046,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-C12,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: ~0.5°ø10^6 RLU (No ApoE), ~1°ø10^6 RLU (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
436,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,,0.046,,99,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-C15,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~40% knockdown (No ApoE), ~45% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
437,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,,0.041,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-C15,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: baseline level (No ApoE), baseline level (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
438,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,,"mRNA, siRNA",empty,C14-PEG 2000,OF-Deg-C18,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: ; sterilization: ; storage_buffer: ,gene_expression_result: Not formulated (limited solubility in ethanol),Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
439,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,85,0.05,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-Ole,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~85% knockdown (No ApoE), ~90% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
440,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,71,0.05,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-Ole,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: baseline level (No ApoE), baseline level (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
441,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,84,0.047,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-Ela,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~85% knockdown (No ApoE), ~90% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
442,Custom lipid,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,68,0.047,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-Ela,DOPE,cholesterol,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: baseline level (No ApoE), baseline level (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
443,OF-Deg-Lin,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,60,0.061,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~95% knockdown (No ApoE), ~95% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
444,OF-Deg-Lin,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,59,0.055,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; dose: 50 ng per well; gene_expression_result: ~2°ø10^6 RLU (No ApoE), ~5°ø10^6 RLU (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
445,OF-C4-Deg-Lin,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,64,0.016,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,OF-C4-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCC[C@@H]1NC(=O)[C@@H](NC1=O)CCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~100% knockdown (No ApoE), ~100% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
446,OF-C4-Deg-Lin,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,59,0.041,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,OF-C4-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCC[C@@H]1NC(=O)[C@@H](NC1=O)CCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; animal_model: female C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.75 mg/kg; gene_expression_result: ~6°ø10^6 RLU (No ApoE), ~8°ø10^6 RLU (with ApoE); biodistribution_result: >85% luminescence in spleen, minimal in liver and other organs",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
447,cKK-E12,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,61,0.066,,98,WR:10(wt/wt)[ionizable_lipid:RNA],siRNA,"firefly_luciferase, aso",C14-PEG 2000,cKK-E12,DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells expressing firefly and Renilla luciferase; dose: 50 ng per well; gene_expression_result: ~100% knockdown (No ApoE), ~100% knockdown (with ApoE); toxicity_profile: minimal toxicity observed",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
448,cKK-E12,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,70,0.169,,99,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,firefly_luciferase,C14-PEG 2000,cKK-E12,DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","cell_line: HeLa cells; animal_model: female C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.75 mg/kg; gene_expression_result: baseline level (No ApoE), baseline level (with ApoE); biodistribution_result: majority of expression in liver (control)",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
449,OF-C4-Deg-Lin,C14-PEG 2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,WR:10(wt/wt)[ionizable_lipid:RNA],mRNA,not_specified,C14-PEG 2000,OF-C4-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCC[C@@H]1NC(=O)[C@@H](NC1=O)CCCCN(CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipid mixture at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: female C57BL/6 mice; administration_route: IV (tail vein injection); dose: 0.75 mg/kg; biodistribution_result: ~80% fluorescence in liver, ~5% in spleen",Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'James C. Kaczmarek', 'Manhao D. Zeng', 'Jason L. Andresen', 'Luke H. Rhym', 'Michael W. Heartlein', 'Frank DeRosa', 'Daniel G. Anderson']",10.1002/anie.201809056,Angewandte Chemie International Edition,2018
189,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPE,50:1:38.5:10,76.17 °æ 4.03,0.059 °æ 0.014,23.10 °æ 0.26,97.58 °æ 0.63,0.029 mg DNA per •Ïmol lipid (NP:6.0(molar)),DNA,"firefly_luciferase, gfp, plasmid_dna",PEG-DMG,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: micromixer (Precision Nanosystems); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mM sodium acetate pH 4, 0.116 mg/ml pDNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis and concentration to ~0.2 mg/mL pDNA; sterilization: ; storage_buffer: ","cell_line: HeLa, primary embryonic mesenchyme cells; animal_model: white leghorn chicken embryos; administration_route: microinjection into limb bud; dose: 0.75-40 •Ïg/ml pDNA; gene_expression_result: 85-90% transfection efficiency, highest in vivo; biodistribution_result: limb bud, penetration into chondrogenic condensations; toxicity_profile: >85% cell viability, superior to Lipofectamine (33%)",Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA,"['Jayesh A. Kulkarni', 'Johnathan Layne Myhre', 'Sam Chen', 'Yuen Yi C. Tam', 'Adrian Danescu', 'Joy M. Richman', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2016.12.014,"Nanomedicine: Nanotechnology, Biology, and Medicine",2017
190,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DOPC,50:1:38.5:10,74.44 °æ 1.67,0.060 °æ 0.009,25.80 °æ 0.50,96.59 °æ 2.02,0.029 mg DNA per •Ïmol lipid (NP:6.0(molar)),DNA,"firefly_luciferase, gfp, plasmid_dna",PEG-DMG,DLin-KC2-DMA,DOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: micromixer (Precision Nanosystems); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mM sodium acetate pH 4, 0.116 mg/ml pDNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis and concentration to ~0.2 mg/mL pDNA; sterilization: ; storage_buffer: ","cell_line: HeLa, HepG2, PC12, MCF7, Hep3B, MDA-231, JHOC-9, primary embryonic mesenchyme cells; animal_model: white leghorn chicken embryos; administration_route: microinjection into limb bud; dose: 0.75-6.0 •Ïg/ml pDNA (in vitro), 10 •Ïg/ml pDNA (in vivo); gene_expression_result: 3-fold enhancement vs DSPC with DLin-KC2-DMA; biodistribution_result: limb bud transfection; toxicity_profile: >85% cell viability",Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA,"['Jayesh A. Kulkarni', 'Johnathan Layne Myhre', 'Sam Chen', 'Yuen Yi C. Tam', 'Adrian Danescu', 'Joy M. Richman', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2016.12.014,"Nanomedicine: Nanotechnology, Biology, and Medicine",2017
191,DLin-KC2-DMA,DMG-PEG2000,cholesterol,SOPC,50:1:38.5:10,66.45 °æ 4.25,0.062 °æ 0.007,25.03 °æ 0.76,95.93 °æ 1.97,0.029 mg DNA per •Ïmol lipid (NP:6.0(molar)),DNA,"firefly_luciferase, gfp, plasmid_dna",PEG-DMG,DLin-KC2-DMA,SOPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,,"synthesis_method: Microfluidic; device_used: micromixer (Precision Nanosystems); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mM sodium acetate pH 4, 0.116 mg/ml pDNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis and concentration to ~0.2 mg/mL pDNA; sterilization: ; storage_buffer: ","cell_line: HeLa, HepG2, PC12, MCF7, Hep3B, MDA-231, JHOC-9, primary embryonic mesenchyme cells; animal_model: white leghorn chicken embryos; administration_route: microinjection into limb bud; dose: 0.75-6.0 •Ïg/ml pDNA (in vitro), 10 •Ïg/ml pDNA (in vivo); gene_expression_result: 4-fold enhancement vs DSPC, >50-fold vs MC3+DSPC combination; biodistribution_result: limb bud transfection; toxicity_profile: >85% cell viability",Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA,"['Jayesh A. Kulkarni', 'Johnathan Layne Myhre', 'Sam Chen', 'Yuen Yi C. Tam', 'Adrian Danescu', 'Joy M. Richman', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2016.12.014,"Nanomedicine: Nanotechnology, Biology, and Medicine",2017
192,DLin-KC2-DMA,DMG-PEG2000,cholesterol,DSPC,50:1:38.5:10,69.99 °æ 1.69,0.071 °æ 0.002,24.07 °æ 3.84,94.89 °æ 2.55,0.029 mg DNA per •Ïmol lipid (NP:6.0(molar)),DNA,firefly_luciferase,PEG-DMG,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: micromixer (Precision Nanosystems); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mM sodium acetate pH 4, 0.116 mg/ml pDNA; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis and concentration to ~0.2 mg/mL pDNA; sterilization: ; storage_buffer: ",cell_line: HeLa; dose: 0.75-6.0 •Ïg/ml pDNA; gene_expression_result: baseline for KC2-DMA comparisons,Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA,"['Jayesh A. Kulkarni', 'Johnathan Layne Myhre', 'Sam Chen', 'Yuen Yi C. Tam', 'Adrian Danescu', 'Joy M. Richman', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2016.12.014,"Nanomedicine: Nanotechnology, Biology, and Medicine",2017
198,OF-Deg-Lin,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,75 °æ 10,0.197,,?60,OTHER:OF-Deg-Lin:mRNA weight ratio of 10:1,mRNA,firefly_luciferase,C14-PEG-2000,OF-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device using syringe pumps; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: 100% ethanol with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in a 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C prior to injection","cell_line: HeLa; animal_model: C57BL/6 mice (female, 18-22 g); administration_route: IV (tail vein); dose: 0.75 mg/kg, 1.5 mg/kg, 2.25 mg/kg; gene_expression_result: ?60 pg luciferase per million B cells at highest dose (2.25 mg/kg); biodistribution_result: >85% of total protein production in spleen; toxicity_profile: negligible toxicity at doses up to 4 mg/kg",Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes,"['Owen S. Fenton', 'Kevin J. Kauffman', 'James C. Kaczmarek', 'Rebecca L. McClellan', 'Siddharth Jhunjhunwala', 'Mark W. Tibbitt', 'Manhao D. Zeng', 'Eric A. Appel', 'Joseph R. Dorkin', 'Faryal F. Mir', 'Jung H. Yang', 'Matthias A. Oberli', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201606944,Advanced Materials,2017
199,OF-Deg-Lin,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,75 °æ 10,0.197,,?60,OTHER:OF-Deg-Lin:mRNA weight ratio of 10:1,mRNA,firefly_luciferase,C14-PEG-2000,OF-Deg-Lin,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device using syringe pumps; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: 100% ethanol with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in a 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C prior to injection","animal_model: C57BL/6 mice (female, 18-22 g); administration_route: IV (tail vein); dose: 0.75 mg/kg; gene_expression_result: N/A (non-translating mRNA); biodistribution_result: transient transport to liver (>100-fold more fluorescent signal in liver than spleen)",Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes,"['Owen S. Fenton', 'Kevin J. Kauffman', 'James C. Kaczmarek', 'Rebecca L. McClellan', 'Siddharth Jhunjhunwala', 'Mark W. Tibbitt', 'Manhao D. Zeng', 'Eric A. Appel', 'Joseph R. Dorkin', 'Faryal F. Mir', 'Jung H. Yang', 'Matthias A. Oberli', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201606944,Advanced Materials,2017
200,OF-02,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,OTHER:OF-02:mRNA weight ratio of 10:1,mRNA,firefly_luciferase,C14-PEG-2000,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device using syringe pumps; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: 100% ethanol with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in a 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C prior to injection","animal_model: C57BL/6 mice (female, 18-22 g); administration_route: IV (tail vein); dose: 0.75 mg/kg; gene_expression_result: predominantly in liver; biodistribution_result: majority of protein expression in liver (non-degradable ionizable lipid control)",Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes,"['Owen S. Fenton', 'Kevin J. Kauffman', 'James C. Kaczmarek', 'Rebecca L. McClellan', 'Siddharth Jhunjhunwala', 'Mark W. Tibbitt', 'Manhao D. Zeng', 'Eric A. Appel', 'Joseph R. Dorkin', 'Faryal F. Mir', 'Jung H. Yang', 'Matthias A. Oberli', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201606944,Advanced Materials,2017
201,OF-02,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,,,,,OTHER:OF-02:mRNA weight ratio of 10:1,mRNA,firefly_luciferase,C14-PEG-2000,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device using syringe pumps; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: 100% ethanol with lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in a 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C prior to injection","animal_model: C57BL/6 mice (female, 18-22 g); administration_route: IV (tail vein); dose: 0.75 mg/kg; gene_expression_result: N/A (non-translating mRNA); biodistribution_result: transported predominantly to liver",Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes,"['Owen S. Fenton', 'Kevin J. Kauffman', 'James C. Kaczmarek', 'Rebecca L. McClellan', 'Siddharth Jhunjhunwala', 'Mark W. Tibbitt', 'Manhao D. Zeng', 'Eric A. Appel', 'Joseph R. Dorkin', 'Faryal F. Mir', 'Jung H. Yang', 'Matthias A. Oberli', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201606944,Advanced Materials,2017
429,Custom lipid,C16-PEG2000-ceramide,cholesterol,DOPE,16:1:4:1,74.7,,12.5,,OTHER:25 nM protein with 2 •Ïg/mL lipid,protein,"gfp, cre_recombinase",C16-PEG2000-ceramide,3-O14B,DOPE,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Film hydration; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (200 mM, pH 5.2); organic_phase_composition: ethanol/sodium acetate buffer (vol:vol = 9:1); mixing_time_sec: 1800; temperature_condition: 37°∆C; post_processing: dialysis against water or PBS in 3500 MWCO cassettes; sterilization: ; storage_buffer: phosphate buffer (25 mM, pH 7.2)","cell_line: HeLa-DsRed, GFP-HEK; dose: 25 nM protein; gene_expression_result: Good GFP-positive cells (~35%), 70% EGFP knockout efficiency with Cas9:sgRNA",Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles,"['Ming Wang', 'John A. Zuris', 'Fantao Meng', 'Holly Rees', 'Shuo Sun', 'Pu Deng', 'Yong Han', 'Xue Gao', 'Dimitra Pouli', 'Qi Wu', 'Irene Georgakoudi', 'David R. Liu', 'Qiaobing Xu']",10.1073/pnas.1520244113,PNAS,2016
430,Custom lipid,C16-PEG2000-ceramide,cholesterol,DOPE,16:1:4:1,106.6,,7.1,>90,OTHER:25 nM protein with 2 •Ïg/mL lipid,protein,"gfp, cre_recombinase",C16-PEG2000-ceramide,8-O14B,DOPE,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Film hydration; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (200 mM, pH 5.2); organic_phase_composition: ethanol/sodium acetate buffer (vol:vol = 9:1); mixing_time_sec: 1800; temperature_condition: 37°∆C; post_processing: dialysis against water or PBS in 3500 MWCO cassettes; sterilization: ; storage_buffer: phosphate buffer (25 mM, pH 7.2)","cell_line: HeLa-DsRed, GFP-HEK; animal_model: Rosa26tdTomato mice; administration_route: Intracranial microinjection; dose: 5 pmol protein in 0.1-0.2 •ÏL; gene_expression_result: Highest GFP-positive cells (>80%), 80% DsRed-positive cells, efficient Cre-mediated recombination; biodistribution_result: Brain regions: DM, DG, MD, cortex, BNST, LSV, PVN, LH - localized to injection sites; toxicity_profile: Cell viability >85% up to 50 nM protein, low cytotoxicity",Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles,"['Ming Wang', 'John A. Zuris', 'Fantao Meng', 'Holly Rees', 'Shuo Sun', 'Pu Deng', 'Yong Han', 'Xue Gao', 'Dimitra Pouli', 'Qi Wu', 'Irene Georgakoudi', 'David R. Liu', 'Qiaobing Xu']",10.1073/pnas.1520244113,PNAS,2016
431,Custom lipid,C16-PEG2000-ceramide,cholesterol,DOPE,16:1:4:1,292.2,,'-9.1,,PCT:9°æ25(%),protein,"gfp, cas9",C16-PEG2000-ceramide,3-O14B,DOPE,cholesterol,,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Film hydration; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: sodium acetate buffer (200 mM, pH 5.2); organic_phase_composition: ethanol/sodium acetate buffer (vol:vol = 9:1); mixing_time_sec: 1800; temperature_condition: 37°∆C; post_processing: dialysis against water or PBS in 3500 MWCO cassettes; sterilization: ; storage_buffer: phosphate buffer (25 mM, pH 7.2)",cell_line: GFP-HEK; dose: 25 nM Cas9:sgRNA complex; gene_expression_result: 70% EGFP knockout efficiency,Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles,"['Ming Wang', 'John A. Zuris', 'Fantao Meng', 'Holly Rees', 'Shuo Sun', 'Pu Deng', 'Yong Han', 'Xue Gao', 'Dimitra Pouli', 'Qi Wu', 'Irene Georgakoudi', 'David R. Liu', 'Qiaobing Xu']",10.1073/pnas.1520244113,PNAS,2016
583,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:0.25:49.25:10,117,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.8 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
584,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:0.5:49:10,78,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.04 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
585,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:1.5:47.5:10,43,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.15 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
586,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:2.5:45:10,38,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.4 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
587,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:5:35:10,27,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.8 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
588,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:1.5:47.5:10,45,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.15 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
589,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:0.5:49:10,80,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.04 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
590,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,50:1.5:47.5:10,30,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.01-3 mg siRNA/kg; gene_expression_result: ED50 ~0.8 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
591,DMAP-BLP,DMG-PEG2000,cholesterol,DSPC,60:5:25:10,30,,,,NP:6(molar),siRNA,factor_vii,PEG-DMG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.3-1 mg siRNA/kg; gene_expression_result: ED50 <0.3 mg/kg; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
592,DMAP-BLP,DSG-PEG2000,cholesterol,DSPC,50:0.5:49:10,80,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DSG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.3 mg siRNA/kg; gene_expression_result: circulation half-life ~3 h; biodistribution_result: Liver accumulation ~50% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
593,DMAP-BLP,DSG-PEG2000,cholesterol,DSPC,50:1.5:47.5:10,45,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DSG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.3 mg siRNA/kg; gene_expression_result: circulation half-life ~0.5 h; biodistribution_result: Liver accumulation ~70% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
594,DMAP-BLP,DSG-PEG2000,cholesterol,DSPC,50:5:35:10,30,,,,CONC:0.056(mg/•Ïmol)[siRNA:lipid],siRNA,factor_vii,PEG-DSG,DMAP-BLP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(CC(=O)OCCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Microfluidic; device_used: Precision Nanosystems microfluidic mixers; total_flow_rate_ml_min: 4; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM acetate buffer (pH 4.0); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against 50 mM MES and 50 mM citrate buffer (pH 6.7) for at least 4 h followed by PBS (pH 7.4) overnight; sterilization: ; storage_buffer: PBS (pH 7.4),animal_model: Female C57Bl/6 mice; administration_route: IV; dose: 0.3 mg siRNA/kg; gene_expression_result: circulation half-life ~10.9 h; biodistribution_result: Liver accumulation ~30% at 24h,Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA,"['Sam Chen', 'Yuen Yi C. Tam', 'Paulo J.C. Lin', 'Molly M.H. Sung', 'Ying K. Tam', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.jconrel.2016.05.059,Journal of Controlled Release,2016
941,cKK-E12,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,83,0.217,,54,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,epo,C14-PEG2000,cKK-E12,DOPE,cholesterol,CCCCCCCCCCCC(O)CN1CCCCC(C(=O)NC2CCCCCNC(=O)C3N(CC(O)CCCCCCCCCCCC)CCC(CC3)N(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)C1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: C57BL/6 mice (female, 18-22g); administration_route: IV (tail vein); dose: 0.75 mg/kg EPO mRNA; gene_expression_result: 7100 °æ 700 ng/mL serum EPO at 6h; biodistribution_result: predominantly liver with minimal spleen translation; toxicity_profile: no animal mortality, similar weight loss profiles",Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'Eric A. Appel', 'J. Robert Dorkin', 'Mark W. Tibbitt', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201505822,Advanced Materials,2016
942,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,92,0.147,,74,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,epo,C14-PEG2000,OF-00,DOPE,cholesterol,CCCCCCCCC/C=C\CCCCCCCC(O)CN1C(=O)C(CCCCN(CC(O)CCCCCCC/C=C\CCCCCCCCC)CC(O)CCCCCCC/C=C\CCCCCCCCC)NC(=O)C(CCCCN(CC(O)CCCCCCC/C=C\CCCCCCCCC)CC(O)CCCCCCC/C=C\CCCCCCCCC)N1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: C57BL/6 mice (female, 18-22g); administration_route: IV (tail vein); dose: 0.75 mg/kg EPO mRNA; gene_expression_result: 2100 °æ 500 ng/mL serum EPO at 6h; biodistribution_result: predominantly liver with minimal spleen translation; toxicity_profile: no animal mortality, similar weight loss profiles",Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'Eric A. Appel', 'J. Robert Dorkin', 'Mark W. Tibbitt', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201505822,Advanced Materials,2016
943,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,78,0.194,,81,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,epo,C14-PEG2000,OF-01,DOPE,cholesterol,CCCCCCCCC/C=C/CCCCCCCC(O)CN1C(=O)C(CCCCN(CC(O)CCCCCCC/C=C/CCCCCCCCC)CC(O)CCCCCCC/C=C/CCCCCCCCC)NC(=O)C(CCCCN(CC(O)CCCCCCC/C=C/CCCCCCCCC)CC(O)CCCCCCC/C=C/CCCCCCCCC)N1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: C57BL/6 mice (female, 18-22g); administration_route: IV (tail vein); dose: 0.75 mg/kg EPO mRNA; gene_expression_result: 500 °æ 200 ng/mL serum EPO at 6h; biodistribution_result: predominantly liver with minimal spleen translation; toxicity_profile: no animal mortality, similar weight loss profiles",Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'Eric A. Appel', 'J. Robert Dorkin', 'Mark W. Tibbitt', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201505822,Advanced Materials,2016
944,OF-02,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,122,0.13,,55,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,epo,C14-PEG2000,OF-02,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCC(O)CN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CC(O)CCCCCC/C=C\C/C=C\CCCCC)CC(O)CCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: C57BL/6 mice (female, 18-22g); administration_route: IV (tail vein); dose: 0.75 mg/kg EPO mRNA; gene_expression_result: 14200 °æ 1500 ng/mL serum EPO at 6h; biodistribution_result: predominantly liver with minimal spleen translation; toxicity_profile: no animal mortality, similar weight loss profiles",Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'Eric A. Appel', 'J. Robert Dorkin', 'Mark W. Tibbitt', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201505822,Advanced Materials,2016
945,Custom lipid,C14-PEG2000,cholesterol,DOPE,35:16:46.5:2.5,75,0.239,,76,WR:10(wt/wt)[ionizable_lipid:mRNA],mRNA,epo,C14-PEG2000,OF-03,DOPE,cholesterol,CCC/C=C\C/C=C\C/C=C\CCCCCCCC(O)CN1C(=O)C(CCCCN(CC(O)CCCCCCC/C=C\C/C=C\C/C=C\CCC)CC(O)CCCCCCC/C=C\C/C=C\C/C=C\CCC)NC(=O)C(CCCCN(CC(O)CCCCCCC/C=C\C/C=C\C/C=C\CCC)CC(O)CCCCCCC/C=C\C/C=C\C/C=C\CCC)N1,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer (pH 3); organic_phase_composition: ethanol with lipids at 10 mg/mL; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against 1X PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: 1X PBS, stored at 4°∆C","animal_model: C57BL/6 mice (female, 18-22g); administration_route: IV (tail vein); dose: 0.75 mg/kg EPO mRNA; gene_expression_result: 140 °æ 3 ng/mL serum EPO at 6h; biodistribution_result: predominantly liver with minimal spleen translation; toxicity_profile: no animal mortality, similar weight loss profiles",Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery,"['Owen S. Fenton', 'Kevin J. Kauffman', 'Rebecca L. McClellan', 'Eric A. Appel', 'J. Robert Dorkin', 'Mark W. Tibbitt', 'Michael W. Heartlein', 'Frank DeRosa', 'Robert Langer', 'Daniel G. Anderson']",10.1002/adma.201505822,Advanced Materials,2016
70,C12-200,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,152,0.102,'-25.4,24,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 962 °æ 141 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
71,C12-200,C14-PEG2000,cholesterol,DOPE,60:2.5:33.5:4,111,0.182,,5,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 169 °æ 14 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
72,C12-200,C14-PEG2000,cholesterol,DOPE,40:1.5:42.5:16,122,0.121,,56,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 6445 °æ 1237 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
73,C12-200,C14-PEG2000,cholesterol,DOPC,60:2.5:31.5:16,135,0.341,,4,WR:2.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 176 °æ 21 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
74,C12-200,C14-PEG2000,cholesterol,DSPC,60:1.5:34.5:4,169,0.217,,1,WR:2.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 72 °æ 4 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
75,C12-200,C14-PEG2000,cholesterol,DOPE,60:0.5:29.5:10,275,0.173,,2,WR:2.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 86 °æ 5 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
76,C12-200,C14-PEG2000,cholesterol,DOPC,40:0.5:55.5:4,352,0.2,,18,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 297 °æ 18 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
77,C12-200,C14-PEG2000,cholesterol,DSPE,50:1.5:38.5:10,,,,,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: LNP could not be synthesized due to DSPE insolubility,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
78,C12-200,C14-PEG2000,cholesterol,DOPE,40:2.5:53.5:4,149,0.341,,2,WR:2.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 238 °æ 20 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
79,C12-200,C14-PEG2000,cholesterol,DSPC,40:2.5:47.5:10,79,0.177,,46,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 2072 °æ 302 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
80,C12-200,C14-PEG2000,cholesterol,DSPC,60:0.5:23.5:16,149,0.212,,43,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 443 °æ 104 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
81,C12-200,C14-PEG2000,cholesterol,DSPC,40:0.5:43.5:16,368,0.43,,2,WR:2.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 86 °æ 2 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
82,C12-200,C14-PEG2000,cholesterol,DSPE,60:2.5:21.5:16,,,,,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: LNP could not be synthesized due to DSPE insolubility,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
83,C12-200,C14-PEG2000,cholesterol,DOPC,50:1.5:38.5:10,173,0.151,,10,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 595 °æ 225 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
84,C12-200,C14-PEG2000,cholesterol,DSPE,50:0.5:45.5:4,,,,,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: LNP could not be synthesized due to DSPE insolubility,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
85,C12-200,C14-PEG2000,cholesterol,DSPC,30:2.5:45.5:22,95,0.336,,59,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 326 °æ 85 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
86,C12-200,C14-PEG2000,cholesterol,DOPE,40:3:35:22,117,0.195,,30,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 4307 °æ 403 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
87,C12-200,C14-PEG2000,cholesterol,DOPE,40:2.5:29.5:28,113,0.168,,42,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 5937 °æ 1272 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
88,C12-200,C14-PEG2000,cholesterol,DSPC,40:2.5:35.5:22,88,0.245,,55,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 753 °æ 88 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
89,C12-200,C14-PEG2000,cholesterol,DSPC,35:3:34:28,89,0.228,,46,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 285 °æ 14 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
90,C12-200,C14-PEG2000,cholesterol,DOPE,30:2.5:51.5:16,109,0.284,,24,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 2989 °æ 307 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
91,C12-200,C14-PEG2000,cholesterol,DSPC,35:3.5:45.5:16,77,0.196,,40,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 348 °æ 262 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
92,C12-200,C14-PEG2000,cholesterol,DOPE,30:3.5:38.5:28,87,0.182,,42,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 6400 °æ 2405 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
93,C12-200,C14-PEG2000,cholesterol,DOPE,40:3.5:28.5:28,85,0.208,,32,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 5464 °æ 843 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
94,C12-200,C14-PEG2000,cholesterol,DOPE,35:3:40:22,96,0.154,,39,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 4084 °æ 452 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
95,C12-200,C14-PEG2000,cholesterol,DSPC,35:2.5:34.5:28,109,0.303,,58,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 316 °æ 58 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
96,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,89,0.174,,44,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 7485 °æ 854 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
97,C12-200,C14-PEG2000,cholesterol,DSPC,30:3.5:44.5:22,74,0.328,,57,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 648 °æ 311 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
98,C12-200,C14-PEG2000,cholesterol,DOPE,35:3.5:39.5:22,93,0.205,,35,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 5960 °æ 834 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
99,C12-200,C14-PEG2000,cholesterol,DOPE,30:3:51:16,77,0.198,,38,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 4792 °æ 620 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
100,C12-200,C14-PEG2000,cholesterol,DSPC,30:3:39:28,86,0.287,,60,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 293 °æ 13 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
101,C12-200,C14-PEG2000,cholesterol,DSPC,40:3:41:16,65,0.396,,45,WR:12.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 1795 °æ 298 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
102,C12-200,C14-PEG2000,cholesterol,DSPC,40:3.5:40.5:16,64,0.295,,39,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 1126 °æ 260 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
103,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,106,0.216,,33,WR:5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 3134 °æ 502 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
104,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,106,0.159,,40,WR:7.5(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 4504 °æ 586 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
105,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,102,0.158,'-5,43,WR:10(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 7065 °æ 513 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
106,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,102,0.147,,48,WR:15(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 7548 °æ 208 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
107,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,98,0.177,,53,WR:20(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 7268 °æ 366 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
108,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,109,0.151,,52,WR:25(wt/wt)[C12-200:mRNA],mRNA,epo,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 6179 °æ 361 ng/mL serum EPO at 6 hours,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
109,C12-200,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,113,0.147,,27,WR:5(wt/wt)[C12-200:mRNA],mRNA,luciferase,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 0.99 °æ 0.44 °ø 10^9 p/s total flux; biodistribution_result: predominantly liver expression,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
110,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,82,0.221,,48,WR:10(wt/wt)[C12-200:mRNA],mRNA,luciferase,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous; dose: 15 •Ïg total mRNA per mouse; gene_expression_result: 3.21 °æ 1.18 °ø 10^9 p/s total flux; biodistribution_result: predominantly liver expression,Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
111,C12-200,C14-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,65,0.15,,59,WR:5(wt/wt)[C12-200:siRNA],siRNA,factor_vii,C14-PEG2000,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.1 mg/kg, 0.03 mg/kg, 0.01 mg/kg siRNA; gene_expression_result: 0.1 mg/kg: 10 °æ 3% FVII, 0.03 mg/kg: 43 °æ 12% FVII, 0.01 mg/kg: 79 °æ 9% FVII at 72 hours; biodistribution_result: hepatocyte-specific silencing",Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
112,C12-200,C14-PEG2000,cholesterol,DOPE,35:2.5:46.5:16,109,0.288,,58,WR:10(wt/wt)[C12-200:siRNA],siRNA,factor_vii,C14-PEG2000,C12-200,DOPE,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: microfluidic chip device; total_flow_rate_ml_min: ; flow_rate_ratio: 3:1 (ethanol:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3; organic_phase_composition: ethanol phase containing lipid mixture; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed against PBS in 20,000 MWCO cassette at 4°∆C for 2 hours; sterilization: ; storage_buffer: PBS","animal_model: C57BL/6 mice; administration_route: intravenous; dose: 0.1 mg/kg, 0.03 mg/kg, 0.01 mg/kg siRNA; gene_expression_result: 0.1 mg/kg: 7 °æ 1% FVII, 0.03 mg/kg: 48 °æ 5% FVII, 0.01 mg/kg: 76 °æ 9% FVII at 72 hours; biodistribution_result: hepatocyte-specific silencing",Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in vivo with Fractional Factorial and Definitive Screening Designs,"['Kevin J. Kauffman', 'J. Robert Dorkin', 'Jung H. Yang', 'Michael W. Heartlein', 'Frank DeRosa', 'Faryal F. Mir', 'Owen S. Fenton', 'Daniel G. Anderson']",10.1021/acs.nanolett.5b02497,Nano Letters,2015
688,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,48,,,90,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
689,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,31,,,87,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
690,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:2.5:35:11.5,32,,,88,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
691,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:2.5:35:11.5,30,,,87,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
692,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:5:33.5:11.5,27,,,84,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
693,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:5:33.5:11.5,26,,,84,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
694,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,60:1:27.5:11.5,58,,,92,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
695,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,60:1:27.5:11.5,39,,,91,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
696,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,60:2.5:25:11.5,37,,,85,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
697,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,60:2.5:25:11.5,35,,,82,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
698,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,60:5:23.5:11.5,29,,,65,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
699,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,60:5:23.5:11.5,30,,,80,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
700,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,70:1:17.5:11.5,81,,,92,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
701,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,70:1:17.5:11.5,48,,,75,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
702,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,70:2.5:15:11.5,44,,,68,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
703,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,70:2.5:15:11.5,42,,,77,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
704,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,70:5:13.5:11.5,32,,,32,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
705,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,70:5:13.5:11.5,32,,,75,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
706,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,101,,,60,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
707,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,54,,,20,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
708,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:2.5:6:11.5,53,,,20,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
709,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:2.5:6:11.5,49,,,33,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
710,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:5:3.5:11.5,33,,,0,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
711,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:5:3.5:11.5,32,,,0,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
712,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,90,,,82,OTHER:plasmid DNA/lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
713,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,100,,,74,OTHER:plasmid DNA/lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
714,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,95,,,8,OTHER:plasmid DNA/lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
715,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,42,,,37,OTHER:plasmid DNA/lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
716,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,180,,,95,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
717,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,160,,,97,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
718,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,180,,,47,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
719,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,160,,,52,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
720,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,40:1:47.5:11.5,51.6,,,,CONC:2.2e13(particles/•Ïmol)[particles:lipid],gold_nanoparticles,gold_nanoparticles,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
721,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,40:1:47.5:11.5,92.7,,,,CONC:2.2e13(particles/•Ïmol)[particles:lipid],gold_nanoparticles,gold_nanoparticles,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis for 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS; sterilization: ; storage_buffer: 1x PBS, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
722,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,40:1:47.5:11.5,,,,,,siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
723,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,20:1:47.5:31.5,,,,,,siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
724,Custom lipid,PEG-c-DMA,cholesterol,DSPC,40:1:47.5:11.5,,,,,,siRNA,empty,PEG-c-DMA,DO-KC2-DMA,DSPC,cholesterol,,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
725,Custom lipid,PEG-c-DMA,cholesterol,DSPC,20:1:47.5:31.5,,,,,,siRNA,empty,PEG-c-DMA,DO-KC2-DMA,DSPC,cholesterol,,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
726,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,46.2,,,~95,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
727,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,70:1:17.5:11.5,,,,~85,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
728,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,,,,~20,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
729,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,31.1,,,~80,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
730,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,70:1:17.5:11.5,,,,~90,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
731,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,26.9,,,~100,CR:0.25(charge)[siRNA:lipid],siRNA,empty,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:siRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
732,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,~85,,,~80,OTHER:plasmid DNA/cationic lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:DNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
733,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,~95,,,~10,OTHER:plasmid DNA/cationic lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:DNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
734,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,~100,,,~75,OTHER:plasmid DNA/cationic lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:DNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
735,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,~140,,,~50,OTHER:plasmid DNA/cationic lipid charge ratio 0.17,DNA,"gfp, plasmid_dna",PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:DNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
736,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,50:1:37.5:11.5,~50,,,~95,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:mRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
737,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,80:1:7.5:11.5,~65,,,~45,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:mRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
738,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,50:1:37.5:11.5,~95,,,~95,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:mRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
739,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,80:1:7.5:11.5,~40,,,~50,CR:0.25(charge)[mRNA:lipid],mRNA,firefly_luciferase,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:mRNA/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
740,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DSPC,40:1:47.5:11.5,51.6 °æ 8.5,,,,Au-NP-to-lipid ratio of CONC:2.2e13(particles/•Ïmol)[particles:lipid],gold_nanoparticles,gold_nanoparticles,PEG-c-DMA,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:Au-NP/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
741,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DOPE,40:1:47.5:11.5,92.7 °æ 17.8,,,,Au-NP-to-lipid ratio of CONC:2.2e13(particles/•Ïmol)[particles:lipid],gold_nanoparticles,gold_nanoparticles,PEG-c-DMA,DLin-KC2-DMA,DOPE,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: Microfluidic mixing; device_used: staggered herringbone micromixer; total_flow_rate_ml_min: 2.0; flow_rate_ratio: 1:3 (lipid/ethanol:Au-NP/aqueous); aqueous_phase_composition: 25 mM sodium acetate buffer, pH 4.0; organic_phase_composition: 100% ethanol (effectively 25% after mixing); mixing_time_sec: ; temperature_condition: ; post_processing: dialysis 4h against 50 mM MES/50 mM sodium citrate buffer (pH 6.7), then overnight against 1x PBS pH 7.4; sterilization: ; storage_buffer: 1x phosphate buffered saline, pH 7.4",,Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems,"['Alex K. K. Leung', 'Yuen Yi C. Tam', 'Sam Chen', 'Ismail M. Hafez', 'Pieter R. Cullis']",10.1021/acs.jpcb.5b02891,The Journal of Physical Chemistry B,2015
193,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,51:10:39:1.5,58,0.088,32,96,"WR:9.75(wt/wt)[lipid:siRNA], siRNA concentration 0.6mg/ml",siRNA,factor_vii,PEG-DMG (1.4-1.5%),DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Rapid precipitation (two-stage formulation); device_used: T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mmol/l acetate buffer, pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: overnight dialysis against 1°ø phosphate buffer saline; sterilization: ; storage_buffer: 1°ø phosphate buffer saline","cell_line: human whole blood assay; animal_model: CD-1 mice, C57BL/6 mice, apoE-/- mice; administration_route: intravenous; dose: 0.01-10 mg/kg siRNA; gene_expression_result: ~50% FVII protein reduction at 0.03 mg/kg; biodistribution_result: hepatic targeting via ApoE-mediated mechanism; toxicity_profile: elevated cytokines (G-CSF, IP-10, KC, MCP-1) at 3-6 hours; cytokine_response: highest cytokine induction among tested formulations","Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","['Varun Kumar', 'June Qin', 'Yongfeng Jiang', 'Richard G Duncan', 'Benjamin Brigham', 'Shannon Fishman', 'Jayaprakash K Nair', 'Akin Akinc', 'Scott A Barros', 'Pia V Kasperkovitz']",10.1038/mtna.2014.61,Molecular Therapy?Nucleic Acids,2014
194,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,51:10:39:5,47,0.127,24,81,"WR:9.75(wt/wt)[lipid:siRNA], siRNA concentration 0.6mg/ml",siRNA,factor_vii,PEG-DMG (4-5%),DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Rapid precipitation (two-stage formulation); device_used: T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mmol/l acetate buffer, pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: overnight dialysis against 1°ø phosphate buffer saline; sterilization: ; storage_buffer: 1°ø phosphate buffer saline","cell_line: human whole blood assay; animal_model: CD-1 mice, C57BL/6 mice, apoE-/- mice; administration_route: intravenous; dose: 0.01-10 mg/kg siRNA; gene_expression_result: ~25% FVII protein reduction at 0.1 mg/kg; biodistribution_result: reduced hepatic targeting, lower ApoE binding affinity; toxicity_profile: moderate cytokine elevation; cytokine_response: intermediate cytokine induction","Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","['Varun Kumar', 'June Qin', 'Yongfeng Jiang', 'Richard G Duncan', 'Benjamin Brigham', 'Shannon Fishman', 'Jayaprakash K Nair', 'Akin Akinc', 'Scott A Barros', 'Pia V Kasperkovitz']",10.1038/mtna.2014.61,Molecular Therapy?Nucleic Acids,2014
195,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,51:10:39:10,46,0.139,18,82,"WR:9.75(wt/wt)[lipid:siRNA], siRNA concentration 0.6mg/ml",siRNA,factor_vii,PEG-DMG (6-8%),DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Rapid precipitation (two-stage formulation); device_used: T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mmol/l acetate buffer, pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: overnight dialysis against 1°ø phosphate buffer saline; sterilization: ; storage_buffer: 1°ø phosphate buffer saline","cell_line: human whole blood assay; animal_model: CD-1 mice, C57BL/6 mice, apoE-/- mice; administration_route: intravenous; dose: 0.01-10 mg/kg siRNA; gene_expression_result: minimal FVII protein reduction even at 0.3 mg/kg; biodistribution_result: very low hepatic targeting, minimal ApoE association; toxicity_profile: lowest cytokine elevation; cytokine_response: minimal cytokine induction, very low hemolytic activity","Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","['Varun Kumar', 'June Qin', 'Yongfeng Jiang', 'Richard G Duncan', 'Benjamin Brigham', 'Shannon Fishman', 'Jayaprakash K Nair', 'Akin Akinc', 'Scott A Barros', 'Pia V Kasperkovitz']",10.1038/mtna.2014.61,Molecular Therapy?Nucleic Acids,2014
196,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,51:10:39:1.5 (with 0.5% GalNAc targeting ligand),,,,,WR:9.75(wt/wt)[lipid:siRNA],siRNA,factor_vii,PEG-DMG (1%) + GalNAc-PEG-DSG (0.5%),DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Rapid precipitation with targeting ligand incorporation; device_used: T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mmol/l acetate buffer, pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: overnight dialysis against 1°ø phosphate buffer saline; sterilization: ; storage_buffer: 1°ø phosphate buffer saline","animal_model: apoE-/- mice; administration_route: intravenous; dose: 0.01-0.1 mg/kg siRNA; gene_expression_result: dose-dependent FVII silencing, similar to LNP1.5; biodistribution_result: ASGPR-mediated hepatic targeting","Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","['Varun Kumar', 'June Qin', 'Yongfeng Jiang', 'Richard G Duncan', 'Benjamin Brigham', 'Shannon Fishman', 'Jayaprakash K Nair', 'Akin Akinc', 'Scott A Barros', 'Pia V Kasperkovitz']",10.1038/mtna.2014.61,Molecular Therapy?Nucleic Acids,2014
197,DLin-MC3-DMA,DMG-PEG2000,cholesterol,DSPC,51:10:39:5 (with 0.5% GalNAc targeting ligand),,,,,WR:9.75(wt/wt)[lipid:siRNA],siRNA,factor_vii,PEG-DMG (4.5%) + GalNAc-PEG-DSG (0.5%),DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Rapid precipitation with targeting ligand incorporation; device_used: T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 25 mmol/l acetate buffer, pH 4; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: overnight dialysis against 1°ø phosphate buffer saline; sterilization: ; storage_buffer: 1°ø phosphate buffer saline","animal_model: apoE-/- mice; administration_route: intravenous; dose: 0.01-0.1 mg/kg siRNA; gene_expression_result: dose-dependent FVII silencing, restored efficacy; biodistribution_result: ASGPR-mediated hepatic targeting","Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","['Varun Kumar', 'June Qin', 'Yongfeng Jiang', 'Richard G Duncan', 'Benjamin Brigham', 'Shannon Fishman', 'Jayaprakash K Nair', 'Akin Akinc', 'Scott A Barros', 'Pia V Kasperkovitz']",10.1038/mtna.2014.61,Molecular Therapy?Nucleic Acids,2014
1026,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:0.75:38.5:10.75,86,,13.7,84.2,WR:5(wt/wt)[lipidoid:siRNA] to 10:1,siRNA,factor_vii,PEG2000-DMG,304O13 (lipidoid),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing or pipet mixing; device_used: Microfluidic device or pipet; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (lipid solution:siRNA solution); aqueous_phase_composition: 10 mM sodium citrate; organic_phase_composition: 90% ethanol, 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: diluted in PBS, dialysed against PBS for 90 min in 3,500 MWCO cassettes; sterilization: ; storage_buffer: PBS","cell_line: HeLa cells (firefly and Renilla luciferase); animal_model: Female C57BL/6 mice; administration_route: IV (lateral tail vein injection); dose: 0.01 mg/kg (EC50); gene_expression_result: >95% Factor VII silencing; biodistribution_result: 42% liver, 24% spleen, 18% kidneys at 1h post injection; toxicity_profile: No liver toxicity up to 5 mg/kg in multidose studies; cytokine_response: Lower cytokine levels compared to C12-200 control",Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity,"['Kathryn A. Whitehead', 'J. Robert Dorkin', 'Arturo J. Vegas', 'Philip H. Chang', 'Omid Veiseh', 'Jonathan Matthews', 'Owen S. Fenton', 'Yunlong Zhang', 'Karsten T. Olejnik', 'Volkan Yesilyurt', 'Delai Chen', 'Scott Barros', 'Boris Klebanov', 'Tatiana Novobrantseva', 'Robert Langer', 'Daniel G. Anderson']",10.1038/ncomms5277,Nature Communications,2014
1027,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,98.2,,12.5,79,WR:5(wt/wt)[lipidoid:siRNA] to 10:1,siRNA,factor_vii,PEG2000-DMG,306O12 (lipidoid),DSPC,cholesterol,CCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing or pipet mixing; device_used: Microfluidic device or pipet; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (lipid solution:siRNA solution); aqueous_phase_composition: 10 mM sodium citrate; organic_phase_composition: 90% ethanol, 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: diluted in PBS, dialysed against PBS for 90 min in 3,500 MWCO cassettes; sterilization: ; storage_buffer: PBS",cell_line: HeLa cells (firefly and Renilla luciferase); animal_model: Female C57BL/6 mice; administration_route: IV (lateral tail vein injection); dose: 1 mg/kg (EC50); gene_expression_result: >95% Factor VII silencing at 5 mg/kg,Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity,"['Kathryn A. Whitehead', 'J. Robert Dorkin', 'Arturo J. Vegas', 'Philip H. Chang', 'Omid Veiseh', 'Jonathan Matthews', 'Owen S. Fenton', 'Yunlong Zhang', 'Karsten T. Olejnik', 'Volkan Yesilyurt', 'Delai Chen', 'Scott Barros', 'Boris Klebanov', 'Tatiana Novobrantseva', 'Robert Langer', 'Daniel G. Anderson']",10.1038/ncomms5277,Nature Communications,2014
1028,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,91.1,,16.5,75.8,WR:5(wt/wt)[lipidoid:siRNA] to 10:1,siRNA,factor_vii,PEG2000-DMG,113O13 (lipidoid),DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic mixing or pipet mixing; device_used: Microfluidic device or pipet; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (lipid solution:siRNA solution); aqueous_phase_composition: 10 mM sodium citrate; organic_phase_composition: 90% ethanol, 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: diluted in PBS, dialysed against PBS for 90 min in 3,500 MWCO cassettes; sterilization: ; storage_buffer: PBS",cell_line: HeLa cells (firefly and Renilla luciferase); animal_model: Female C57BL/6 mice; administration_route: IV (lateral tail vein injection); dose: 0.05 mg/kg (EC50); gene_expression_result: >95% Factor VII silencing at 5 mg/kg,Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity,"['Kathryn A. Whitehead', 'J. Robert Dorkin', 'Arturo J. Vegas', 'Philip H. Chang', 'Omid Veiseh', 'Jonathan Matthews', 'Owen S. Fenton', 'Yunlong Zhang', 'Karsten T. Olejnik', 'Volkan Yesilyurt', 'Delai Chen', 'Scott Barros', 'Boris Klebanov', 'Tatiana Novobrantseva', 'Robert Langer', 'Daniel G. Anderson']",10.1038/ncomms5277,Nature Communications,2014
142,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,90,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 1 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN(C)C)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC ,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
143,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,140,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 2 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN(CC)CC)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
144,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,140,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 3 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN(C)C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
145,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,89,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 4 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN(C(C)C)C(C)C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
146,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,140,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 5 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CC(C)(C)CN(C)C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
147,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,135,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 6 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN(CCCC)CCCC)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
148,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,86,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 7 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCCCC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
149,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,85,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 8 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCOCC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
150,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,170,,,84,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 9 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCCC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
151,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,165,,,86,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 10 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C1CN(C)C1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
152,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,140,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 11 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C1CCN(C)C1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
153,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 12 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN1CCCC1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
154,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,160,,,85,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 13 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC1=NC=CC=C1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
155,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,89,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 14 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCC(C)C1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
156,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,120,,,90,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 15 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC1CCN(C)C1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
157,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 16 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC1CCCN1C)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
158,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,150,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 17 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCCC1C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
159,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,220,,,18,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 18 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC1CCCC1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
160,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,89,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 19 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN1CCCCC1C)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
161,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,135,,,91,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 20 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN1C=CN=C1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
162,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,120,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 21 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN1CCCN(C)CC1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
163,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 22 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCN1CCN(C)CC1)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
164,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,150,,,86,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 23 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCN(C)CC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
165,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,20,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 24 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCCN(C)CC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
166,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,140,,,89,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 25 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CC1CN(C)CCN1C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
167,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,130,,,90,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 26 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCCC)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
168,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,125,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 27 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C1CCN(C)CC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
169,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,115,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 28 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)CCN1CCS(=O)(=O)CC1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
170,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,105,,,89,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 29 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C1CCN(CC1)CC2=CC=CC=C2)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
171,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,100,,,88,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 30 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C1CCN(CC2=CC=CC=C2)C1)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: Low efficacy (<50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
172,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,95,,,87,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 31 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)C(C)CN(C)C)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
173,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:1.5:38.5:10,95,,,90,WR:5(wt/wt)[synth_lipid:siRNA],siRNA,"firefly_luciferase, factor_vii",mPEG2000-DMG,Lipid 32 (thiol-yne derived),DSPC,cholesterol,CCCCCCCCCCSCC(COC(=O)CCN(C)CCN(C)CCC(=O)OCC(CSCCCCCCCCCC)SCCCCCCCCCC)SCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate buffer, pH 3.0; organic_phase_composition: 200-proof ethanol; mixing_time_sec: ; temperature_condition: room temperature; post_processing: dialysis against 1°ø PBS for 75 min in 3500 MWCO cassettes; sterilization: ; storage_buffer: 1°ø PBS",cell_line: HeLa cells (dual luciferase); animal_model: C57BL/6 mice; administration_route: IV; dose: 1 mg/kg siRNA; gene_expression_result: High efficacy (>50% gene silencing); biodistribution_result: hepatocyte-specific delivery; toxicity_profile: Non-toxic at tested doses,Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,"['Christopher A. Alabi', 'Kevin T. Love', 'Gaurav Sahay', 'Hao Yin', 'Kathryn M. Luly', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.1306529110,PNAS,2013
570,DLinDAP,PEG-s-DMG,cholesterol,DSPC,40:2.5:39.8:17.5 (cationic lipid:PEG-s-DMG:cholesterol:DSPC),85.4 °æ 20.9,,,,OTHER:0.085 (siRNA/lipid wt/wt),siRNA,aso(5°«-UGGCCAAGGUCAUCCAUGAdTdT-3°«),PEG-s-DMG,"DLinDAP (1,2-dilinoleoyl-3-dimethylaminopropane)",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)SCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection with extrusion; device_used: Extruder (Northern Lipids, Vancouver, British Columbia, Canada); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM acetate, pH 4.0; organic_phase_composition: 30% ethanol/70% 50 mM acetate, pH 4.0; mixing_time_sec: 1800 (30 minutes incubation at 31°∆C); temperature_condition: 31°∆C during incubation; post_processing: extrusion through two stacked 80 nm Nuclepore polycarbonate filters at ~300 psi, followed by dialysis in PBS for 16 hours; sterilization: ; storage_buffer: PBS",cell_line: Raw 264.7 macrophage cells; dose: 10 •Ïg/mL (700 nM) siRNA; gene_expression_result: Minimal GAPDH silencing (lowest potency among tested lipids),Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA,"['Paulo J.C. Lin', 'Yuen Yi C. Tam', 'Ismail Hafez', 'Ammen Sandhu', 'Sam Chen', 'Marco A. Ciufolini', 'Ivan R. Nabi', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2012.05.019,"Nanomedicine: Nanotechnology, Biology, and Medicine",2013
571,DLinDMA,PEG-s-DMG,cholesterol,DSPC,40:2.5:39.8:17.5 (cationic lipid:PEG-s-DMG:cholesterol:DSPC),80.7 °æ 17.3,,,,OTHER:0.087 (siRNA/lipid wt/wt),siRNA,aso(5°«-UGGCCAAGGUCAUCCAUGAdTdT-3°«),PEG-s-DMG,"DLinDMA (1,2-dilinoleyloxy-3-dimethylaminopropane)",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)SCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection with extrusion; device_used: Extruder (Northern Lipids, Vancouver, British Columbia, Canada); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM acetate, pH 4.0; organic_phase_composition: 30% ethanol/70% 50 mM acetate, pH 4.0; mixing_time_sec: 1800 (30 minutes incubation at 31°∆C); temperature_condition: 31°∆C during incubation; post_processing: extrusion through two stacked 80 nm Nuclepore polycarbonate filters at ~300 psi, followed by dialysis in PBS for 16 hours; sterilization: ; storage_buffer: PBS",cell_line: Raw 264.7 macrophage cells; dose: 10 •Ïg/mL (700 nM) siRNA; gene_expression_result: Moderate GAPDH silencing (intermediate potency),Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA,"['Paulo J.C. Lin', 'Yuen Yi C. Tam', 'Ismail Hafez', 'Ammen Sandhu', 'Sam Chen', 'Marco A. Ciufolini', 'Ivan R. Nabi', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2012.05.019,"Nanomedicine: Nanotechnology, Biology, and Medicine",2013
572,Custom lipid,PEG-s-DMG,cholesterol,DSPC,40:2.5:39.8:17.5 (cationic lipid:PEG-s-DMG:cholesterol:DSPC),82.5 °æ 26.6,,,,OTHER:0.086 (siRNA/lipid wt/wt),siRNA,aso(5°«-UGGCCAAGGUCAUCCAUGAdTdT-3°«),PEG-s-DMG,"DLinKDMA (2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane)",DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)SCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection with extrusion; device_used: Extruder (Northern Lipids, Vancouver, British Columbia, Canada); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM acetate, pH 4.0; organic_phase_composition: 30% ethanol/70% 50 mM acetate, pH 4.0; mixing_time_sec: 1800 (30 minutes incubation at 31°∆C); temperature_condition: 31°∆C during incubation; post_processing: extrusion through two stacked 80 nm Nuclepore polycarbonate filters at ~300 psi, followed by dialysis in PBS for 16 hours; sterilization: ; storage_buffer: PBS",cell_line: Raw 264.7 macrophage cells; dose: 10 •Ïg/mL (700 nM) siRNA; gene_expression_result: Good GAPDH silencing (higher potency than DLinDMA),Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA,"['Paulo J.C. Lin', 'Yuen Yi C. Tam', 'Ismail Hafez', 'Ammen Sandhu', 'Sam Chen', 'Marco A. Ciufolini', 'Ivan R. Nabi', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2012.05.019,"Nanomedicine: Nanotechnology, Biology, and Medicine",2013
573,DLin-KC2-DMA,PEG-s-DMG,cholesterol,DSPC,40:2.5:39.8:17.5 (cationic lipid:PEG-s-DMG:cholesterol:DSPC),75.2 °æ 29.3,,,,OTHER:0.091 (siRNA/lipid wt/wt),siRNA,aso(5°«-UGGCCAAGGUCAUCCAUGAdTdT-3°«),PEG-s-DMG,"DLinKC2-DMA (2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane)",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)SCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection with extrusion; device_used: Extruder (Northern Lipids, Vancouver, British Columbia, Canada); total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM acetate, pH 4.0; organic_phase_composition: 30% ethanol/70% 50 mM acetate, pH 4.0; mixing_time_sec: 1800 (30 minutes incubation at 31°∆C); temperature_condition: 31°∆C during incubation; post_processing: extrusion through two stacked 80 nm Nuclepore polycarbonate filters at ~300 psi, followed by dialysis in PBS for 16 hours; sterilization: ; storage_buffer: PBS",cell_line: Raw 264.7 macrophage cells; dose: 10 •Ïg/mL (700 nM) siRNA; gene_expression_result: Maximum GAPDH silencing (highest potency among all tested lipids),Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA,"['Paulo J.C. Lin', 'Yuen Yi C. Tam', 'Ismail Hafez', 'Ammen Sandhu', 'Sam Chen', 'Marco A. Ciufolini', 'Ivan R. Nabi', 'Pieter R. Cullis']",http://dx.doi.org/10.1016/j.nano.2012.05.019,"Nanomedicine: Nanotechnology, Biology, and Medicine",2013
1020,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10 (DLinDMA:PEG-DMG:cholesterol:DSPC),162,0.13,,85.3,NP:8(molar) (nitrogen on DLinDMA to phosphate on RNA),mRNA,not_specified,PEG-DMG 2000,"DLinDMA (1,2-dilinoleyloxy-3-dimethylaminopropane)","DSPC (1,2-Diastearoyl-sn-glycero-3-phosphocholine)",cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump (kdScientific) with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1 (lipid in ethanol:RNA in buffer:buffer); aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using tangential flow filtration (TFF) with polyethersulfone (PES) hollow fiber membranes (100-kDa pore size cutoff, 20 cm©˜ surface area); sterilization: ; storage_buffer: 1°ø PBS",animal_model: BALB/c mice; administration_route: intramuscular (i.m.); dose: 0.1 •Ïg RNA; gene_expression_result: SEAP expression measured by serum SEAP concentration,Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
1021,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10,145.8,0.09,,93.6,NP:8(molar),mRNA,luciferase,PEG-DMG 2000,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1; aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using TFF with PES hollow fiber membranes (100-kDa cutoff, 20 cm©˜); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice; administration_route: intramuscular (i.m.), bilateral injection; dose: 1 •Ïg RNA; gene_expression_result: Bioluminescence imaging, measurable expression from day 3 to day 63, peak at day 7; biodistribution_result: Localized to injection site (muscle)",Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
1022,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10,158.6,0.09,,90.7,NP:8(molar),mRNA,viral_antigen,PEG-DMG 2000,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1; aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using TFF with PES hollow fiber membranes (100-kDa cutoff, 20 cm©˜); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice; administration_route: intramuscular (i.m.); dose: 0.1 •Ïg RNA (comparative study), 0.01-10 •Ïg RNA (dose-response study); gene_expression_result: F-specific IgG GMT of 26,170 (0.1 •Ïg dose); cytokine_response: TH1-biased response (IgG2a > IgG1), antigen-specific IFN-•„ producing CD4+ and CD8+ T cells",Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
1023,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10,164.3,0.14,,95,NP:8(molar),mRNA,viral_antigen,PEG-DMG 2000,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1; aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using TFF with PES hollow fiber membranes (100-kDa cutoff, 20 cm©˜); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice; administration_route: intramuscular (i.m.); dose: 0.01-10 •Ïg RNA; gene_expression_result: Dose-dependent F-specific IgG response, 10 •Ïg dose elicited higher titers than VRPs; cytokine_response: TH1-biased response with elevated IgG2a relative to IgG1",Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
1024,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10,157.7,0.1,,97.5,NP:8(molar),mRNA,viral_antigen,PEG-DMG 2000,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1; aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using TFF with PES hollow fiber membranes (100-kDa cutoff, 20 cm©˜); sterilization: ; storage_buffer: 1°ø PBS","animal_model: Cotton rats (Sigmodon hispidis); administration_route: intramuscular (i.m.); dose: 1 •Ïg RNA; gene_expression_result: F-specific IgG GMT of 4,355, RSV neutralization GMT of 1,493; cytokine_response: Protective immune response, >1,000-fold reduction in lung viral load after RSV challenge",Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
1025,DLinDMA,DMG-PEG2000,cholesterol,DSPC,40:2:48:10,129.9,0.104,,92,NP:8(molar),mRNA,viral_antigen,PEG-DMG 2000,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol dilution process; device_used: KDS-220 syringe pump with T-junction mixing; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1:1; aqueous_phase_composition: 100 mM citrate buffer (pH 6); organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: room temperature equilibration for 1 hour; post_processing: concentrated and dialyzed against 1°ø PBS using TFF with PES hollow fiber membranes (100-kDa cutoff, 20 cm©˜); sterilization: ; storage_buffer: 1°ø PBS","animal_model: BALB/c mice; administration_route: intramuscular (i.m.), intradermal (i.d.), subcutaneous (s.c.); dose: 1 •Ïg RNA; gene_expression_result: Env-specific serum IgG GMT of 107,204 (i.m. route, 2 vaccinations), 14-fold higher than pDNA/EP; biodistribution_result: i.m. route superior to i.d. (10-fold higher) and s.c. routes; cytokine_response: Balanced IgG1/IgG2a response suggesting TH1 phenotype, Env-specific IFN-•„ producing CD4+ and CD8+ T cells at levels similar to or higher than pDNA/EP",Nonviral delivery of self-amplifying RNA vaccines,"['Andrew J. Geall', 'Ayush Verma', 'Gillis R. Otten', 'Christine A. Shaw', 'Armin Hekele', 'Kaustuv Banerjee', 'Yen Cu', 'Clayton W. Beard', 'Luis A. Brito', 'Thomas Krucker', ""Derek T. O'Hagan"", 'Manmohan Singh', 'Peter W. Mason', 'Nicholas M. Valiente', 'Philip R. Dormitzer', 'Susan W. Barnett', 'Rino Rappuoli', 'Jeffrey B. Ulmer', 'Christian W. Mandl']",10.1073/pnas.1209367109,PNAS,2012
832,DLinDMA,PEG-lipid,cholesterol,DSPC,40:10:40:10,71 °æ 24,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLinDMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~1 mg/kg; biodistribution_result: plasma 15.3%, liver 50.0%, spleen 0.8% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
833,DLinDAP,PEG-lipid,cholesterol,DSPC,40:10:40:10,65 °æ 21,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLinDAP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 40-50 mg/kg; biodistribution_result: plasma 46.6%, liver 20.5%, spleen 0.7% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
834,DLin-2-DMAP,PEG-lipid,cholesterol,DSPC,40:10:40:10,79 °æ 26,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-2-DMAP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOC(CN(C)C)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 5-12 mg/kg; biodistribution_result: plasma 17.5%, liver 20.5%, spleen 0.3% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
835,DLin-C-DAP,PEG-lipid,cholesterol,DSPC,40:10:40:10,73 °æ 25,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-C-DAP,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCNC(=O)OCC(CN(C)C)OC(=O)NCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 12-25 mg/kg; biodistribution_result: plasma 69.4%, liver 28.5%, spleen 0.8% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
836,DLin-S-DMA,PEG-lipid,cholesterol,DSPC,40:10:40:10,69 °æ 25,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-S-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCSCC(CN(C)C)SCCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 12-25 mg/kg; biodistribution_result: plasma 10.7%, liver 2.5%, spleen <0.1% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
837,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,67 °æ 22,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-K-DMA,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)CN(C)C,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~0.4 mg/kg; biodistribution_result: plasma 1.1%, liver 32.0%, spleen <0.1% at 0.5h",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
838,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,71 °æ 21,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-K-MPZ,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)CN1CCN(C)CC1,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~1.5 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
839,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,58 °æ 21,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-K-MA,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)CN1CCOCC1,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 >15 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
840,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,150 °æ 69,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-K-TMA.Cl,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)C[N+](C)(C)C.[Cl-],CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 >5 mg/kg (lethal at 15 mg/kg); toxicity_profile: lethal at 15 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
841,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,68 °æ 32,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-K2-DMA,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)CC(=O)CN(C)C,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~0.4 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
842,DLin-KC2-DMA,PEG-lipid,cholesterol,DSPC,40:10:40:10,72 °æ 23,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-KC2-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~0.1 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
843,DLin-KC3-DMA,PEG-lipid,cholesterol,DSPC,40:10:40:10,80 °æ 22,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-KC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 ~0.6 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
844,Custom lipid,PEG-lipid,cholesterol,DSPC,40:10:40:10,64 °æ 15,,,,WR:0.05(wt/wt)[siRNA:lipid],siRNA,factor_vii,PEG-lipid,DLin-KC4-DMA,DSPC,cholesterol,CCCCCCC=CCC=CCCCCCCCOCC(COC(=O)CCC=CCC=CCCCCCCCC)CCCC(=O)CN(C)C,CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Preformed vesicle method; device_used: Lipex Extruder; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 50 mM citrate, pH 4; organic_phase_composition: 30% ethanol; mixing_time_sec: ; temperature_condition: 22°∆C for formulation, 35°∆C for encapsulation; post_processing: dialysis or tangential flow diafiltration; sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: various doses tested; gene_expression_result: ED50 >3 mg/kg,Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
845,DLin-KC2-DMA,PEG-c-DMA,cholesterol,DPPC,57.1:7.1:34.3:1.4,75-85,,,90-95,OTHER:siRNA/lipid ratio ~0.15 (wt/wt),siRNA,factor_vii,PEG-C-DMA,DLin-KC2-DMA,DPPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC1(OC(CO1)CCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"synthesis_method: Controlled step-wise dilution method; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: ; organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS, filter sterilized through 0.2 •Ïm filter; sterilization: 0.2 •Ïm filter; storage_buffer: PBS","animal_model: C57BL/6 mice, rats, cynomolgus monkeys; administration_route: intravenous; dose: 0.01-1 mg/kg in rodents, 0.03-1 mg/kg in NHP; gene_expression_result: ED50 ~0.02 mg/kg in mice, ~0.3 mg/kg in NHP (TTR); toxicity_profile: well tolerated at doses up to 50-fold higher than ED50",Rational design of cationic lipids for siRNA delivery,"['Sean C Semple', 'Akin Akinc', 'Jianxin Chen', 'Ammen P Sandhu', 'Barbara L Mui', 'Connie K Cho', 'Dinah W Y Sah', 'Derrick Stebbing', 'Erin J Crosley', 'Ed Yaworski', 'Ismail M Hafez', 'J Robert Dorkin', 'June Qin', 'Kieu Lam', 'Kallanthottathil G Rajeev', 'Kim F Wong', 'Lloyd B Jeffs', 'Lubomir Nechev', 'Merete L Eisenhardt', 'Muthusamy Jayaraman', 'Mikameh Kazem', 'Martin A Maier', 'Masuna Srinivasulu', 'Michael J Weinstein', 'Qingmin Chen', 'Rene Alvarez', 'Scott A Barros', 'Soma De', 'Sandra K Klimuk', 'Todd Borland', 'Verbena Kosovrasti', 'William L Cantley', 'Ying K Tam', 'Muthiah Manoharan', 'Marco A Ciufolini', 'Mark A Tracy', 'Antonin de Fougerolles', 'Ian MacLachlan', 'Pieter R Cullis', 'Thomas D Madden', 'Michael J Hope']",10.1038/nbt.1602,Nature Biotechnology,2010
993,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,65-250,,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C16-96,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCCCCCC)CCN(CC(O)CCCCCCCCCCCCCCCC)CC(O)CCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: complete silencing at administered dose; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
994,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,65-250,,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C14-110,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCCCC)CCN(CN)CCN(CC(O)CCCCCCCCCCCCCC)CC(O)CCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 0.25-5 mg/kg total siRNA; gene_expression_result: dose-dependent gene silencing; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
995,C12-200,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,80,,,90,OTHER:7:1 total lipid to siRNA ratio (wt:wt),siRNA,factor_vii,mPEG2000-DMG,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction mixing; device_used: peristaltic pump with dual pump heads; total_flow_rate_ml_min: equivalent volumetric flow rates; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate, pH 3 buffer; organic_phase_composition: 90% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5); sterilization: ; storage_buffer: PBS (155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5)","cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 0.003-6 mg/kg entrapped siRNA; gene_expression_result: >90% silencing at 0.01 mg/kg, two orders-of-magnitude higher potency than LNP01; biodistribution_result: liver-specific delivery; toxicity_profile: no toxicity at 1 mg/kg (ALT: 37.0°æ7.8 U/L, AST: 77.7°æ25.5 U/L, ALP: 123.3°æ25.6 U/L)","Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
996,C12-200,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,80,,,90,OTHER:7:1 total lipid to siRNA ratio (wt:wt),siRNA,factor_vii,mPEG2000-DMG,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction mixing; device_used: peristaltic pump with dual pump heads; total_flow_rate_ml_min: equivalent volumetric flow rates; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate, pH 3 buffer; organic_phase_composition: 90% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS; sterilization: ; storage_buffer: PBS",animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 0.005-0.2 mg/kg per siRNA (1 mg/kg total siRNA); gene_expression_result: >65% silencing of all five genes at 0.2 mg/kg per siRNA; biodistribution_result: liver-specific delivery; toxicity_profile: no adverse side effects observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
997,C12-200,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,80,,,90,OTHER:7:1 total lipid to siRNA ratio (wt:wt),siRNA,not_specified,mPEG2000-DMG,C12-200,DSPC,cholesterol,NCCN1CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CC1CN(CC(O)CCCCCCCCCCCC)CN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: T-junction mixing; device_used: peristaltic pump with dual pump heads; total_flow_rate_ml_min: equivalent volumetric flow rates; flow_rate_ratio: 1:1 (organic:aqueous); aqueous_phase_composition: 10 mM citrate, pH 3 buffer; organic_phase_composition: 90% ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: dialysis against PBS; sterilization: ; storage_buffer: PBS","animal_model: Cynomolgus monkeys; administration_route: intravenous (cephalic vein); dose: 0.03-0.3 mg/kg siTTR; gene_expression_result: high levels of specific knockdown at all doses, most efficacious knockdown yet reported in primates; biodistribution_result: liver-specific delivery","Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
998,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,251.2 °æ 8.4,0.224 °æ 0.047,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C14-100,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCCCC)CCN(CC(O)CCCCCCCCCCCCCC)CC(O)CCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
999,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,126.1 °æ 0.5,0.243 °æ 0.017,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C14-96,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCCCC)CCN(CC(O)CCCCCCCCCCCCCC)CC(O)CCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
1000,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,65.1 °æ 0.2,0.128 °æ 0.023,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C12-120,DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
1001,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,67.7 °æ 0.4,0.147 °æ 0.021,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C12-113,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCC)CCN(CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC)CCN(CC(O)CCCCCCCCCCCC)CC(O)CCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
1002,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,167.4 °æ 5.9,0.142 °æ 0.070,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C18-62,DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
1003,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,250.6 °æ 16.1,0.227 °æ 0.045,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C14-98,DSPC,cholesterol,,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
1004,Custom lipid,DMG-PEG2000,cholesterol,DSPC,50:10:38.5:1.5,252.2 °æ 5.9,0.178 °æ 0.024,,,OTHER:10:1 total lipids:siRNA weight ratio,siRNA,factor_vii,mPEG2000-DMG,C18-96,DSPC,cholesterol,N(CC(O)CCCCCCCCCCCCCCCCCC)CCN(CC(O)CCCCCCCCCCCCCCCCCC)CC(O)CCCCCCCCCCCCCCCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Ethanol injection; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: 200 mM sodium acetate buffer (pH 5); organic_phase_composition: absolute ethanol; mixing_time_sec: ; temperature_condition: 37°∆C incubation for 30 min; post_processing: dialysis against PBS in 3,500 MWCO dialysis cassettes for 75 min; sterilization: ; storage_buffer: PBS",cell_line: HeLa-derived luciferase expressing cells; animal_model: C57BL/6 mice; administration_route: intravenous (tail vein); dose: 3 mg/kg total siRNA; gene_expression_result: gene silencing observed; biodistribution_result: liver-specific delivery; toxicity_profile: no body-weight loss observed,"Lipid-like materials for low-dose, in vivo gene silencing","['Kevin T. Love', 'Kerry P. Mahon', 'Christopher G. Levins', 'Kathryn A. Whitehead', 'William Querbes', 'J. Robert Dorkin', 'June Qin', 'William Cantley', 'Liu Liang Qin', 'Timothy Racie', 'Maria Frank-Kamenetsky', 'Ka Ning Yip', 'Rene Alvarez', 'Dinah W. Y. Sah', 'Antonin de Fougerolles', 'Kevin Fitzgerald', 'Victor Koteliansky', 'Akin Akinc', 'Robert Langer', 'Daniel G. Anderson']",10.1073/pnas.0910603106,PNAS,2010
185,DSDMA,PEG-c-DMA,cholesterol,DSPC,30:2:48:20,182,0.15,,67,,siRNA,"luciferase, aso",PEG2000-C-DMA,"DSDMA (1,2-distearyloxy-N,N-dimethyl-3-aminopropane)",DSPC,cholesterol,CCCCCCCCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCCCCCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection (spontaneous vesicle formation); device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: PBS; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: diafiltered against 100 mL of PBS (20 wash volumes) using cross flow ultrafiltration cartridge; sterilization: sterile filtered through Acrodisc 0.8/0.2 •Ïm syringe filters; storage_buffer: PBS,cell_line: Neuro2A-G cells (luciferase-expressing); administration_route: in vitro; dose: 0.0625-1.0 •Ïg/mL siRNA; gene_expression_result: No significant luciferase knockdown,Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,"['James Heyes', 'Lorne Palmer', 'Kaz Bremner', 'Ian MacLachlan']",10.1016/j.jconrel.2005.06.014,Journal of Controlled Release,2005
186,DODMA,PEG-c-DMA,cholesterol,DSPC,30:2:48:20,137,0.12,,84,,siRNA,"luciferase, aso",PEG2000-C-DMA,"DODMA (1,2-dioleyloxy-N,N-dimethyl-3-aminopropane)",DSPC,cholesterol,CCCCCCCC/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\CCCCCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection (spontaneous vesicle formation); device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: PBS; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: diafiltered against 100 mL of PBS (20 wash volumes) using cross flow ultrafiltration cartridge; sterilization: sterile filtered through Acrodisc 0.8/0.2 •Ïm syringe filters; storage_buffer: PBS,cell_line: Neuro2A-G cells (luciferase-expressing); administration_route: in vitro; dose: 0.0625-1.0 •Ïg/mL siRNA; gene_expression_result: ~54% luciferase expression (46% knockdown) at 1.0 •Ïg/mL,Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,"['James Heyes', 'Lorne Palmer', 'Kaz Bremner', 'Ian MacLachlan']",10.1016/j.jconrel.2005.06.014,Journal of Controlled Release,2005
187,DLinDMA,PEG-c-DMA,cholesterol,DSPC,30:2:48:20,140,0.11,,84,,siRNA,"luciferase, aso",PEG2000-C-DMA,"DLinDMA (1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane)",DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection (spontaneous vesicle formation); device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: PBS; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: diafiltered against 100 mL of PBS (20 wash volumes) using cross flow ultrafiltration cartridge; sterilization: sterile filtered through Acrodisc 0.8/0.2 •Ïm syringe filters; storage_buffer: PBS,cell_line: Neuro2A-G cells (luciferase-expressing); administration_route: in vitro; dose: 0.0625-1.0 •Ïg/mL siRNA; gene_expression_result: ~21% luciferase expression (79% knockdown) at 1.0 •Ïg/mL,Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,"['James Heyes', 'Lorne Palmer', 'Kaz Bremner', 'Ian MacLachlan']",10.1016/j.jconrel.2005.06.014,Journal of Controlled Release,2005
188,DLenDMA,PEG-c-DMA,cholesterol,DSPC,30:2:48:20,132,0.13,,85,,siRNA,"luciferase, aso",PEG2000-C-DMA,"DLenDMA (1,2-dilinolenoyloxy-N,N-dimethyl-3-aminopropane)",DSPC,cholesterol,CC/C=C\C/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\C/C=C\CC,CN(C)CCC(O)COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,synthesis_method: Ethanol injection (spontaneous vesicle formation); device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: PBS; organic_phase_composition: ethanol; mixing_time_sec: ; temperature_condition: ; post_processing: diafiltered against 100 mL of PBS (20 wash volumes) using cross flow ultrafiltration cartridge; sterilization: sterile filtered through Acrodisc 0.8/0.2 •Ïm syringe filters; storage_buffer: PBS,cell_line: Neuro2A-G cells (luciferase-expressing); administration_route: in vitro; dose: 0.0625-1.0 •Ïg/mL siRNA; gene_expression_result: ~32% luciferase expression (68% knockdown) at 1.0 •Ïg/mL,Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,"['James Heyes', 'Lorne Palmer', 'Kaz Bremner', 'Ian MacLachlan']",10.1016/j.jconrel.2005.06.014,Journal of Controlled Release,2005
1016,DODAC,DMG-PEG2000,,DOPE,7.5:10:0:82.5 (DODAC:PEG-lipid:sterol:DOPE),~100,,,,"OTHER:400 •Ïg DNA for 10 mg lipid, final DNA concentration 0.5 mg/ml",DNA,"luciferase, plasmid_dna","PEG-S-DMG (PEG-dimyristoylglycerol, C14)",DODAC,DOPE,,CCCCCCCC/C=C\CCCCCCCC[N+](CCCCCCCC/C=C\CCCCCCCC)(C)C.[Cl-],CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: detergent dialysis; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: aqueous solutions of octyl glucopyranoside (OGP); organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed for 48 h, anion exchange chromatography (DEAE Sepharose CL6B), sucrose density ultracentrifugation, Amicon ultrafiltration; sterilization: filter sterilized (0.22 •Ïm); storage_buffer: HBS (HEPES buffered saline)","cell_line: Neuro-2a; animal_model: A/J mice with Neuro-2a neuroblastoma tumors; administration_route: IV (lateral tail vein injection); dose: 200 •ÏL containing 2 mg total lipid and 100 •Ïg total DNA; gene_expression_result: ~22,000 fg luciferase/50,000 cells at 96h in vitro; ~25 pg luciferase/g tumor at 72h in vivo; biodistribution_result: t1/2 = 1h in plasma; high liver accumulation (~40% injected dose/g at 4h); low tumor accumulation (~2% injected dose/g)",Stabilized plasmid?lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression,"['E. Ambegia', 'S. Ansell', 'P. Cullis', 'J. Heyes', 'L. Palmer', 'I. MacLachlan']",10.1016/j.bbamem.2005.02.001,Biochimica et Biophysica Acta,2005
1017,DODAC,C16-PEG2000,,DOPE,7.5:10:0:82.5 (DODAC:PEG-lipid:sterol:DOPE),~100,,,,"OTHER:400 •Ïg DNA for 10 mg lipid, final DNA concentration 0.5 mg/ml",DNA,"luciferase, plasmid_dna","PEG-S-DPG (PEG-dipalmitoylglycerol, C16)",DODAC,DOPE,,CCCCCCCC/C=C\CCCCCCCC[N+](CCCCCCCC/C=C\CCCCCCCC)(C)C.[Cl-],CCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: detergent dialysis; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: aqueous solutions of octyl glucopyranoside (OGP); organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed for 48 h, anion exchange chromatography (DEAE Sepharose CL6B), sucrose density ultracentrifugation, Amicon ultrafiltration; sterilization: filter sterilized (0.22 •Ïm); storage_buffer: HBS (HEPES buffered saline)","cell_line: Neuro-2a; animal_model: A/J mice with Neuro-2a neuroblastoma tumors; administration_route: IV (lateral tail vein injection); dose: 200 •ÏL containing 2 mg total lipid and 100 •Ïg total DNA; gene_expression_result: ~5,000 fg luciferase/50,000 cells at 96h in vitro; ~80 pg luciferase/g tumor at 72h in vivo; biodistribution_result: t1/2 = 6h in plasma; moderate liver accumulation (~25% injected dose/g at 24h); moderate tumor accumulation (~8% injected dose/g)",Stabilized plasmid?lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression,"['E. Ambegia', 'S. Ansell', 'P. Cullis', 'J. Heyes', 'L. Palmer', 'I. MacLachlan']",10.1016/j.bbamem.2005.02.001,Biochimica et Biophysica Acta,2005
1018,DODAC,C18-PEG2000,,DOPE,7.5:10:0:82.5 (DODAC:PEG-lipid:sterol:DOPE),~100,,,,"OTHER:400 •Ïg DNA for 10 mg lipid, final DNA concentration 0.5 mg/ml",DNA,"luciferase, plasmid_dna","PEG-S-DSG (PEG-distearoylglycerol, C18)",DODAC,DOPE,,CCCCCCCC/C=C\CCCCCCCC[N+](CCCCCCCC/C=C\CCCCCCCC)(C)C.[Cl-],CCCCCCCCCCCCCCCCCCOC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: detergent dialysis; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: aqueous solutions of octyl glucopyranoside (OGP); organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed for 48 h, anion exchange chromatography (DEAE Sepharose CL6B), sucrose density ultracentrifugation, Amicon ultrafiltration; sterilization: filter sterilized (0.22 •Ïm); storage_buffer: HBS (HEPES buffered saline)","cell_line: Neuro-2a; animal_model: A/J mice with Neuro-2a neuroblastoma tumors; administration_route: IV (lateral tail vein injection); dose: 200 •ÏL containing 2 mg total lipid and 100 •Ïg total DNA; gene_expression_result: ~5,000 fg luciferase/50,000 cells at 96h in vitro; ~120 pg luciferase/g tumor at 72h in vivo; biodistribution_result: t1/2 = 15h in plasma; low liver accumulation (~15% injected dose/g at 24h); high tumor accumulation (~12% injected dose/g)",Stabilized plasmid?lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression,"['E. Ambegia', 'S. Ansell', 'P. Cullis', 'J. Heyes', 'L. Palmer', 'I. MacLachlan']",10.1016/j.bbamem.2005.02.001,Biochimica et Biophysica Acta,2005
1019,DODAC,C20-Ceramide-PEG2000,,DOPE,7.5:10:0:82.5 (DODAC:PEG-lipid:sterol:DOPE),~100,,,,"OTHER:400 •Ïg DNA for 10 mg lipid, final DNA concentration 0.5 mg/ml",DNA,"luciferase, plasmid_dna",PEG-CerC20 (PEG-ceramide C20),DODAC,DOPE,,CCCCCCCC/C=C\CCCCCCCC[N+](CCCCCCCC/C=C\CCCCCCCC)(C)C.[Cl-],CCCCCCCCCCCCCCCCCCCC(=O)NC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C(O)C=CCCCCCCCCCCCC,,CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCC/C=C\CCCCCCCC,"synthesis_method: detergent dialysis; device_used: ; total_flow_rate_ml_min: ; flow_rate_ratio: ; aqueous_phase_composition: aqueous solutions of octyl glucopyranoside (OGP); organic_phase_composition: ; mixing_time_sec: ; temperature_condition: ; post_processing: dialyzed for 48 h, anion exchange chromatography (DEAE Sepharose CL6B), sucrose density ultracentrifugation, Amicon ultrafiltration; sterilization: filter sterilized (0.22 •Ïm); storage_buffer: HBS (HEPES buffered saline)","cell_line: Neuro-2a; animal_model: A/J mice with Neuro-2a neuroblastoma tumors; administration_route: IV (lateral tail vein injection); dose: 200 •ÏL containing 2 mg total lipid and 100 •Ïg total DNA; gene_expression_result: ~5,000 fg luciferase/50,000 cells at 96h in vitro; ~130 pg luciferase/g tumor at 72h in vivo; biodistribution_result: t1/2 = 7h in plasma; moderate liver accumulation (~18% injected dose/g at 24h); high tumor accumulation (~11% injected dose/g)",Stabilized plasmid?lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression,"['E. Ambegia', 'S. Ansell', 'P. Cullis', 'J. Heyes', 'L. Palmer', 'I. MacLachlan']",10.1016/j.bbamem.2005.02.001,Biochimica et Biophysica Acta,2005
46,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,50:1.5:37.5:10,61 (Z-average); 36 (number average),0.16,,,,empty,empty,DMPE-PEG 2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision NanoSystems Inc); total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 100 mM RNAse free citrate buffer pH 3 (Teknova); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: 4-8°∆C storage; post_processing: dialysis for 24 hours against 400x sample volume PBS pH 7.4, ultrafiltration with Amicon 30k MWCO, D2O exchange; sterilization: ; storage_buffer: D2O, stored at 4°∆C",,Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization Enhanced NMR Spectroscopy,"['Jasmine Viger-Gravel', 'Anna Schantz', 'Arthur C. Pinon', 'Aaron J. Rossini', 'Staffan Schantz', 'Lyndon Emsley']",,,
47,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,50:1.5:37.5:10,52 (Z-average); 36 (number average),0.12,,99,,siRNA,"barcode(25 nucleotide duplex strand, 100% phosphorothioated backbone)",DMPE-PEG 2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision NanoSystems Inc); total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 100 mM RNAse free citrate buffer pH 3 (Teknova); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: 4-8°∆C storage; post_processing: dialysis for 24 hours against 400x sample volume PBS pH 7.4, ultrafiltration with Amicon 30k MWCO, D2O exchange; sterilization: ; storage_buffer: D2O, stored at 4°∆C",,Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization Enhanced NMR Spectroscopy,"['Jasmine Viger-Gravel', 'Anna Schantz', 'Arthur C. Pinon', 'Aaron J. Rossini', 'Staffan Schantz', 'Lyndon Emsley']",,,
48,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,50:1.5:37.5:10,65 (Z-average); 43 (number average),0.13,,96,,siRNA,"barcode(25 nucleotide duplex strand, 50% phosphorothioated backbone)",DMPE-PEG 2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision NanoSystems Inc); total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 100 mM RNAse free citrate buffer pH 3 (Teknova); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: 4-8°∆C storage; post_processing: dialysis for 24 hours against 400x sample volume PBS pH 7.4, ultrafiltration with Amicon 30k MWCO, D2O exchange; sterilization: ; storage_buffer: D2O, stored at 4°∆C",,Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization Enhanced NMR Spectroscopy,"['Jasmine Viger-Gravel', 'Anna Schantz', 'Arthur C. Pinon', 'Aaron J. Rossini', 'Staffan Schantz', 'Lyndon Emsley']",,,
49,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,50:1.5:37.5:10,94 (Z-average); 53 (number average),0.2,,98,,mRNA,epo,DMPE-PEG 2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision NanoSystems Inc); total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 100 mM RNAse free citrate buffer pH 3 (Teknova); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: 4-8°∆C storage; post_processing: dialysis for 24 hours against 400x sample volume PBS pH 7.4, ultrafiltration with Amicon 30k MWCO, D2O exchange; sterilization: ; storage_buffer: D2O, stored at 4°∆C",,Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization Enhanced NMR Spectroscopy,"['Jasmine Viger-Gravel', 'Anna Schantz', 'Arthur C. Pinon', 'Aaron J. Rossini', 'Staffan Schantz', 'Lyndon Emsley']",,,
50,DLin-MC3-DMA,DMPE-PEG2000,cholesterol,DSPC,50:1.5:37.5:10,53 (Z-average); 42 (number average),0.06,,95,,siRNA,"barcode(25 nucleotide duplex strand, 0% phosphorothioated (standard siRNA))",DMPE-PEG 2000,DLin-MC3-DMA,DSPC,cholesterol,CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC,CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCN[C@@H](CO)C(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"synthesis_method: Microfluidic; device_used: NanoAssemblr (Precision NanoSystems Inc); total_flow_rate_ml_min: 12; flow_rate_ratio: 1:3 (organic:aqueous); aqueous_phase_composition: 100 mM RNAse free citrate buffer pH 3 (Teknova); organic_phase_composition: 100% ethanol; mixing_time_sec: ; temperature_condition: 4-8°∆C storage; post_processing: dialysis for 24 hours against 400x sample volume PBS pH 7.4, ultrafiltration with Amicon 30k MWCO, D2O exchange; sterilization: ; storage_buffer: D2O, stored at 4°∆C",,Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization Enhanced NMR Spectroscopy,"['Jasmine Viger-Gravel', 'Anna Schantz', 'Arthur C. Pinon', 'Aaron J. Rossini', 'Staffan Schantz', 'Lyndon Emsley']",,,
